Biomarker Gene Alteration type Alteration Targeting Drug status Drug family Drug Association Evidence level Assay type Source Curator Curation date Primary Tumor type Metastatic Tumor Type TCGI included Comments Drug full name ABL1 (T315I) ABL1 MUT ABL1:T315I Approved [BCR-ABL inhibitor 2nd gen] [Nilotinib,Dasatinib] Resistant European LeukemiaNet guidelines PMID:21562040 CRubio-Perez 12/15 CML TRUE Has to be rechecked BCR-ABL inhibitor 2nd gens (Nilotinib,Dasatinib,etc) ABL1 (T315I) ABL1 MUT ABL1:T315I Approved BCR-ABL inhibitor 3rd gen Bosutinib Resistant European LeukemiaNet guidelines PMID:21562040 CRubio-Perez 12/15 CML TRUE Has to be rechecked Bosutinib (BCR-ABL inhibitor 3rd gen) ABL1 (V299L,T315A,F317L,F317V,F317I,F317C) ABL1 MUT ABL1:V299L,T315A,F317L,F317V,F317I,F317C Approved BCR-ABL inhibitor 2nd gen Dasatinib Resistant European LeukemiaNet guidelines PMID:21562040 CRubio-Perez 12/15 CML TRUE Has to be rechecked Dasatinib (BCR-ABL inhibitor 2nd gen) ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G) ABL1 MUT ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G Approved BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Resistant European LeukemiaNet guidelines PMID:21562040 CRubio-Perez 12/15 CML TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I) ABL1 MUT ABL1:E255K,E255V,Y253H,F359V,F359C,F359I Approved BCR-ABL inhibitor 2nd gen Nilotinib Resistant European LeukemiaNet guidelines PMID:21562040 CRubio-Perez 12/15 CML TRUE Nilotinib (BCR-ABL inhibitor 2nd gen) ABL1-BCR fusion ABL1 FUS ABL1__BCR Approved BCR-ABL inhibitor 3rd gen Bosutinib Responsive FDA guidelines FDA CRubio-Perez;DTamborero;RDientsmann CML TRUE Bosutinib (BCR-ABL inhibitor 3rd gen) ABL1-BCR fusion ABL1 FUS ABL1__BCR Approved BCR-ABL inhibitor 2nd gen Dasatinib Responsive FDA guidelines FDA CRubio-Perez;DTamborero;RDientsmann CML;ALL TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) ABL1-BCR fusion ABL1 FUS ABL1__BCR Approved BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive FDA guidelines EMA CRubio-Perez;DTamborero;RDientsmann CML;ALL TRUE http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) ABL1-BCR fusion ABL1 FUS ABL1__BCR Approved BCR-ABL inhibitor 2nd gen Nilotinib Responsive FDA guidelines FDA CRubio-Perez;DTamborero;RDientsmann CML TRUE Nilotinib (BCR-ABL inhibitor 2nd gen) ABL1-BCR fusion ABL1 FUS ABL1__BCR Approved BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor Ponatinib Responsive FDA guidelines FDA CRubio-Perez;DTamborero;RDientsmann CML;ALL TRUE Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor) ABL1 (T315I) ABL1 MUT ABL1:T315I Approved BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor Ponatinib Responsive FDA guidelines FDA CRubio-Perez;DTamborero;RDientsmann 12/15 CML;ALL TRUE REMAP: from T315. to T315I, 12/15 label update states the complete aminoacid change Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor) ABL1 (T315I) ABL1 MUT ABL1:T315I VEGFR inhibitor Axitinib Responsive Pre-clinical PMID:25686603 DTamborero 03/16 CANCER TRUE Axitinib (VEGFR inhibitor) ABL1 (V299L) ABL1 MUT ABL1:V299L Pan-kinase inhibitor Cabozantinib Responsive Pre-clinical PMID:26924578 DTamborero 03/16 CANCER TRUE Cabozantinib (Pan-kinase inhibitor) ABL1 (V299L) ABL1 MUT ABL1:V299L ALK inhibitor Crizotinib Responsive Pre-clinical PMID:26924578 DTamborero 03/16 CANCER TRUE Crizotinib (ALK inhibitor) ABL1 (V299L) ABL1 MUT ABL1:V299L MET inhibitor Foretinib  Responsive Pre-clinical PMID:26924578 DTamborero 03/16 CANCER TRUE Foretinib  (MET inhibitor) ABL1 (V299L) ABL1 MUT ABL1:V299L Pan-TK inhibitor Vandetanib Responsive Pre-clinical PMID:26924578 DTamborero 03/16 CANCER TRUE Vandetanib (Pan-TK inhibitor) ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I) ABL1 MUT ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I Approved BCR-ABL inhibitor 3rd gen Bosutinib Responsive NCCN guidelines PMID:21562040 RDientsmann CML TRUE Bosutinib (BCR-ABL inhibitor 3rd gen) ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V) ABL1 MUT ABL1:F359V,F359C,F359I,Y253H,E255K,E255V Approved BCR-ABL inhibitor 2nd gen Dasatinib Responsive NCCN guidelines PMID:21562040 RDientsmann CML TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) ABL1 (T315A,F317L,F317V,F317I,F317C,V299L) ABL1 MUT ABL1:T315A,F317L,F317V,F317I,F317C,V299L Approved BCR-ABL inhibitor 2nd gen Nilotinib Responsive NCCN guidelines PMID:21562040 RDientsmann CML TRUE Nilotinib (BCR-ABL inhibitor 2nd gen) ABL1 (T315I) ABL1 MUT ABL1:T315I Approved BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor Ponatinib Responsive NCCN guidelines PMID:21562040 RDientsmann CML TRUE Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor) AKT1 (E17K) AKT1 MUT AKT1:E17K Clinical Trials [non-allosteric AKT inhibitor] [] Responsive Early trials ENA 2015 (abstract B109) RDientsmann CANCER TRUE non-allosteric AKT inhibitors AKT1 (E17K) AKT1 MUT AKT1:E17K Clinical Trials [allosteric AKT inhibitor] [] Responsive Pre-clinical PMID:21464312;PMID:17611497 RDientsmann BRCA TRUE allosteric AKT inhibitors AKT1 (E17K) AKT1 MUT AKT1:E17K Clinical Trials [AKT inhibitor] [] Responsive Pre-clinical PMID:21464312;PMID:17611497;PMID:23134728; ENA 2015 (abstr B109) RDientsmann 11/15 CANCER TRUE AKT inhibitors AKT1 (H238Y) AKT1 MUT AKT1:H238Y MTOR inhibitor Everolimus Responsive Case report ASCO 2015 (abstr 11010) RDientsmann FH TRUE Everolimus (MTOR inhibitor) AKT1 (Q79K,E17K) AKT1 MUT AKT1:Q79K,E17K [BRAF inhibitor] [] Resistant Case report PMID:24265152 RDientsmann;DTamborero 03/16 CM TRUE BRAF inhibitors AKT1 (E17K) AKT1 MUT AKT1:E17K [PI3K pathway inhibitor] [] Responsive Case report PMID:26763254 RDientsmann 07/16 HNSC TRUE PI3K pathway inhibitors AKT1 (E17K) AKT1 MUT AKT1:E17K MTOR inhibitor Tensirolimus Responsive Early trials PMID:27016228 RDientsmann 07/16 ED TRUE Tensirolimus (MTOR inhibitor) AKT2 amplification AKT2 CNA AKT2:amp Clinical Trials Allosteric AKT inhibitor MK2206 Responsive Pre-clinical ENA 2014 (abstr 373) RDientsmann CANCER TRUE MK2206 (Allosteric AKT inhibitor) AKT3 fusion AKT3 FUS AKT3__. Direct Clinical Trials;Clinical Trials [ATP competitive AKT inhibitor] [AZD5363,GSK2141795] Responsive Pre-clinical Cell line PMID:22722202 JAlbanell;ARovira;RDientsmann 09/15 BRCA TRUE ATP competitive AKT inhibitors (AZD5363,GSK2141795,etc) ALK fusion ALK FUS ALK__. Approved ALK inhibitor Ceritinib Responsive FDA guidelines FDA CRubio-Perez;DTamborero;RDientsmann NSCLC TRUE Ceritinib (ALK inhibitor) ALK fusion ALK FUS ALK__. Approved ALK inhibitor Crizotinib Responsive FDA guidelines FDA CRubio-Perez;DTamborero;RDientsmann NSCLC TRUE Crizotinib (ALK inhibitor) ALK (G1123S) ALK MUT ALK:G1123S ALK inhibitor Ceritinib Resistant Case report PMID:26134233 EArriola 09/15 LUAD TRUE Ceritinib (ALK inhibitor) ALK (C1156Y,L1196M) ALK MUT ALK:C1156Y,L1196M Approved ALK inhibitor Crizotinib Resistant Case report PMID:20979473 EArriola 09/15 NSCLC TRUE Crizotinib (ALK inhibitor) ALK oncogenic mutation ALK MUT ALK:. Approved ALK inhibitor Crizotinib Resistant Clinical trial PMID:22235099 EArriola 09/15 NSCLC TRUE Crizotinib (ALK inhibitor) ALK amplification ALK CNA ALK:amp Approved ALK inhibitor Crizotinib Resistant Clinical trial PMID:22235099 EArriola 09/15 NSCLC TRUE Crizotinib (ALK inhibitor) ALK fusion ALK FUS ALK__. Clinical_Trials ALK inhibitor Alectinib Responsive FDA guidelines FDA EArriola;CRubio-Perez NSCLC TRUE Alectinib (ALK inhibitor) ALK fusion ALK FUS ALK__. Direct Clinical Trials ALK inhibitor Ceritinib Responsive Early trials NCT02186821 ECampo HEMATO TRUE Ceritinib (ALK inhibitor) ALK fusion ALK FUS ALK__. ALK inhibitor Crizotinib Responsive Early trials PMID:24491302;NCT02270034 MMartínez;RDientsmann 09/15 LY;GB TRUE Crizotinib (ALK inhibitor) ALK fusion ALK FUS ALK__. [HSP90 inhibitor] [] Responsive Early trials PMID:23553849 RDientsmann 01/16 LUAD TRUE HSP90 inhibitors ALK fusion ALK FUS ALK__. [novel ALK inhibitor] [] Responsive Early trials PMID:23639470 RDientsmann 01/16 LUAD TRUE novel ALK inhibitors ALK (F1174L) ALK MUT ALK:F1174L [novel ALK inhibitor] [] Responsive Pre-clinical PMID:24327273 RDientsmann 01/16 LUAD TRUE novel ALK inhibitors ALK fusion ALK FUS ALK__. [ALK inhibitor;IGF1R inhibitor] [] Responsive Pre-clinical PMID:25173427 RDientsmann 01/16 LUAD TRUE ALK inhibitor + IGF1R inhibitors ALK fusion ALK FUS ALK__. [ALK inhibitor;SRC inhibitor] [] Responsive Pre-clinical PMID:25394791 RDientsmann 01/16 LUAD TRUE ALK inhibitor + SRC inhibitors ALK fusion ALK FUS ALK__. [ALK inhibitor;MEK inhibitor] [] Responsive Pre-clinical PMID:26301689 RDientsmann 01/16 LUAD TRUE ALK inhibitor + MEK inhibitors ALK fusion ALK FUS ALK__. [ALK inhibitor] [] Responsive Case report PMID:26633560 RDientsmann 01/16 COREAD TRUE ALK inhibitors ALK (I1171T) ALK MUT ALK:I1171T ALK inhibitor Alectinib Resistant Case report PMID:25228534 RDientsmann 01/16 LUAD TRUE Alectinib (ALK inhibitor) ALK inframe insertion (1151T) ALK MUT ALK::consequence::inframe_insertion:.1151T. ALK inhibitor Ceritinib Responsive FDA guidelines PMID:24670165 RDientsmann 01/16 LUAD TRUE Ceritinib (ALK inhibitor) ALK (L1196M,S1206Y,G1269A,I1171T) ALK MUT ALK:L1196M,S1206Y,G1269A,I1171T ALK inhibitor Ceritinib Responsive FDA guidelines PMID:24670165;PMID:24327273 RDientsmann 01/16 LUAD TRUE Ceritinib (ALK inhibitor) ALK fusion ALK FUS ALK__. ALK inhibitor Crizotinib Responsive Case report PMID:20979472;PMID:24687827 RDientsmann IM;THCA TRUE Crizotinib (ALK inhibitor) ALK (F1174L) ALK MUT ALK:F1174L ALK inhibitor Crizotinib Resistant Pre-clinical PMID:22072639 RDientsmann G TRUE Crizotinib (ALK inhibitor) ALK (R1275Q,G1128A,I1171N,R1192P,F1245C) ALK MUT ALK:R1275Q,G1128A,I1171N,R1192P,F1245C ALK inhibitor Crizotinib Responsive Pre-clinical PMID:22072639 RDientsmann G TRUE Crizotinib (ALK inhibitor) ALK inframe insertion (1151T) ALK MUT ALK::consequence::inframe_insertion:.1151T. ALK inhibitor Crizotinib Resistant Case report PMID:22277784 RDientsmann LUAD TRUE Crizotinib (ALK inhibitor) ALK amplification ALK CNA ALK:amp ALK inhibitor Crizotinib Resistant Case report PMID:22277784 RDientsmann LUAD TRUE Crizotinib (ALK inhibitor) ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T) ALK MUT ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T ALK inhibitor Crizotinib Resistant Case report PMID:22277784;PMID:25228534 RDientsmann LUAD TRUE Crizotinib (ALK inhibitor) ALK (F856S,A348D) ALK MUT ALK:F856S,A348D ALK inhibitor Crizotinib Responsive Pre-clinical PMID:26032424 RDientsmann 01/16 AML TRUE Crizotinib (ALK inhibitor) ALK (L1198F) ALK MUT ALK:L1198F ALK inhibitor Crizotinib Responsive Case report PMID:26698910 RDientsmann 04/16 LUAD TRUE Crizotinib (ALK inhibitor) APC oncogenic mutation APC MUT APC:. [Tankyrase inhibitor] [] Responsive Pre-clinical PMID:22440753;PMID:23539443 RDientsmann COREAD TRUE Tankyrase inhibitors AR overexpression AR EXPR AR:over Direct Approved AR inhibitor Enzalutamide Responsive Early trials PMID:24882673 ARodriguez-Vida 09/15 PRAD PRAD TRUE Enzalutamide (AR inhibitor) AR overexpression AR EXPR AR:over Direct Clinical Trials [AR inhibitor] [Bicalutamide,Enzalutamide,Orterone,4OHtestosterone] Responsive Early trials ASCO 2015 (abstr 1003) JAlbanell;ARovira 09/15 BRCA TRUE AR inhibitors (Bicalutamide,Enzalutamide,Orterone,4OHtestosterone,etc) AR (L702H,T878A) AR MUT AR:L702H,T878A Approved AR inhibitor Abiraterone Resistant Early trials PMID:26537258 RDienstmann 11/15 PRAD TRUE REMAP:T877A to T878A the previous mutation was not found in . transcript to our knowledge. Abiraterone (AR inhibitor) AR amplification AR CNA AR:amp Approved AR inhibitor Abiraterone Resistant Early trials PMID:26537258 RDienstmann 11/15 PRAD TRUE Abiraterone (AR inhibitor) AR amplification AR CNA AR:amp [AR inhibitor next gen] [] Responsive Pre-clinical PMID:23589709;PMID:21859989 RDientsmann PRAD TRUE AR inhibitor next gens AR (W741,T878A) AR MUT AR:W741.,T878A AR inhibitor Arn-509 Responsive Pre-clinical PMID:23779130 RDientsmann 01/16 PRAD TRUE REMAP:T877A to T878A the previous mutation was not found in . transcript to our knowledge. Arn-509 (AR inhibitor) AR (W741,T878A) AR MUT AR:W741.,T878A AR inhibitor Enzalutamide Responsive Pre-clinical PMID:23779130 RDientsmann 01/16 PRAD TRUE REMAP:T877A to T878A the previous mutation was not found in . transcript to our knowledge. Enzalutamide (AR inhibitor) AR (F877L) AR MUT AR:F877L AR inhibitor Arn-509 Resistant Case report PMID:23779130 RDientsmann;ARodriguez-Vida 09/15 PRAD PRAD TRUE REMAP:F876L to F877L the previous mutation was not found in . transcript to our knowledge. Arn-509 (AR inhibitor) AR (F877L) AR MUT AR:F877L AR inhibitor Enzalutamide Resistant Case report PMID:23779130 RDientsmann;ARodriguez-Vida 09/15 PRAD PRAD TRUE REMAP:F876L to F877L the previous mutation was not found in . transcript to our knowledge. Enzalutamide (AR inhibitor) AR (T878A) AR MUT AR:T878A AR inhibitor Flutamide Resistant Case report PMID:2260966 RDientsmann;ARodriguez-Vida 09/15 PRAD PRAD TRUE REMAP:T877A to T878A the previous mutation was not found in . transcript to our knowledge. Flutamide (AR inhibitor) ARAF (S214C) ARAF MUT ARAF:S214C Direct:primary target FDA approved Pan-TK inhibitor Sorafenib Responsive Case report http://www.jci.org/articles/view/72763;PMID:24569458 JAlbanell;ARovira;RDientsmann 09/15 LUAD TRUE Sorafenib (Pan-TK inhibitor) ARAF oncogenic mutation ARAF MUT ARAF:. [BRAF inhibitor;EGFR mAb inhibitor] [] Resistant Case report ENA 2014 (abstr 428) RDientsmann COREAD TRUE BRAF inhibitor + EGFR mAb inhibitors ARAF oncogenic mutation ARAF MUT ARAF:. [BRAF inhibitor;MEK inhibitor] [] Resistant Case report ENA 2014 (abstr 428) RDientsmann COREAD TRUE BRAF inhibitor + MEK inhibitors AREG amplification AREG CNA AREG:amp [EGFR mAb inhibitor] [] Responsive Early trials PMID:19738126;PMID:26341080 RDientsmann 04/16 COREAD TRUE EGFR mAb inhibitors ARID1A oncogenic mutation ARID1A MUT ARID1A:. [PARP inhibitor] [] Responsive Pre-clinical PMID:26069190 RDienstmann 11/15 CANCER TRUE PARP inhibitors ARID1A oncogenic mutation ARID1A MUT ARID1A:. [EZH2 inhibitor] [] Responsive Pre-clinical PMID:25686104 Rdientsmann 01/16 OV TRUE EZH2 inhibitors ATM deletion ATM CNA ATM:del Indirect Approved Chemotherapy Cisplatin Responsive Early trials PMID:26238431 ARodriguez-Vida 09/15 BLCA BLCA TRUE Cisplatin (Chemotherapy) ATM oncogenic mutation ATM MUT ATM:. Indirect Approved Chemotherapy Cisplatin Responsive Early trials PMID:26238431 ARodriguez-Vida 09/15 BLCA BLCA TRUE Cisplatin (Chemotherapy) ATM biallelic inactivation ATM BIA ATM:. Indirect Clinical Trials ATR inhibitor AZD6738 Responsive Early trials NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html ECampo BCL TRUE AZD6738 (ATR inhibitor) ATM oncogenic mutation ATM MUT ATM:. [ATR inhibitor] [] Responsive Case report ENA 2015 (abstr A48) RDienstmann 11/15 COREAD TRUE ATR inhibitors ATM deletion ATM CNA ATM:del [ATR inhibitor] [] Responsive Case report ENA 2015 (abstr A48) RDienstmann 11/15 COREAD TRUE ATR inhibitors ATM oncogenic mutation ATM MUT ATM:. PARP inhibitor Olaparib Responsive Early trials ENA 2014 (abstr 8LBA);PMID:26510020 RDienstmann 01/16 ST;PRAD TRUE Olaparib (PARP inhibitor) ATM oncogenic mutation ATM MUT ATM:. [PARP inhibitor] [] Responsive Early trials ENA 2014 (abstr 8LBA) RDientsmann ST TRUE PARP inhibitors ATM deletion ATM CNA ATM:del [PARP inhibitor] [] Responsive Early trials ENA 2014 (abstr 8LBA) RDientsmann ST TRUE PARP inhibitors ATM oncogenic mutation ATM MUT ATM:. [DNA-PKc inhibitor] [] Responsive Pre-clinical PMID:23761041 RDientsmann 11/15 LY TRUE DNA-PKc inhibitors ATM deletion ATM CNA ATM:del [DNA-PKc inhibitor] [] Responsive Pre-clinical PMID:23761041 RDientsmann 11/15 LY TRUE DNA-PKc inhibitors ATM oncogenic mutation ATM MUT ATM:. Chemotherapy Temozolomide Responsive Pre-clinical PMID:23960094 RDientsmann G TRUE Temozolomide (Chemotherapy) ATR oncogenic mutation ATR MUT ATR:. Indirect Approved PARP inhibitor Olaparib Responsive Pre-clinical Cell line PMID:23548269 CRubio-Perez;Ecampo;RDientsmann OV;CANCER TRUE Olaparib (PARP inhibitor) ATR deletion ATR CNA ATR:del Indirect Approved PARP inhibitor Olaparib Responsive Pre-clinical Cell line PMID:23548269 CRubio-Perez;Ecampo;RDientsmann OV;CANCER TRUE Olaparib (PARP inhibitor) ATR oncogenic mutation ATR MUT ATR:. Chemotherapy Temozolomide Responsive Pre-clinical PMID:23960094 RDientsmann G TRUE Temozolomide (Chemotherapy) AURKA amplification AURKA CNA AURKA:amp [AURK inhibitor] [] Responsive Pre-clinical PMID:22302096;PMID:22389870 RDientsmann PRAD;CANCER TRUE AURK inhibitors B2M oncogenic mutation B2M MUT B2M:. [PD1 Ab inhibitor] [] Resistant Case report PMID:27433843 RDientsmann 07/16 CM TRUE PD1 Ab inhibitors BAP1 oncogenic mutation BAP1 MUT BAP1:. [HDAC inhibitor] [] Responsive Pre-clinical PMID:22038994 RDientsmann CM TRUE HDAC inhibitors BAP1 deletion BAP1 CNA BAP1:del [HDAC inhibitor] [] Responsive Pre-clinical PMID:22038994 RDientsmann CM TRUE HDAC inhibitors BAP1 oncogenic mutation BAP1 MUT BAP1:. [PARP inhibitor] [] Responsive Pre-clinical PMID:22683710 RDientsmann R;CANCER TRUE PARP inhibitors BAP1 deletion BAP1 CNA BAP1:del [PARP inhibitor] [] Responsive Pre-clinical PMID:22683710 RDientsmann R;CANCER TRUE PARP inhibitors BAP1 oncogenic mutation BAP1 MUT BAP1:. [EZH2 inhibitor] [] Responsive Pre-clinical PMID:26437366 RDientsmann 11/15 MESO TRUE EZH2 inhibitors BAP1 deletion BAP1 CNA BAP1:del [EZH2 inhibitor] [] Responsive Pre-clinical PMID:26437366 RDientsmann 11/15 MESO TRUE EZH2 inhibitors BCL2 amplification BCL2 CNA BCL2:amp [BCL2 inhibitor] [] Responsive Pre-clinical PMID:22649144 RDientsmann LY TRUE BCL2 inhibitors BCOR oncogenic mutation BCOR MUT BCOR:. PKCb inhibitor Enzastaurin Responsive Pre-clinical PMID:27397505 RDientsmann 07/16 ST TRUE Enzastaurin (PKCb inhibitor) BRAF (V600E) BRAF MUT BRAF:V600E BRAF inhibitor Dabrafenib Responsive NCCN guidelines NCCN CRubio-Perez 06/16 NSCLC TRUE Dabrafenib (BRAF inhibitor) BRAF (V600D,V600K,V600M,V600G,V600R) BRAF MUT BRAF:V600D,V600K,V600M,V600G,V600R Approved BRAF inhibitor Vemurafenib Responsive NCCN guidelines NCCN CRubio-Perez 16/06 CM TRUE Vemurafenib (BRAF inhibitor) BRAF (V600E) BRAF MUT BRAF:V600E Approved BRAF inhibitor Dabrafenib Responsive FDA guidelines FDA CRubio-Perez;DTamborero;RDientsmann CM TRUE Dabrafenib (BRAF inhibitor) BRAF (V600E,V600K) BRAF MUT BRAF:V600E,V600K Approved MEK inhibitor Trametinib Responsive FDA guidelines FDA CRubio-Perez;DTamborero;RDientsmann CM TRUE Trametinib (MEK inhibitor) BRAF (V600E) BRAF MUT BRAF:V600E Approved BRAF inhibitor Vemurafenib Responsive FDA guidelines FDA CRubio-Perez;DTamborero;RDientsmann CM TRUE Vemurafenib (BRAF inhibitor) BRAF (V600) BRAF MUT BRAF:V600. Approved BRAF inhibitor Vemurafenib No Responsive Early trials PMID:26287849 DTamborero COREAD TRUE Vemurafenib (BRAF inhibitor) BRAF (V600E,V600D,V600K,V600M,V600G,V600R) BRAF MUT BRAF:V600E,V600D,V600K,V600M,V600G,V600R Indirect Approved BRAF inhibitor Vemurafenib Responsive NCCN guidelines PMID:26287849 DTamborero NSCLC;HISLC;HISEC TRUE Vemurafenib (BRAF inhibitor) BRAF (V600E) BRAF MUT BRAF:V600E BRAF inhibitor PLX4720 Responsive Pre-clinical Cell line PMC3638050 MMartínez 09/15 MA TRUE PLX4720 (BRAF inhibitor) BRAF (V600E) BRAF MUT BRAF:V600E Clinical Trials MEK inhibitor Selumetinib Responsive Early trials NCT01089101 MMartínez 09/15 PG TRUE Selumetinib (MEK inhibitor) BRAF (V600E) BRAF MUT BRAF:V600E Approved BRAF inhibitor Vemurafenib Responsive Early trials PMID:22586120 MMartínez 09/15 MA TRUE Vemurafenib (BRAF inhibitor) BRAF (V600E) BRAF MUT BRAF:V600E BRAF inhibitor;MEK inhibitor Dabrafenib;Trametinib Responsive Early trials PMID:26392102;ASCO 2015 (abstr 8006) RDienstmann 01/16 COREAD;LUAD TRUE Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor) BRAF (V600) BRAF MUT BRAF:V600. Indirect Approved; Approved;Clinical Trials EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor Panitumumab;Dabrafenib;BYL719 Responsive Early trials ENA 2014 (abstr 11LBA) RDienstmann 01/16 COREAD TRUE Panitumumab + Dabrafenib + BYL719 (EGFR mAb inhibitor + BRAF inhibitor + PI3K inhibitor) BRAF (V600E) BRAF MUT BRAF:V600E Indirect Approved; Approved;Clinical Trials EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor Panitumumab;Dabrafenib;Trametinib Responsive Early trials ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103) RDienstmann 01/16 COREAD TRUE Panitumumab + Dabrafenib + Trametinib (EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor) BRAF fusion BRAF FUS BRAF__. MEK inhibitor Selumetinib Responsive Case report PMID:26324360 RDienstmann 01/16 OV TRUE Selumetinib (MEK inhibitor) BRAF (V600E) BRAF MUT BRAF:V600E [BRAF inhibitor;MEK inhibitor] [] Responsive Early trials ASCO 2013 (abstr 9029) RDientsmann 01/16 TH TRUE BRAF inhibitor + MEK inhibitors BRAF (V600E) BRAF MUT BRAF:V600E [Pan-RAF inhibitor] [] Responsive Early trials ESMO 2015 (abstract 300);AACR 2016 (abstr CT005) RDientsmann 06/16 CM;TH TRUE Pan-RAF inhibitors BRAF (V600E) BRAF MUT BRAF:V600E [MEK inhibitor] [] Responsive Pre-clinical PMID:19018267 RDientsmann OV TRUE MEK inhibitors BRAF (V600E) BRAF MUT BRAF:V600E [BRAF inhibitor] [] Responsive Pre-clinical PMID:22038996;PMID:22586120 RDientsmann G TRUE BRAF inhibitors BRAF (V600E) BRAF MUT BRAF:V600E [MEK inhibitor] [] Responsive Early trials PMID:22241789 RDientsmann 01/16 TH TRUE MEK inhibitors BRAF (V600E) BRAF MUT BRAF:V600E [BRAF inhibitor;HSP90 inhibitor] [] Responsive Pre-clinical PMID:22351686 RDientsmann 01/16 CM TRUE BRAF inhibitor + HSP90 inhibitors BRAF (V600E) BRAF MUT BRAF:V600E [BRAF inhibitor;PI3K pathway inhibitor] [] Responsive Pre-clinical PMID:22389471;PMID:21156289 RDientsmann 01/16 CM TRUE BRAF inhibitor + PI3K pathway inhibitors BRAF (V600E) BRAF MUT BRAF:V600E [BRAF inhibitor] [] Responsive Case report PMID:22608338 RDientsmann OV TRUE BRAF inhibitors BRAF (V600E,G469A) BRAF MUT BRAF:V600E,G469A [EGFR TK inhibitor] [] Resistant Case report PMID:22773810 RDientsmann 04/16 LUAD TRUE UPDATE: delete G469A mutation in v16 GDKD? EGFR TK inhibitors BRAF (V600E) BRAF MUT BRAF:V600E [BRAF inhibitor;CDK2/4 inhibitor] [] Responsive Pre-clinical PMID:22997239 RDientsmann 01/16 CM TRUE BRAF inhibitor + CDK2/4 inhibitors BRAF (V600E) BRAF MUT BRAF:V600E [ERK inhibitor] [] Responsive Pre-clinical PMID:23614898;PMID:22997239 RDientsmann 01/16 CM TRUE ERK inhibitors BRAF (L597R) BRAF MUT BRAF:L597R [BRAF inhibitor] [] Responsive Case report PMID:23715574 RDientsmann 01/16 CM TRUE BRAF inhibitors BRAF inframe deletion (L485),inframe deletion (P490) BRAF MUT BRAF::consequence::inframe_deletion:L485.,::inframe_deletion:P490. [Pan-RAF inhibitor] [] Responsive Pre-clinical PMID:26732095 RDientsmann 04/16 CANCER TRUE Pan-RAF inhibitors BRAF (K601R,L597R,V600R) BRAF MUT BRAF:K601R,L597R,V600R [MEK inhibitor] [Trametinib] Responsive Case report PMID:23248257;PMID:22805292;PMID:23248257 RDientsmann CM TRUE MEK inhibitors (Trametinib,etc) BRAF fusion BRAF FUS BRAF__. [MEK inhibitor] [Trametinib] Responsive Pre-clinical PMID:24727320;PMID:24345920;PMID:20526349 RDientsmann LUAD;CM;PRAD TRUE MEK inhibitors (Trametinib,etc) BRAF (V600E) BRAF MUT BRAF:V600E EGFR mAb inhibitor Cetuximab Resistant Late trials PMID:20619739;PMID:21163703;PMID:23325582 RDientsmann COREAD TRUE Cetuximab (EGFR mAb inhibitor) BRAF (V600R) BRAF MUT BRAF:V600R BRAF inhibitor Dabrafenib Responsive Early trials PMID:23237741 RDientsmann CM TRUE Dabrafenib (BRAF inhibitor) BRAF (V600E) BRAF MUT BRAF:V600E BRAF inhibitor Dabrafenib Responsive Case report PMID:23470635;PMID:22608338 RDientsmann GIST TRUE Dabrafenib (BRAF inhibitor) BRAF (V600E) BRAF MUT BRAF:V600E BRAF inhibitor Dabrafenib Responsive Early trials PMID:23524406;PMID:22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);PMID:20818844;PMID:23489023;PMID:27080216 RDientsmann 04/16 LUAD;TH TRUE Dabrafenib (BRAF inhibitor) BRAF (V600E,V600K) BRAF MUT BRAF:V600E,V600K Approved BRAF inhibitor;MEK inhibitor Dabrafenib;Trametinib Responsive FDA guidelines FDA RDientsmann CM TRUE Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor) BRAF (Y472C) BRAF MUT BRAF:Y472C BCR-ABL inhibitor 2nd gen Dasatinib Responsive Case report PMID:22649091 RDientsmann LUAD TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) BRAF (G466V) BRAF MUT BRAF:G466V BCR-ABL inhibitor 2nd gen Dasatinib Responsive Pre-clinical PMID:22649091 RDientsmann LUAD TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) BRAF (V600E) BRAF MUT BRAF:V600E EGFR mAb inhibitor Panitumumab Resistant Late trials PMID:20619739;PMID:21163703;PMID:23325582 RDientsmann COREAD TRUE Panitumumab (EGFR mAb inhibitor) BRAF (D594G,G469E) BRAF MUT BRAF:D594G,G469E Pan-TK inhibitor Sorafenib Responsive Pre-clinical PMID:18794803 RDientsmann CM TRUE Sorafenib (Pan-TK inhibitor) BRAF fusion BRAF FUS BRAF__. Pan-TK inhibitor Sorafenib Responsive Pre-clinical PMID:238900088;PMID:20526349;PMID:24727320 RDientsmann CM;LUAD;PRAD TRUE Sorafenib (Pan-TK inhibitor) BRAF (V600E) BRAF MUT BRAF:V600E Approved BRAF inhibitor Vemurafenib Responsive Early trials PMID:22608338;PMID:20818844;PMID:23489023 RDientsmann THCA TRUE Vemurafenib (BRAF inhibitor) BRAF (V600E) BRAF MUT BRAF:V600E Approved BRAF inhibitor Vemurafenib Responsive Case report PMID:22743296;PMID:22621641;PMID:23612012 RDientsmann 04/16 LUAD;HCL;MYMA TRUE Vemurafenib (BRAF inhibitor) BRAF inframe deletion (L485),inframe deletion (P490) BRAF MUT BRAF::consequence::inframe_deletion:L485.,::inframe_deletion:P490. Approved BRAF inhibitor Vemurafenib Resistant Pre-clinical PMID:26732095 RDientsmann 04/16 CANCER TRUE Vemurafenib (BRAF inhibitor) BRAF (V600E,V600K) BRAF MUT BRAF:V600E,V600K Approved BRAF inhibitor;MEK inhibitor Vemurafenib;Cobimetinib Responsive FDA guidelines FDA RDientsmann 11/15 CM TRUE Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor) BRAF (V600E) BRAF MUT BRAF:V600E BRAF inhibitor;MEK inhibitor Dabrafenib;Trametinib Responsive Case report PMID:27048246 RDientsmann 07/16 NEU TRUE Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor) BRAF (G469A) + EGFR oncogenic mutation BRAF;EGFR MUT;MUT BRAF:G469A;EGFR:. [EGFR TK inhibitor;MEK inhibitor] [] Responsive Pre-clinical PMID:22773810 RDientsmann 01/16 LUAD TRUE EGFR TK inhibitor + MEK inhibitors BRCA1 oncogenic mutation BRCA1 MUT BRCA1:. PARP inhibitor Olaparib Responsive Early trials PMID:26510020 RDienstmann 01/16 PRAD TRUE Olaparib (PARP inhibitor) BRCA1 oncogenic mutation BRCA1 MUT BRCA1:. [PARP inhibitor;Chemotherapy] [] Responsive Early trials PMID:22307137;ASCO 2012 (abstr 1009) RDientsmann 04/16 OV TRUE PARP inhibitor + Chemotherapys BRCA1 deletion BRCA1 CNA BRCA1:del [PARP inhibitor] [] Responsive Pre-clinical PMID:22392482 RDientsmann OV TRUE PARP inhibitors BRCA1 oncogenic mutation BRCA1 MUT BRCA1:. [PARP inhibitor] [] Responsive Case report PMID:25366685;PMID:25719666;PMID:19553641;PMID:25366685 RDientsmann PA TRUE PARP inhibitors BRCA1 oncogenic mutation BRCA1 MUT BRCA1:. [WEE1 inhibitor] [] Responsive Case report PMID:25964244 RDientsmann CANCER TRUE WEE1 inhibitors BRCA1 oncogenic mutation BRCA1 MUT BRCA1:. Approved PARP inhibitor Olaparib Responsive FDA guidelines FDA RDientsmann 04/16 OV TRUE Olaparib (PARP inhibitor) BRCA1 oncogenic mutation BRCA1 MUT BRCA1:. Chemotherapy Platinum Agent Responsive Late trials PMID:22406760;PMID:22711857 RDientsmann 04/16 OV TRUE Platinum Agent (Chemotherapy) BRCA1 oncogenic mutation BRCA1 MUT BRCA1:. Chemotherapy Platinum Agent Responsive Early trials PMID:25847936 RDientsmann 01/16 BRCA TRUE Platinum Agent (Chemotherapy) BRCA1 oncogenic mutation BRCA1 MUT BRCA1:. PARP inhibitor Rucaparib Responsive FDA guidelines FDA RDientsmann 04/16 OV TRUE Rucaparib (PARP inhibitor) BRCA1 oncogenic mutation BRCA1 MUT BRCA1:. [PARP inhibitor] [Olaparib] Responsive Early trials PMID:20609467;PMID:25366685 RDientsmann;JAlbanell BRCA TRUE PARP inhibitors (Olaparib,etc) BRCA1 oncogenic mutation BRCA1 MUT BRCA1:. PARP inhibitor;Chemotherapy Veliparib;Cisplatin Responsive Early trials PMID:26801247 RDientsmann 07/16 BRCA TRUE Veliparib + Cisplatin (PARP inhibitor + Chemotherapy) BRCA2 oncogenic mutation BRCA2 MUT BRCA2:. Indirect Approved [PARP inhibitor] [Olaparib] Responsive Early trials PMID:20609467 JAlbanell;ARovira;RDientsmann 09/15 BRCA TRUE PARP inhibitors (Olaparib,etc) BRCA2 oncogenic mutation BRCA2 MUT BRCA2:. [PARP inhibitor;Chemotherapy] [] Responsive Early trials PMID:22307137;ASCO 2012 (abstr 1009) RDientsmann 04/16 OV TRUE PARP inhibitor + Chemotherapys BRCA2 oncogenic mutation BRCA2 MUT BRCA2:. [PD1 Ab inhibitor] [] Responsive Case report PMID:26997480 RDientsmann 04/16 CM TRUE PD1 Ab inhibitors BRCA2 deletion BRCA2 CNA BRCA2:del [PARP inhibitor] [Olaparib] Responsive Pre-clinical PMID:22392482 RDientsmann OV TRUE PARP inhibitors (Olaparib,etc) BRCA2 oncogenic mutation BRCA2 MUT BRCA2:. Approved PARP inhibitor Olaparib Responsive FDA guidelines FDA RDientsmann OV TRUE Olaparib (PARP inhibitor) BRCA2 oncogenic mutation BRCA2 MUT BRCA2:. Chemotherapy Platinum Agent Responsive Late trials PMID:22406760;PMID:22711857 RDientsmann 04/16 OV TRUE Platinum Agent (Chemotherapy) BRCA2 oncogenic mutation BRCA2 MUT BRCA2:. Chemotherapy Platinum Agent Responsive Case report PMID:25719666 RDientsmann PA TRUE Platinum Agent (Chemotherapy) BRCA2 oncogenic mutation BRCA2 MUT BRCA2:. Chemotherapy Platinum Agent Responsive Early trials PMID:25847936 RDientsmann 01/16 BRCA TRUE Platinum Agent (Chemotherapy) BRCA2 oncogenic mutation BRCA2 MUT BRCA2:. PARP inhibitor Rucaparib Responsive FDA guidelines FDA RDientsmann 04/16 OV TRUE Rucaparib (PARP inhibitor) BRCA2 oncogenic mutation BRCA2 MUT BRCA2:. Indirect Approved PARP inhibitor Olaparib Responsive Early trials PMID:26510020;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322 RDientsmann;ARodriguez-Vida 01/16 PRAD TRUE Olaparib (PARP inhibitor) BRCA2 oncogenic mutation BRCA2 MUT BRCA2:. PARP inhibitor;Chemotherapy Veliparib;Cisplatin Responsive Early trials PMID:26801247 RDientsmann 07/16 BRCA TRUE Veliparib + Cisplatin (PARP inhibitor + Chemotherapy) BTK (C481S) BTK MUT BTK:C481S BTK inhibitor Ibrutinib Resistant Early trials PMID:24869598;PMID:27199251 RDientsmann CLL TRUE Ibrutinib (BTK inhibitor) BTK (C481) BTK MUT BTK:C481. BTK inhibitor Ibrutinib Resistant Case report PMID:25082755 RDientsmann MCL TRUE Ibrutinib (BTK inhibitor) BRD4-C15orf55 fusion C15orf55 FUS BRD4__C15orf55 [BET inhibitor] [] Responsive Case report ENA 2015 (abstr A49) RDientsmann 11/15 NMC TRUE BET inhibitors CA9 overexpression CA9 EXPR CA9:over Indirect Approved Pan-TK inhibitor Sunitinib Responsive Pre-clinical Cell line PMID:24086736 ARodriguez-Vida 09/15 R TRUE Sunitinib (Pan-TK inhibitor) CBL (Y371H,C384R) CBL MUT CBL:Y371H,C384R [JAK inhibitor] [] Responsive Pre-clinical PMID:23696637 RDientsmann MDPS TRUE JAK inhibitors CBL (Y371H,C384R) CBL MUT CBL:Y371H,C384R BCR-ABL inhibitor 2nd gen Dasatinib Responsive Pre-clinical PMID:23696637 RDientsmann MDPS TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) CCND1 amplification CCND1 CNA CCND1:amp [CDK4/6 inhibitor] [] Responsive Case report ASCO 2014 (abstr 2528) RDientsmann CM TRUE CDK4/6 inhibitors CCND1 amplification CCND1 CNA CCND1:amp [CDK4/6 inhibitor] [] Responsive Pre-clinical PMID:22471707 RDientsmann CANCER TRUE CDK4/6 inhibitors CCND2 amplification CCND2 CNA CCND2:amp Indirect Approved CDK4/6 inhibitor Palbociclib Responsive Early trials NCT02154490 CRubio-Perez;DTamborero L TRUE Palbociclib (CDK4/6 inhibitor) CCND2 amplification CCND2 CNA CCND2:amp [CDK4/6 inhibitor] [] Responsive Pre-clinical PMID:22471707 RDientsmann CANCER TRUE CDK4/6 inhibitors CCND3 amplification CCND3 CNA CCND3:amp [CDK4/6 inhibitor] [] Responsive Pre-clinical PMID:22471707 RDientsmann CANCER TRUE CDK4/6 inhibitors CCNE1 amplification CCNE1 CNA CCNE1:amp [CDK2 inhibitor] [] Responsive Pre-clinical PMID:22471707 RDientsmann CANCER TRUE CDK2 inhibitors CD274 overexpression CD274 EXPR CD274:over Direct Clinical Trials PDL1 inhibitor Atezolizumab Responsive Early trials NCT01375842;doi: 10.1093/annonc/mdu337.2 ARodriguez-Vida 09/15 CM;R;CANCER BLCA TRUE Atezolizumab (PDL1 inhibitor) CD274 overexpression CD274 EXPR CD274:over Indirect Clinical Trials PD1 Ab inhibitor Nivolumab Responsive Early trials PMID:25452452 ARodriguez-Vida 09/15 R R TRUE Nivolumab (PD1 Ab inhibitor) CD274 overexpression CD274 EXPR CD274:over Indirect Clinical Trials PD1 Ab Pembrolizumab Responsive Early trials NCT01848834 ARodriguez-Vida 09/15 BLCA BLCA TRUE Pembrolizumab (PD1 Ab) CD274 amplification CD274 CNA CD274:amp [PDL1 inhibitor] [] Responsive Pre-clinical PMID:25079317 RDientsmann CANCER TRUE PDL1 inhibitors CD69 undexpression CD69 EXPR CD69:under Approved Alkylating agent Bendamustine Responsive Pre-clinical Cell line PMID:26701728 CRubio-Perez 01/16 CLL TRUE Ibrutinib and idelalisib as adjuvants (not added) Bendamustine (Alkylating agent) CDH1 oncogenic mutation CDH1 MUT CDH1:. AR inhibitor Bicalutamide Responsive Pre-clinical PMID:27397505 RDientsmann 07/16 BRCA TRUE Bicalutamide (AR inhibitor) CDK4 oncogenic mutation CDK4 MUT CDK4:. Direct Clinical Trials CDK4/6 inhibitor LEE011 Responsive Early trials NCT02187783;NCT01237236; http://meetinglibrary.asco.org/content/83791-102 CRubio-Perez;DTamborero LIP;LY;CANCER TRUE LEE011 (CDK4/6 inhibitor) CDK4 amplification CDK4 CNA CDK4:amp Direct Clinical Trials CDK4/6 inhibitor LEE011 Responsive Early trials NCT02187783;NCT01237236; http://meetinglibrary.asco.org/content/83791-102 CRubio-Perez;DTamborero LIP;LY;CANCER TRUE LEE011 (CDK4/6 inhibitor) CDK4 amplification + RB1 expression CDK4;RB1 CNA;EXPR CDK4:amp;RB1:norm [CDK4 inhibitor] [] Responsive Early trials PMID:23569312 RDientsmann LIP TRUE CDK4 inhibitors CDK6 oncogenic mutation CDK6 MUT CDK6:. Direct Clinical Trials CDK4/6 inhibitor LEE011 Responsive Early trials NCT02187783;NCT01237236 CRubio-Perez;DTamborero LIP;LY;CANCER TRUE LEE011 (CDK4/6 inhibitor) CDK6 amplification CDK6 CNA CDK6:amp Direct Clinical Trials CDK4/6 inhibitor LEE011 Responsive Early trials NCT02187783;NCT01237236;http://meetinglibrary.asco.org/content/83791-102 CRubio-Perez;DTamborero LIP;LY;CANCER TRUE LEE011 (CDK4/6 inhibitor) CDK6 amplification CDK6 CNA CDK6:amp [CDK6 inhibitor] [] Responsive Pre-clinical PMID:22471707 RDientsmann CANCER TRUE CDK6 inhibitors CDKN1A deletion CDKN1A CNA CDKN1A:del [CDK2/4 inhibitor] [] Responsive Pre-clinical PMID:22471707;PMID:22997239 RDientsmann CANCER TRUE CDK2/4 inhibitors CDKN1A oncogenic mutation CDKN1A MUT CDKN1A:. [CDK2/4 inhibitor] [] Responsive Pre-clinical PMID:22471707;PMID:22997239 RDientsmann CANCER TRUE CDK2/4 inhibitors CDKN1B deletion CDKN1B CNA CDKN1B:del [CDK2/4 inhibitor] [] Responsive Pre-clinical PMID:22471707 RDientsmann CANCER TRUE CDK2/4 inhibitors CDKN1B oncogenic mutation CDKN1B MUT CDKN1B:. [CDK2/4 inhibitor] [] Responsive Pre-clinical PMID:22471707 RDientsmann CANCER TRUE CDK2/4 inhibitors CDKN2A oncogenic mutation CDKN2A MUT CDKN2A:. Indirect Clinical Trials AURKA-VEGF inhibitor Ilorasertib Responsive Early trials NCT02478320 CRubio-Perez;DTamborero CANCER TRUE Ilorasertib (AURKA-VEGF inhibitor) CDKN2A deletion CDKN2A CNA CDKN2A:del Indirect Clinical Trials AURKA-VEGF inhibitor Ilorasertib Responsive Early trials NCT02478320 CRubio-Perez;DTamborero CANCER TRUE Ilorasertib (AURKA-VEGF inhibitor) CDKN2A deletion CDKN2A CNA CDKN2A:del [CDK4/6 inhibitor] [] Responsive Case report ASCO 2013 (abstr 2500) RDientsmann CM TRUE CDK4/6 inhibitors CDKN2A oncogenic mutation CDKN2A MUT CDKN2A:. [CDK4/6 inhibitor] [] Responsive Case report ASCO 2013 (abstr 2500) RDientsmann CM TRUE CDK4/6 inhibitors CDKN2A oncogenic mutation CDKN2A MUT CDKN2A:. [CDK4/6 inhibitor] [] Responsive Pre-clinical PMID:22471707;PMID:22586120;PMID:22711607 RDientsmann G;CANCER TRUE CDK4/6 inhibitors CDKN2A deletion CDKN2A CNA CDKN2A:del [CDK4/6 inhibitor] [] Responsive Pre-clinical PMID:22471707;PMID:22586120;PMID:22711607 RDientsmann G;CANCER TRUE CDK4/6 inhibitors CDKN2B oncogenic mutation CDKN2B MUT CDKN2B:. [CDK4/6 inhibitor] [] Responsive Pre-clinical PMID:22471707;PMID:22711607 RDientsmann G;CANCER TRUE CDK4/6 inhibitors CDKN2B deletion CDKN2B CNA CDKN2B:del [CDK4/6 inhibitor] [] Responsive Pre-clinical PMID:22471707;PMID:22711607 RDientsmann G;CANCER TRUE CDK4/6 inhibitors CDKN2C oncogenic mutation CDKN2C MUT CDKN2C:. [CDK2 inhibitor] [] Responsive Pre-clinical PMID:22471707;PMID:22997239;PMID:22711607 RDientsmann G;CANCER TRUE CDK2 inhibitors CDKN2C deletion CDKN2C CNA CDKN2C:del [CDK2 inhibitor] [] Responsive Pre-clinical PMID:22471707;PMID:22997239;PMID:22711607 RDientsmann G;CANCER TRUE CDK2 inhibitors CHEK2 deletion CHEK2 CNA CHEK2:del PARP inhibitor Olaparib Responsive Early trials AACR 2015 (abstr CT322) RDientsmann PRAD TRUE Olaparib (PARP inhibitor) CHEK2 oncogenic mutation CHEK2 MUT CHEK2:. PARP inhibitor Olaparib Responsive Early trials PMID:26510020;AACR 2015 (abstr CT322) RDientsmann 01/16 PRAD TRUE Olaparib (PARP inhibitor) CRBN undexpression CRBN EXPR CRBN:under Immunomodulator Lenalidomide Resistant Case report PMID:21860026 DTamborero MYMA TRUE several manuscripts reporting that the IMiD resistant patients exhibit lower CRBN expression Lenalidomide (Immunomodulator) CRBN (Q100*,R283K) CRBN MUT CRBN:Q100*,R283K Immunomodulator Lenalidomide Resistant Case report PMID:23480694 DTamborero MYMA TRUE REMAP:Q99 changed to Q100 (meaning that i change from ENSTENST00000432408 to ENST00000231948) (chr3:g.3195747C>T chr3:g.3215822G>A) Lenalidomide (Immunomodulator) CRBN oncogenic mutation CRBN MUT CRBN:. Immunomodulator Lenalidomide Resistant Case report PMID:25108355 DTamborero MYMA TRUE . other mutation disrupting IMID - CRBN or CRBN - ubiqutin complex may confer IMiD resistance Lenalidomide (Immunomodulator) CRBN undexpression CRBN EXPR CRBN:under Immunomodulator Pomalidomide Resistant Case report PMID:21860026 DTamborero MYMA TRUE several manuscripts reporting that the IMiD resistant patients exhibit lower CRBN expression Pomalidomide (Immunomodulator) CRBN (Q100*,R283K) CRBN MUT CRBN:Q100*,R283K Immunomodulator Pomalidomide Resistant Case report PMID:23480694 DTamborero MYMA TRUE REMAP:Q99 changed to Q100 (meaning that i changed from ENSTENST00000432408 to ENST00000231948) (chr3:g.3195747C>T chr3:g.3215822G>A) Pomalidomide (Immunomodulator) CRBN oncogenic mutation CRBN MUT CRBN:. Immunomodulator Pomalidomide Resistant Case report PMID:25108355 DTamborero MYMA TRUE IMiD-compound pocket in TBD of the CRBN is formed by three tryptophan residues, Trp380, Trp386 and Trp400 Pomalidomide (Immunomodulator) CRLF2 fusion CRLF2 FUS CRLF2__. [BET inhibitor] [] Responsive Pre-clinical PMID:22904298 RDientsmann 01/16 ALL TRUE BET inhibitors CRLF2 fusion CRLF2 FUS CRLF2__. [MTOR inhibitor] [] Responsive Pre-clinical PMID:22955920 RDientsmann 01/16 ALL TRUE MTOR inhibitors CSF1R (Y571D) CSF1R MUT CSF1R:Y571D BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive Pre-clinical PMID:18971950 RDientsmann MDPS TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) CSF3R (Q741,Y752,W791,T615A,T618I) CSF3R MUT CSF3R:Q741.,Y752.,W791.,T615A,T618I BCR-ABL inhibitor 2nd gen Dasatinib Responsive Pre-clinical PMID:23656643 RDientsmann 01/16 ACML TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) CSF3R frameshift variant (D771),frameshift variant (S783) CSF3R MUT CSF3R::consequence::frameshift_variant:D771.,::frameshift_variant:S783. BCR-ABL inhibitor 2nd gen Dasatinib Responsive Pre-clinical PMID:23656643 RDientsmann 01/16 ACML TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) CTNNB1 oncogenic mutation CTNNB1 MUT CTNNB1:. [Tankyrase inhibitor] [] Resistant Pre-clinical PMID:23539443 RDientsmann COREAD TRUE Tankyrase inhibitors CTNNB1 (H36Y,S37C,S37Y,D32V) CTNNB1 MUT CTNNB1:H36Y,S37C,S37Y,D32V MTOR inhibitor;Hormonal therapy Everolimus;Letrozole Responsive Early trials PMID:25624430 RDientsmann ED TRUE Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy) CYP17A1 expression CYP17A1 EXPR CYP17A1:norm Direct Approved AR inhibitor Abiraterone Responsive Early trials PMID:22184395 ARodriguez-Vida 09/15 PRAD PRAD TRUE Abiraterone (AR inhibitor) CYP17A1 expression CYP17A1 EXPR CYP17A1:norm Indirect Approved AR inhibitor Enzalutamide Responsive Early trials PMID:24882673 ARodriguez-Vida 09/15 PRAD PRAD TRUE Enzalutamide (AR inhibitor) DDR2 (S768R) DDR2 MUT DDR2:S768R BCR-ABL inhibitor 2nd gen Dasatinib Responsive Case report PMID:22328973 RDientsmann LUSC TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) DDR2 (I638F,L239R,G253C,G774V,L63V,G505S) DDR2 MUT DDR2:I638F,L239R,G253C,G774V,L63V,G505S BCR-ABL inhibitor 2nd gen Dasatinib Responsive Pre-clinical PMID:22328973 RDientsmann LUSC TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) DDR2 (S768R) DDR2 MUT DDR2:S768R EGFR inhibitor 1st gen Erlotinib Responsive Case report PMID:22328973 RDientsmann LUSC TRUE Erlotinib (EGFR inhibitor 1st gen) DNMT3A oncogenic mutation DNMT3A MUT DNMT3A:. Approved Chemotherapy Daunorubicin Responsive FDA guidelines PMID:22417203 RDientsmann AML TRUE Daunorubicin (Chemotherapy) DPYD biallelic inactivation DPYD BIA DPYD:. Approved Fluoropyrimidine Capecitabine Increased Toxicity FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Capecitabine (Fluoropyrimidine) DPYD splice donor variant DPYD MUT DPYD::consequence::splice_donor_variant:. Approved Fluoropyrimidine Capecitabine Increased Toxicity FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Capecitabine (Fluoropyrimidine) DPYD (I560S,D949V) DPYD MUT DPYD:I560S,D949V Approved Fluoropyrimidine Capecitabine Increased Toxicity FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Capecitabine (Fluoropyrimidine) DPYD biallelic inactivation DPYD BIA DPYD:. Approved Fluoropyrimidine Flourouracil Increased Toxicity FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Flourouracil (Fluoropyrimidine) DPYD splice donor variant DPYD MUT DPYD::consequence::splice_donor_variant:. Approved Fluoropyrimidine Flourouracil Increased Toxicity FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Flourouracil (Fluoropyrimidine) DPYD (I560S,D949V) DPYD MUT DPYD:I560S,D949V Approved Fluoropyrimidine Flourouracil Increased Toxicity FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Flourouracil (Fluoropyrimidine) DPYD biallelic inactivation DPYD BIA DPYD:. Approved Fluoropyrimidine Tegafur Increased Toxicity CPIC guidelines PMID:23988873 DTamborero;CRubio-Perez 01/16 CANCER TRUE Tegafur (Fluoropyrimidine) DPYD splice donor variant DPYD MUT DPYD::consequence::splice_donor_variant:. Approved Fluoropyrimidine Tegafur Increased Toxicity CPIC guidelines PMID:23988873 DTamborero;CRubio-Perez 01/16 CANCER TRUE Tegafur (Fluoropyrimidine) DPYD (I560S,D949V) DPYD MUT DPYD:I560S,D949V Approved Fluoropyrimidine Tegafur Increased Toxicity CPIC guidelines PMID:23988873 DTamborero;CRubio-Perez 01/16 CANCER TRUE Tegafur (Fluoropyrimidine) EGFR (D761Y) EGFR MUT EGFR:D761Y [EGFR inhibitor 1st gen] [] Resistant Case report PMID:19680293 DTamborero NSCLC TRUE EGFR inhibitor 1st gens EGFR (T790M) EGFR MUT EGFR:T790M [EGFR inhibitor 1st gen] [] Resistant Late trials PMID:19680293 DTamborero 01/16 NSCLC TRUE EGFR inhibitor 1st gens EGFR (T790M) EGFR MUT EGFR:T790M [EGFR inhibitor 2nd gen] [] Resistant Late trials PMID:22452896 DTamborero 01/16 NSCLC TRUE EGFR inhibitor 2nd gens EGFR inframe insertion (762-823) EGFR MUT EGFR::consequence::inframe_insertion:762-823 [HSP90 inhibitor] [] Responsive Case report ASCO 2014 (abstr 8015) RDienstmann 01/16 L TRUE HSP90 inhibitors EGFR (T790M) EGFR MUT EGFR:T790M [EGFR inhibitor 3rd gen] [] Responsive Early trials ASCO 2014 (abstr 8009);ENA 2014 (abstr 10LBA);ENA 2014 (abstr 9LBA);ASCO 2015 (abstr 8001) RDientsmann 01/16 L TRUE EGFR inhibitor 3rd gens EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R) EGFR MUT EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R [HSP90 inhibitor] [] Responsive Early trials ESMO 2012 (abstr 4380) RDientsmann 01/16 L TRUE HSP90 inhibitors EGFR (T790M) EGFR MUT EGFR:T790M [HSP90 inhibitor] [] Responsive Early trials ESMO 2012 (abstr 4380) RDientsmann 01/16 L TRUE HSP90 inhibitors EGFR inframe insertion (729-761) EGFR MUT EGFR::consequence::inframe_insertion:729-761 [HSP90 inhibitor] [] Responsive Early trials ESMO 2012 (abstr 4380) RDientsmann 01/16 L TRUE HSP90 inhibitors EGFR amplification EGFR CNA EGFR:amp [EGFR inhibitor 1st gen] [] No Responsive Early trials PMID:16282176;PMID:16278407 RDientsmann G TRUE EGFR inhibitor 1st gens EGFR amplification EGFR CNA EGFR:amp [EGFR inhibitor 2nd gen] [] No Responsive Early trials PMID:16282176;PMID:16278407 RDientsmann G TRUE EGFR inhibitor 2nd gens EGFR amplification EGFR CNA EGFR:amp [EGFR inhibitor 3rd gen] [] No Responsive Early trials PMID:16282176;PMID:16278407 RDientsmann G TRUE EGFR inhibitor 3rd gens EGFR amplification EGFR CNA EGFR:amp [EGFR mAb inhibitor] [] Responsive Late trials PMID:18794099;PMID:17664472 RDientsmann COREAD TRUE EGFR mAb inhibitors EGFR inframe deletion (30-336) EGFR MUT EGFR::consequence::inframe_deletion:30-336 [EGFR inhibitor 1st gen] [] No Responsive Early trials PMID:19204207 RDientsmann G TRUE EGFR inhibitor 1st gens EGFR inframe deletion (30-336) EGFR MUT EGFR::consequence::inframe_deletion:30-336 [EGFR inhibitor 2nd gen] [] No Responsive Early trials PMID:19204207 RDientsmann G TRUE EGFR inhibitor 2nd gens EGFR inframe deletion (30-336) EGFR MUT EGFR::consequence::inframe_deletion:30-336 [EGFR inhibitor 3rd gen] [] No Responsive Early trials PMID:19204207 RDientsmann G TRUE EGFR inhibitor 3rd gens EGFR inframe insertion (762-823) EGFR MUT EGFR::consequence::inframe_insertion:762-823 [EGFR inhibitor 1st gen] [] Resistant Late trials PMID:21764376;PMID:21764376 RDientsmann L TRUE EGFR inhibitor 1st gens EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R) EGFR MUT EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R [EGFR TK inhibitor] [] Responsive Late trials PMID:22753918 RDientsmann 01/16 L TRUE EGFR TK inhibitors EGFR inframe insertion (729-761) EGFR MUT EGFR::consequence::inframe_insertion:729-761 [EGFR TK inhibitor] [] Responsive Late trials PMID:22753918 RDientsmann 01/16 L TRUE EGFR TK inhibitors EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M) EGFR MUT EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M [MEK inhibitor (alone or in combination)] [] Responsive Pre-clinical PMID:23102728 RDientsmann 01/16 L TRUE MEK inhibitor (alone or in combination)s EGFR inframe insertion (729-761) EGFR MUT EGFR::consequence::inframe_insertion:729-761 [MEK inhibitor (alone or in combination)] [] Responsive Pre-clinical PMID:23102728 RDientsmann 01/16 L TRUE MEK inhibitor (alone or in combination)s EGFR (C797S) EGFR MUT EGFR:C797S [EGFR inhibitor 3rd gen] [] Resistant Early trials PMID:25939061 RDientsmann L TRUE EGFR inhibitor 3rd gens EGFR (S492R) EGFR MUT EGFR:S492R [novel EGFR mAb inhibitor] [] Responsive Early trials PMID:25962717 RDientsmann 01/16 COREAD TRUE novel EGFR mAb inhibitors EGFR (T790M) EGFR MUT EGFR:T790M [EGFR inhibitor 3rd gen] [Rociletinib,HM61713] Responsive Late trials NCT02322281 CRubio-Perez;RDientsmann 01/16 NSCLC TRUE EGFR inhibitor 3rd gens (Rociletinib,HM61713,etc) EGFR inframe deletion (729-761) EGFR MUT EGFR::consequence::inframe_deletion:729-761 Approved ERBB2 inhibitor&EGFR inhibitor 2nd gen Afatinib Responsive FDA guidelines FDA RDientsmann NSCLC TRUE Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen) EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R) EGFR MUT EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R Approved ERBB2 inhibitor&EGFR inhibitor 2nd gen Afatinib Responsive FDA guidelines FDA RDientsmann NSCLC TRUE Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen) EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R) EGFR MUT EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R Approved ERBB2 inhibitor&EGFR inhibitor 2nd gen Afatinib Responsive NCCN guidelines FDA RDientsmann NSCLC TRUE Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen) EGFR (T790M) EGFR MUT EGFR:T790M ERBB2 inhibitor&EGFR inhibitor 2nd gen Afatinib Resistant NCCN/CAP guidelines NCCN RDientsmann 01/16 L TRUE Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen) EGFR inframe insertion (729-761) EGFR MUT EGFR::consequence::inframe_insertion:729-761 ERBB2 inhibitor&EGFR inhibitor 2nd gen Afatinib Responsive Late trials PMID:22753918;PMID:25589191 RDientsmann 01/16 L TRUE Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen) EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R) EGFR MUT EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor Afatinib;Cetuximab Responsive Early trials ESMO 2012 (abstr 1289) RDientsmann 01/16 L TRUE Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor) EGFR inframe insertion (729-761) EGFR MUT EGFR::consequence::inframe_insertion:729-761 ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor Afatinib;Cetuximab Responsive Early trials ESMO 2012 (abstr 1289) RDientsmann 01/16 L TRUE Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor) EGFR (T790M) EGFR MUT EGFR:T790M ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor Afatinib;Cetuximab Responsive Early trials PMID:25074459 RDientsmann 01/16 L TRUE Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor) EGFR (T790M) EGFR MUT EGFR:T790M ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor Afatinib;Nimotuzumab Responsive Early trials PMID:26667485 RDienstmann 06/16 L TRUE Afatinib + Nimotuzumab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor) EGFR overexpression EGFR EXPR EGFR:over Approved EGFR mAb inhibitor Cetuximab Responsive FDA guidelines FDA CRubio-Perez COREAD TRUE Cetuximab (EGFR mAb inhibitor) EGFR (S492R,G465R,R451C,K467T) EGFR MUT EGFR:S492R,G465R,R451C,K467T EGFR mAb inhibitor Cetuximab Resistant Case report PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827 RDientsmann 07/16 COREAD TRUE Cetuximab (EGFR mAb inhibitor) EGFR (P546S) EGFR MUT EGFR:P546S EGFR mAb inhibitor Cetuximab Responsive Case report PMID:23578570 RDientsmann 01/16 HNC TRUE Cetuximab (EGFR mAb inhibitor) EGFR (S464L,G465R,I491M) EGFR MUT EGFR:S464L,G465R,I491M Approved EGFR mAb inhibitor Cetuximab Resistant Pre-clinical PMID:25623215 RDientsmann COREAD TRUE Cetuximab (EGFR mAb inhibitor) EGFR (P753S) EGFR MUT EGFR:P753S EGFR mAb inhibitor;MTOR inhibitor Cetuximab;Sirolimus Responsive Case report PMID:24934779 RDientsmann 01/16 HNC TRUE Cetuximab + Sirolimus (EGFR mAb inhibitor + MTOR inhibitor) EGFR-RAD51 fusion EGFR FUS EGFR__RAD51 Approved EGFR inhibitor 1st gen Erlotinib Responsive Case report PMID:27102076 EArriola 06/16 NSCLC TRUE Erlotinib (EGFR inhibitor 1st gen) EGFR amplification EGFR CNA EGFR:amp Approved EGFR inhibitor 1st gen Erlotinib No Responsive Early trials ASCO2015(abstre19028) RDientsmann L TRUE Erlotinib (EGFR inhibitor 1st gen) EGFR inframe deletion (729-761) EGFR MUT EGFR::consequence::inframe_deletion:729-761 Approved EGFR inhibitor 1st gen Erlotinib Responsive FDA guidelines FDA RDientsmann NSCLC TRUE Erlotinib (EGFR inhibitor 1st gen) EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R) EGFR MUT EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R Approved EGFR inhibitor 1st gen Erlotinib Responsive FDA guidelines FDA RDientsmann NSCLC TRUE Erlotinib (EGFR inhibitor 1st gen) EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R) EGFR MUT EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R Approved EGFR inhibitor 1st gen Erlotinib Responsive NCCN guidelines FDA RDientsmann NSCLC TRUE Erlotinib (EGFR inhibitor 1st gen) EGFR (T790M) EGFR MUT EGFR:T790M EGFR inhibitor 1st gen Erlotinib Resistant NCCN/CAP guidelines NCCN RDientsmann 01/16 L TRUE Erlotinib (EGFR inhibitor 1st gen) EGFR (A289V,R108K,G598V,T263P) EGFR MUT EGFR:A289V,R108K,G598V,T263P Approved EGFR inhibitor 1st gen Erlotinib Responsive Pre-clinical PMID:17177598 RDientsmann G TRUE Erlotinib (EGFR inhibitor 1st gen) EGFR inframe insertion (729-761) EGFR MUT EGFR::consequence::inframe_insertion:729-761 Approved EGFR inhibitor 1st gen Erlotinib Responsive Early trials PMID:22190593 RDientsmann L TRUE Erlotinib (EGFR inhibitor 1st gen) EGFR-RAD51 fusion EGFR FUS EGFR__RAD51 EGFR inhibitor 1st gen Erlotinib Responsive Case report PMID:27102076 RDientsmann 07/16 L TRUE Erlotinib (EGFR inhibitor 1st gen) EGFR inframe deletion (729-761) EGFR MUT EGFR::consequence::inframe_deletion:729-761 Approved EGFR inhibitor 1st gen Gefitinib Responsive FDA guidelines FDA RDientsmann NSCLC TRUE Gefitinib (EGFR inhibitor 1st gen) EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R) EGFR MUT EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R Approved EGFR inhibitor 1st gen Gefitinib Responsive FDA guidelines FDA RDientsmann NSCLC TRUE Gefitinib (EGFR inhibitor 1st gen) EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R) EGFR MUT EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R Approved EGFR inhibitor 1st gen Gefitinib Responsive NCCN guidelines FDA RDientsmann NSCLC TRUE Gefitinib (EGFR inhibitor 1st gen) EGFR inframe deletion (L747),inframe insertion (P753PS) EGFR MUT EGFR::consequence::inframe_deletion:L747.,::inframe_insertion:P753PS Approved EGFR inhibitor 1st gen Gefitinib No Responsive Case report PMID:21274259 RDientsmann HNC TRUE Gefitinib (EGFR inhibitor 1st gen) EGFR (V843I) EGFR MUT EGFR:V843I Approved EGFR inhibitor 1st gen Gefitinib No Responsive Case report PMID:21274259 RDientsmann HNC TRUE Gefitinib (EGFR inhibitor 1st gen) EGFR amplification EGFR CNA EGFR:amp Approved EGFR inhibitor 1st gen Gefitinib No Responsive Early trials PMID:21274259;PMID:22261807 RDientsmann HNC TRUE Gefitinib (EGFR inhibitor 1st gen) EGFR amplification EGFR CNA EGFR:amp Approved EGFR inhibitor 1st gen Gefitinib Responsive Late trials PMID:24950987 RDientsmann ED TRUE Gefitinib (EGFR inhibitor 1st gen) EGFR (E690K) EGFR MUT EGFR:E690K Approved ERBB2 inhibitor Lapatinib Responsive Case report PMID:22885469 RDientsmann ED TRUE Lapatinib (ERBB2 inhibitor) EGFR (L858R) EGFR MUT EGFR:L858R Approved EGFR inhibitor 3rd gen Osimertinib Responsive Early trials NCT02465060 CRubio-Perez 01/16 L TRUE Osimertinib (EGFR inhibitor 3rd gen) EGFR inframe deletion (729-761) EGFR MUT EGFR::consequence::inframe_deletion:729-761 Approved EGFR inhibitor 3rd gen Osimertinib Responsive Early trials NCT02465060 CRubio-Perez 01/16 L TRUE Osimertinib (EGFR inhibitor 3rd gen) EGFR (L719Q) EGFR MUT EGFR:L719Q Approved EGFR inhibitor 3rd gen Osimertinib Resistant Pre-clinical,Case report PMID:25948633;PMID:27257132 EArriola 06/16 LUAD TRUE Osimertinib (EGFR inhibitor 3rd gen) EGFR (T790M) EGFR MUT EGFR:T790M Approved EGFR inhibitor 3rd gen Osimertinib Responsive FDA guidelines FDA RDienstmann 01/16 NSCLC TRUE Osimertinib (EGFR inhibitor 3rd gen) EGFR inframe insertion (762-823) EGFR MUT EGFR::consequence::inframe_insertion:762-823 EGFR inhibitor 3rd gen Osimertinib Responsive Pre-clinical PMID:26515464 RDienstmann 01/16 L TRUE Insertion exon 20 Osimertinib (EGFR inhibitor 3rd gen) EGFR overexpression EGFR EXPR EGFR:over Approved EGFR mAb inhibitor Panitumumab Resistant FDA guidelines FDA guidelines CRubio-Perez;RDientsmann COREAD TRUE Panitumumab (EGFR mAb inhibitor) EGFR (S492R) EGFR MUT EGFR:S492R EGFR mAb inhibitor Panitumumab Responsive Case report PMID:22270724 RDientsmann 01/16 COREAD TRUE Panitumumab (EGFR mAb inhibitor) EGFR (G465R) EGFR MUT EGFR:G465R EGFR mAb inhibitor Panitumumab Resistant Case report PMID:26059438 RDientsmann 01/16 COREAD TRUE Panitumumab (EGFR mAb inhibitor) EGFR inframe deletion (6-273) EGFR MUT EGFR::consequence::inframe_deletion:6-273 Indirect Clinical Trials Vaccine Rindopepimut Responsive Late trials NCT01480479 MMartínez 09/15 GB TRUE he EGFRvIII variant receptor is characterized by a deletion of exons 2–7 of the wild type (Wt) EGFR gene. This results in an in-frame truncation of amino acids (AA) 6 to 273 in the extracellular domain of the full length protein, Rindopepimut (Vaccine) EGFR (L798I) EGFR MUT EGFR:L798I EGFR inhibitor Rociletinib Resistant Case report PMID:27283993 RDientsmann 07/16 LUAD TRUE Rociletinib (EGFR inhibitor) EGFR amplification EGFR CNA EGFR:amp [EGFR inhibitor] [] Responsive Case report PMID:26763254 RDientsmann 07/16 HNSC TRUE EGFR inhibitors EPHA2 (G391R) EPHA2 MUT EPHA2:G391R [MTOR inhibitor] [] Responsive Pre-clinical PMID:20360610 RDientsmann 01/16 LUSC TRUE MTOR inhibitors EPHA2 (G391R) EPHA2 MUT EPHA2:G391R [MTOR inhibitor] [] Responsive Pre-clinical PMID:20360610 RDientsmann LUSC TRUE MTOR inhibitors EPHA2 amplification EPHA2 CNA EPHA2:amp BCR-ABL inhibitor 2nd gen Dasatinib Responsive Pre-clinical PMID:18047674;PMID:19010823;PMID:19861960 RDientsmann 01/16 CANCER TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) EPHA2 amplification EPHA2 CNA EPHA2:amp BCR-ABL inhibitor 2nd gen Dasatinib Responsive Pre-clinical PMID:18047674;PMID:19010823;PMID:19861960 RDientsmann CANCER TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) EPHA2 (G391R) EPHA2 MUT EPHA2:G391R BCR-ABL inhibitor 2nd gen Dasatinib Responsive Pre-clinical PMID:20360610 RDientsmann 01/16 LUSC TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) EPHA2 (G391R) EPHA2 MUT EPHA2:G391R BCR-ABL inhibitor 2nd gen Dasatinib Responsive Pre-clinical PMID:20360610 RDientsmann LUSC TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) EPHA3 amplification EPHA3 CNA EPHA3:amp [EPHA3 inhibitor] [] Responsive Pre-clinical PMID:25125683 RDientsmann 01/16 CANCER TRUE EPHA3 inhibitors EPHA3 amplification EPHA3 CNA EPHA3:amp [EPHA3 inhibitor] [] Responsive Pre-clinical PMID:25125683 RDientsmann CANCER TRUE EPHA3 inhibitors ERBB2 overexpression ERBB2 EXPR ERBB2:over Approved ERBB2 mAb inhibitor Ado-Trastuzumab Emtansine Responsive FDA guidelines FDA CRubio-Perez BRCA TRUE Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) ERBB2 overexpression ERBB2 EXPR ERBB2:over Approved ERBB2 inhibitor Lapatinib Responsive FDA guidelines FDA CRubio-Perez BRCA TRUE Lapatinib (ERBB2 inhibitor) ERBB2 overexpression ERBB2 EXPR ERBB2:over Approved ERBB2 mAb inhibitor Pertuzumab Responsive FDA guidelines FDA CRubio-Perez BRCA TRUE Pertuzumab (ERBB2 mAb inhibitor) ERBB2 overexpression ERBB2 EXPR ERBB2:over Approved ERBB2 mAb inhibitor Trastuzumab Responsive FDA guidelines FDA CRubio-Perez BRCA TRUE Trastuzumab (ERBB2 mAb inhibitor) ERBB2 overexpression ERBB2 EXPR ERBB2:over Approved ERBB2 mAb inhibitor Trastuzumab Responsive FDA guidelines FDA CRubio-Perez ST;GEJA TRUE Trastuzumab (ERBB2 mAb inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 mAb inhibitor Trastuzumab Responsive FDA guidelines FDA CRubio-Perez 04/16 ST;GEJA TRUE Trastuzumab (ERBB2 mAb inhibitor) ERBB2 overexpression ERBB2 EXPR ERBB2:over Allosteric AKT inhibitor;ERBB2 mAb inhibitor MK2206;Trastuzumab Responsive Early trials ASCO 2013 (abstr 2605);PMID:26104654 DCasadevall SOLID TRUE MK2206 + Trastuzumab (Allosteric AKT inhibitor + ERBB2 mAb inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 mAb inhibitor Trastuzumab No Responsive Early trials PMID:26099744;PMID:19840887 DTamborero;RDientsmann ED TRUE Trastuzumab (ERBB2 mAb inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp [EGFR inhibitor] [] Resistant Pre-clinical PMID:22956644 EArriola 06/16 LUAD TRUE EGFR inhibitors ERBB2 oncogenic mutation ERBB2 MUT ERBB2:. Pan ERBB inhibitor Dacomitinib Responsive Early trials PMID:25899785 EArriola 06/16 NSCLC TRUE Dacomitinib (Pan ERBB inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp Approved 3rd generation EGFR inhibitor Osimertinib Resistant Case report PMID:27252416 EArriola 06/16 LUAD TRUE Osimertinib (3rd generation EGFR inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp 3rd generation EGFR inhibitor Rociletinib Resistant Case report PMID:27252416 EArriola 06/16 LUAD TRUE Rociletinib (3rd generation EGFR inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp [ERBB2 inhibitor;CDK4/6 inhibitor] [] Responsive Pre-clinical PMID:26977878 RDientsmann 04/16 BRCA TRUE ERBB2 inhibitor + CDK4/6 inhibitors ERBB2 amplification ERBB2 CNA ERBB2:amp [EGFR mAb inhibitor] [] Resistant Early trials PMID:22586653;PMID:23348520 RDientsmann COREAD TRUE EGFR mAb inhibitors ERBB2 inframe insertion (775-881) ERBB2 MUT ERBB2::consequence::inframe_insertion:775-881 [ERBB2 inhibitor] [Afatinib,Lapatinib,Neratinib] Responsive Early trials PMID:26598547 RDientsmann LUAD TRUE ERBB2 inhibitors (Afatinib,Lapatinib,Neratinib,etc) ERBB2 inframe insertion (775-881) ERBB2 MUT ERBB2::consequence::inframe_insertion:775-881 [ERBB2 mAb inhibitor] [Trastuzumab] Responsive Early trials PMID:26598547 RDientsmann LUAD TRUE ERBB2 mAb inhibitors (Trastuzumab,etc) ERBB2 amplification ERBB2 CNA ERBB2:amp EGFR mAb inhibitor Ado-Trastuzumab Emtansine Responsive FDA guidelines FDA RDientsmann 04/16 BRCA TRUE Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2&EGFR inhibitor 2nd gen Afatinib Responsive Late trials PMID:20142587;PMID:22418700;PMID:23632474 RDientsmann 04/16 BRCA TRUE Afatinib (ERBB2&EGFR inhibitor 2nd gen) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2&EGFR inhibitor 2nd gen Afatinib Responsive Case report AACR 2014 (abstr CT228) RDientsmann 01/16 ST TRUE Afatinib (ERBB2&EGFR inhibitor 2nd gen) ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A) ERBB2 MUT ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A ERBB2 inhibitor Lapatinib Responsive Pre-clinical PMID:23220880 RDientsmann BRCA TRUE Lapatinib (ERBB2 inhibitor) ERBB2 (V659E) ERBB2 MUT ERBB2:V659E ERBB2 inhibitor Lapatinib Responsive Case report PMID:23950206 RDientsmann BRCA;LUAD TRUE Lapatinib (ERBB2 inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 inhibitor Lapatinib Responsive Early trials ASCO 2015 (abstr e15137) RDientsmann 11/15 BT TRUE Lapatinib (ERBB2 inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 inhibitor;Chemotherapy Lapatinib;Chemotherapy Responsive Early trials PMID:25694417;NCT02015169 RDientsmann 01/16 ST TRUE Lapatinib + Chemotherapy (ERBB2 inhibitor + Chemotherapy) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 inhibitor Neratinib Responsive Late trials PMID:20142587;PMID:22418700;PMID:23632474 RDientsmann 04/16 BRCA TRUE Neratinib (ERBB2 inhibitor) ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I) ERBB2 MUT ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I ERBB2 inhibitor Neratinib Responsive Pre-clinical PMID:23220880 RDientsmann BRCA TRUE Neratinib (ERBB2 inhibitor) ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP) ERBB2 MUT ERBB2::consequence::inframe_deletion:755-759,::inframe_insertion:.780GSP,::inframe_insertion:.781GSP ERBB2 inhibitor Neratinib Responsive Pre-clinical PMID:23220880 RDientsmann BRCA TRUE Neratinib (ERBB2 inhibitor) ERBB2 oncogenic mutation ERBB2 MUT ERBB2:. ERBB2 inhibitor Neratinib Responsive Early trials ESMO 2014 (abstr LBA39_PR) RDientsmann LUAD TRUE Neratinib (ERBB2 inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 mAb inhibitor Pertuzumab Responsive Early trials ASCO 2015 (abstr e15137) RDientsmann 11/15 BT TRUE Pertuzumab (ERBB2 mAb inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 mAb inhibitor Pertuzumab Responsive Early trials PMID:24960402 RDientsmann 01/16 ST TRUE Pertuzumab (ERBB2 mAb inhibitor) ERBB2 oncogenic mutation ERBB2 MUT ERBB2:. MTOR inhibitor Tensirolimus Responsive Early trials ESMO 2014 (abstr LBA39_PR) RDientsmann LUAD TRUE Tensirolimus (MTOR inhibitor) ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R) ERBB2 MUT ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R ERBB2 mAb inhibitor Trastuzumab Responsive Pre-clinical PMID:23220880;PMID:22908275 RDientsmann BRCA;CANCER TRUE Trastuzumab (ERBB2 mAb inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 mAb inhibitor Trastuzumab Responsive Early trials ASCO 2015 (abstr e15137) RDientsmann 11/15 BT TRUE Trastuzumab (ERBB2 mAb inhibitor) ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S) ERBB2 MUT ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S ERBB2 mAb inhibitor Trastuzumab Responsive Pre-clinical PMID:22908275 RDientsmann CANCER TRUE Trastuzumab (ERBB2 mAb inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 mAb inhibitor Trastuzumab Responsive Case report PMID:21380780 RDientsmann HNC TRUE Trastuzumab (ERBB2 mAb inhibitor) ERBB2 (G776L) ERBB2 MUT ERBB2:G776L ERBB2 mAb inhibitor Trastuzumab Responsive Case report PMID:16775247 RDientsmann LUAD TRUE Trastuzumab (ERBB2 mAb inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 mAb inhibitor Trastuzumab Responsive Early trials PMID:20003286;PMID:12525520 RDientsmann OV TRUE Trastuzumab (ERBB2 mAb inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy Trastuzumab;Everolimus;Chemotherapy Responsive Early trials PMID:21107682;PMID:20975068 RDientsmann 04/16 BRCA TRUE Trastuzumab + Everolimus + Chemotherapy (ERBB2 mAb inhibitor + MTOR inhibitor + Chemotherapy) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 mAb inhibitor;HSP90 inhibitor Trastuzumab;HSP90 inhibitor Responsive Early trials PMID:21558407 RDientsmann 04/16 BRCA TRUE Trastuzumab + HSP90 inhibitor (ERBB2 mAb inhibitor + HSP90 inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 mAb inhibitor;ERBB2 inhibitor Trastuzumab;Lapatinib Responsive Late trials ASCO 2015 (abstr 3508);NCT01104571;EBCC10 RDientsmann 01/16 COREAD TRUE Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 mAb inhibitor;ERBB2 inhibitor Trastuzumab;Lapatinib Responsive Pre-clinical PMID:25294905 RDientsmann 01/16 ED TRUE Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 inhibitor Lapatinib Responsive FDA guidelines FDA RDientsmann;CRubio-Perez 04/16 BRCA TRUE Lapatinib (ERBB2 inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 mAb inhibitor Pertuzumab Responsive FDA guidelines FDA RDientsmann;CRubio-Perez 04/16 BRCA TRUE Pertuzumab (ERBB2 mAb inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2 mAb inhibitor Trastuzumab Responsive FDA guidelines FDA RDientsmann;CRubio-Perez 04/16 BRCA TRUE Trastuzumab (ERBB2 mAb inhibitor) ERBB2 amplification ERBB2 CNA ERBB2:amp ERBB2&EGFR inhibitor 2nd gen Afatinib Responsive Case report PMID:27044931 RDientsmann 07/16 BLCA TRUE Afatinib (ERBB2&EGFR inhibitor 2nd gen) ERBB2 expression + ESR1 overexpression ERBB2;ESR1 EXPR;EXPR ERBB2:norm;ESR1:over Approved CDK4/6 inhibitor Palbociclib Responsive FDA guidelines FDA CRubio-Perez BRCA TRUE http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf Palbociclib (CDK4/6 inhibitor) ERBB2 expression + ESR1 overexpression ERBB2;ESR1 EXPR;EXPR ERBB2:norm;ESR1:over CDK4/6 inhibitor Abemaciclib Responsive Early trials PMID:26658964 DTamborero;CRubio-Perez 04/16 BRCA TRUE Abemaciclib (CDK4/6 inhibitor) ERBB2 expression + ESR1 overexpression ERBB2;ESR1 EXPR;EXPR ERBB2:norm;ESR1:over Approved [Hormonal therapy] [Tamoxifen,Letrozole,Anastrozole,Exemestane,Fulvestrant,LHRH analogues or antagonist] Responsive FDA guidelines FDA JAlbanell;ARovira 09/15 BRCA TRUE Hormonal therapys (Tamoxifen,Letrozole,Anastrozole,Exemestane,Fulvestrant,LHRH analogues or antagonist,etc) ERBB2 expression + ESR1 overexpression ERBB2;ESR1 EXPR;EXPR ERBB2:norm;ESR1:over Approved MTOR inhibitor Everolimus Responsive FDA guidelines FDA JAlbanell;ARovira 09/15 BRCA TRUE HER2- (not overexpressed and not amplified) and ER+ (>1% positive tumor cells) Everolimus (MTOR inhibitor) ERBB3 (P262H,G284R) ERBB3 MUT ERBB3:P262H,G284R [ERBB3 mAb inhibitor] [] Responsive Pre-clinical PMID:23680147 RDientsmann CANCER TRUE ERBB3 mAb inhibitors ERBB3 (P262H,G284R,Q809R) ERBB3 MUT ERBB3:P262H,G284R,Q809R [PI3K pathway inhibitor;MEK inhibitor] [] Responsive Pre-clinical PMID:23680147 RDientsmann CANCER TRUE PI3K pathway inhibitor + MEK inhibitors ERBB3 amplification ERBB3 CNA ERBB3:amp [EGFR mAb inhibitor] [] Resistant Early trials PMID:25520391 RDientsmann COREAD TRUE EGFR mAb inhibitors ERBB3 (G284R,R103G) ERBB3 MUT ERBB3:G284R,R103G ERBB2&EGFR inhibitor 2nd gen Afatinib Responsive Case report ASCO 2015 (abstr e15516) RDientsmann BLCA TRUE Afatinib (ERBB2&EGFR inhibitor 2nd gen) ERBB3 (P262H,G284R,Q809R) ERBB3 MUT ERBB3:P262H,G284R,Q809R ERBB2 inhibitor Lapatinib Responsive Pre-clinical PMID:23680147 RDientsmann CANCER TRUE Lapatinib (ERBB2 inhibitor) ERBB3 (P262H,G284R) ERBB3 MUT ERBB3:P262H,G284R ERBB2 mAb inhibitor Pertuzumab Responsive Pre-clinical PMID:23680147 RDientsmann CANCER TRUE Pertuzumab (ERBB2 mAb inhibitor) ERBB3 (P262H,G284R,Q809R) ERBB3 MUT ERBB3:P262H,G284R,Q809R ERBB2 mAb inhibitor Trastuzumab Responsive Pre-clinical PMID:23680147 RDientsmann CANCER TRUE Trastuzumab (ERBB2 mAb inhibitor) ERBB3 (G284R,V104M,R103G) ERBB3 MUT ERBB3:G284R,V104M,R103G ERBB2&EGFR inhibitor 2nd gen Afatinib Responsive Case report PMID:27044931 RDientsmann 07/16 BLCA TRUE Afatinib (ERBB2&EGFR inhibitor 2nd gen) ERBB4 (H809G) ERBB4 MUT ERBB4:H809G [ERBB2 inhibitor] [Lapatinib] Resistant Case report PMID:26530965 RDientsmann 11/15 BRCA TRUE ERBB2 inhibitors (Lapatinib,etc) ERBB4 (E317K,E452K,R544W,R393W,E872K) ERBB4 MUT ERBB4:E317K,E452K,R544W,R393W,E872K ERBB2 inhibitor Lapatinib Responsive Pre-clinical PMID:19718025 RDientsmann CM TRUE Lapatinib (ERBB2 inhibitor) ERBB4 fusion ERBB4 FUS ERBB4__. ERBB2 inhibitor;ERBB2 inhibitor&EGFR inhibitor 2nd gen Lapatinib;Afatinib Responsive Pre-clinical PMID:24727320 RDientsmann LUAD TRUE Lapatinib + Afatinib (ERBB2 inhibitor + ERBB2 inhibitor&EGFR inhibitor 2nd gen) ERCC1 overexpression ERCC1 EXPR ERCC1:over Approved Chemotherapy Cisplatin Resistant Pre-clinical PMID:20846399;PMID:21177407 ARodriguez-Vida 09/15 BLCA BLCA TRUE Cisplatin (Chemotherapy) ERCC1 oncogenic mutation ERCC1 MUT ERCC1:. [PARP inhibitor] [] Responsive Pre-clinical PMID:23934192 RDientsmann L TRUE PARP inhibitors ERCC1 deletion ERCC1 CNA ERCC1:del [PARP inhibitor] [] Responsive Pre-clinical PMID:23934192 RDientsmann L TRUE PARP inhibitors ERCC1 oncogenic mutation ERCC1 MUT ERCC1:. Chemotherapy Cisplatin Responsive Pre-clinical PMID:23275151;PMID:23934192 RDientsmann 01/16 L TRUE Cisplatin (Chemotherapy) ERCC1 deletion ERCC1 CNA ERCC1:del Chemotherapy Cisplatin Responsive Pre-clinical PMID:23275151;PMID:23934192 RDientsmann 01/16 L TRUE Cisplatin (Chemotherapy) ERCC2 oncogenic mutation ERCC2 MUT ERCC2:. Chemotherapy Cisplatin Responsive Early trials PMID:25096233 RDientsmann BLCA TRUE Cisplatin (Chemotherapy) ERCC4 oncogenic mutation ERCC4 MUT ERCC4:. Chemotherapy Cisplatin Responsive Pre-clinical PMID:25634215 RDientsmann OV TRUE Cisplatin (Chemotherapy) ERCC6 oncogenic mutation ERCC6 MUT ERCC6:. Chemotherapy Cisplatin Responsive Pre-clinical PMID:25634215 RDientsmann OV TRUE Cisplatin (Chemotherapy) EREG amplification EREG CNA EREG:amp [EGFR mAb inhibitor] [] Responsive Early trials PMID:19738126;PMID:26341080 RDientsmann 04/16 COREAD TRUE EGFR mAb inhibitors ESR1 (E380Q,537,538,L536,P535H) ESR1 MUT ESR1:E380Q,.537.,.538.,L536.,P535H [novel ER degrader] [GDC-0810] Responsive Case report AACR 2015 (abstr CT231) RDienstmann 01/16 BRCA TRUE novel ER degraders (GDC-0810,etc) ESR1-YAP1 fusion ESR1 FUS ESR1__YAP1 [ESR1 inhibitor] [] Resistant Pre-clinical PMID:24055055 RDientsmann BRCA TRUE ESR1 inhibitors ESR1 oncogenic mutation ESR1 MUT ESR1:. Hormonal therapy Exemestane Resistant Late trials PMID:27269946 RDientsmann 06/16 BRCA TRUE Exemestane (Hormonal therapy) ESR1 oncogenic mutation ESR1 MUT ESR1:. Hormonal therapy Fluvestrant Responsive Late trials PMID:27269946 RDientsmann 06/16 BRCA TRUE Fluvestrant (Hormonal therapy) ESR1 (E380Q,537,538,L536,P535H) ESR1 MUT ESR1:E380Q,.537.,.538.,L536.,P535H Hormonal therapy Tamoxifen Resistant Early trials PMID:24185512;PMID:24185510;PMID:24398047 RDientsmann BRCA TRUE Tamoxifen (Hormonal therapy) EZH2 (Y641,A677) EZH2 MUT EZH2:Y641.,A677. Direct Pre-clinical [EZH2 inhibitor] [EPZ-005687,EPZ-6438] Responsive Pre-clinical Cell line PMID:23023262;PMID:24563539 RDientsmann;ECampo LY TRUE EZH2 inhibitors (EPZ-005687,EPZ-6438,etc) FANCA oncogenic mutation FANCA MUT FANCA:. PARP inhibitor Olaparib Responsive Case report PMID:26510020 RDienstmann 01/16 PRAD TRUE Olaparib (PARP inhibitor) FANCA deletion FANCA CNA FANCA:del PARP inhibitor Olaparib Responsive Case report PMID:26510020 RDienstmann 01/16 PRAD TRUE Olaparib (PARP inhibitor) FANCC oncogenic mutation FANCC MUT FANCC:. Indirect Approved Chemotherapy Cisplatin Responsive Early trials PMID:26238431 ARodriguez-Vida 09/15 BLCA BLCA TRUE Cisplatin (Chemotherapy) FANCC deletion FANCC CNA FANCC:del Indirect Approved Chemotherapy Cisplatin Responsive Early trials PMID:26238431 ARodriguez-Vida 09/15 BLCA BLCA TRUE Cisplatin (Chemotherapy) FAT1 oncogenic mutation FAT1 MUT FAT1:. [BET inhibitor] [] Responsive Pre-clinical PMID:27397505 RDientsmann 07/16 HNSC TRUE BET inhibitors FBXW7 deletion FBXW7 CNA FBXW7:del Indirect Approved MTOR inhibitor Sirolimus Responsive Pre-clinical Cell line PMID:23558291 CRubio-Perez COREAD TRUE Sirolimus (MTOR inhibitor) FBXW7 oncogenic mutation FBXW7 MUT FBXW7:. [Steroid] [] Responsive Late trials PMID:20861909 RDientsmann 01/16 ALL TRUE Steroids FBXW7 deletion FBXW7 CNA FBXW7:del [Tubulin inhibitor] [] Resistant Pre-clinical PMID:21368834 RDientsmann CANCER TRUE Tubulin inhibitors FBXW7 oncogenic mutation FBXW7 MUT FBXW7:. [Tubulin inhibitor] [] Resistant Pre-clinical PMID:21368834 RDientsmann CANCER TRUE Tubulin inhibitors FGF3 amplification FGF3 CNA FGF3:amp Indirect Clinical Trials FGFR inhibitor Lucitanib Responsive Early trials PMID:25193991 JAlbanell;ARovira 09/15 BRCA TRUE Lucitanib (FGFR inhibitor) FGF3 amplification FGF3 CNA FGF3:amp FGFR inhibitor Dovitinib Responsive Early trials PMID:23658459 RDientsmann BRCA TRUE Dovitinib (FGFR inhibitor) FGF4 amplification FGF4 CNA FGF4:amp Indirect Clinical Trials FGFR inhibitor Lucitanib Responsive Early trials PMID:25193991 JAlbanell;ARovira 09/15 BRCA TRUE Lucitanib (FGFR inhibitor) FGF4 amplification FGF4 CNA FGF4:amp FGFR inhibitor Dovitinib Responsive Early trials PMID:23658459 RDientsmann BRCA TRUE Dovitinib (FGFR inhibitor) FGFR1 amplification FGFR1 CNA FGFR1:amp [FGFR inhibitor] [] Responsive Early trials AACR 2012 (abstr LB-122);AACR 2013 (abstr LB-145) RDientsmann LUSC TRUE FGFR inhibitors FGFR1 amplification FGFR1 CNA FGFR1:amp [FGFR inhibitor] [] Responsive Pre-clinical PMID:23418312 RDientsmann HNC TRUE FGFR inhibitors FGFR1 amplification FGFR1 CNA FGFR1:amp [FGFR inhibitor] [Lucitanib] Responsive Early trials PMID:25193991 RDientsmann;JAlbanell BRCA TRUE FGFR inhibitors (Lucitanib,etc) FGFR2 amplification FGFR2 CNA FGFR2:amp [FGFR inhibitor] [] Responsive Early trials ASCO 2015 (abstr 2508) RDientsmann 01/16 ST TRUE FGFR inhibitors FGFR2 fusion FGFR2 FUS FGFR2__. [FGFR inhibitor] [] Responsive Early trials ASCO 2016 (abstr 109) RDientsmann BT TRUE FGFR inhibitors FGFR2 (V565I) FGFR2 MUT FGFR2:V565I [FGFR inhibitor] [] Responsive Pre-clinical ENA 2014 (abstr 381) RDientsmann 01/16 ED TRUE FGFR inhibitors FGFR2 (S252W,N550K) FGFR2 MUT FGFR2:S252W,N550K [FGFR inhibitor] [] Responsive Pre-clinical PMID:18552176;PMID:22238366;PMID:23002168 RDientsmann ED TRUE REMAP: N549K to N500K to have all mutations in same transcript (ENST00000457416) FGFR inhibitors FGFR2 (W290C,S320C,K660N) FGFR2 MUT FGFR2:W290C,S320C,K660N [FGFR inhibitor] [] Responsive Pre-clinical PMID:23786770;PMID:25035393 RDientsmann LUSC TRUE FGFR inhibitors FGFR2 amplification FGFR2 CNA FGFR2:amp [FGFR inhibitor] [] Responsive Case report PMID:25193991 RDientsmann 01/16 BRCA TRUE FGFR inhibitors FGFR2 inframe insertion (A266),inframe insertion (S267) FGFR2 MUT FGFR2::consequence::inframe_insertion:A266.,::inframe_insertion:S267. [FGFR inhibitor] [] Responsive Pre-clinical PMID:26048680 RDientsmann 01/16 L TRUE FGFR inhibitors FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E) FGFR2 MUT FGFR2:V565I,M536I,M538I,I548V,N550.,E566G,L618M,K660E FGFR inhibitor Dovitinib Resistant Pre-clinical PMID:23908597 RDientsmann ED TRUE Dovitinib (FGFR inhibitor) FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E) FGFR2 MUT FGFR2:M536I,M538I,I548V,N550.,E566G,L618M,K660E BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor Ponatinib Responsive Pre-clinical PMID:23908597 RDientsmann 01/16 ED TRUE Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor) FGFR3-TACC3 fusion FGFR3 FUS FGFR3__TACC3 [FGFR inhibitor] Responsive Pre-clinical PMID:25294908 EArriola 06/16 NSCLC TRUE FGFR inhibitors (,etc) FGFR3 oncogenic mutation FGFR3 MUT FGFR3:. [FGFR inhibitor] [] Responsive Early trials AACR 2014 (abstr CT326) RDientsmann 01/16 BLCA TRUE FGFR inhibitors FGFR3 (K650,Y373C) FGFR3 MUT FGFR3:K650.,Y373C [FGFR inhibitor] [] Responsive Pre-clinical PMID:16091734;PMID:20439987;PMID:22869148 RDientsmann 01/16 MYMA TRUE FGFR inhibitors FGFR3 (V555M) FGFR3 MUT FGFR3:V555M [FGFR inhibitor] [] Resistant Pre-clinical PMID:22869148 RDientsmann MYMA TRUE FGFR inhibitors FGFR3 fusion FGFR3 FUS FGFR3__. [FGFR inhibitor] [] Responsive Case report PMID:26324363 RDientsmann 01/16 BLCA TRUE FGFR inhibitors FGFR3 fusion FGFR3 FUS FGFR3__. [FGFR inhibitor] [] Responsive Early trials PMID:26324363 RDientsmann 01/16 G TRUE FGFR inhibitors FGFR3 (Y373C) FGFR3 MUT FGFR3:Y373C Proteasome inhibitor Bortezomib Resistant Pre-clinical PMID:19331127;PMID:21273588 RDientsmann MYMA TRUE Bortezomib (Proteasome inhibitor) FGFR3 (K650) FGFR3 MUT FGFR3:K650. Proteasome inhibitor Bortezomib Responsive Pre-clinical PMID:19331127;PMID:21273588 RDientsmann MYMA TRUE Bortezomib (Proteasome inhibitor) FGFR4 (N535,V550) FGFR4 MUT FGFR4:N535.,V550. [FGFR inhibitor] [] Responsive Pre-clinical PMID:19809159;PMID:24124571 RDientsmann 04/16 RHBDS TRUE REMAP:changed N535 and V550 from K535 and E550. Reference added by carlota FGFR inhibitors FLCN oncogenic mutation FLCN MUT FLCN:. MTOR inhibitor Everolimus Responsive Case report PMID:23995526 RDientsmann 01/16 R TRUE Everolimus (MTOR inhibitor) FLCN deletion FLCN CNA FLCN:del MTOR inhibitor Everolimus Responsive Case report PMID:25295501 RDientsmann 01/16 TH TRUE Everolimus (MTOR inhibitor) FLT1 overexpression FLT1 EXPR VEGFR1:over Direct Approved Pan-TK inhibitor Sunitinib Responsive Pre-clinical Cell line PMID:24086736;PMID:21478036 ARodriguez-Vida 09/15 R TRUE Sunitinib (Pan-TK inhibitor) FLT1 overexpression FLT1 EXPR VEGFR2:over Direct Approved Pan-TK inhibitor Sunitinib Responsive Pre-clinical Cell line PMID:24086736;PMID:21478036 ARodriguez-Vida 09/15 R TRUE Sunitinib (Pan-TK inhibitor) FLT3 (F691) FLT3 MUT FLT3:F691. [novel FLT3 inhibitor] [] Responsive Pre-clinical PMID:25847190 RDientsmann 01/16 AML TRUE novel FLT3 inhibitors FLT3 (N676) FLT3 MUT FLT3:N676. FLT3 inhibitor Crenolanib Responsive Pre-clinical PMID:24619500 RDientsmann 01/16 AML TRUE Crenolanib (FLT3 inhibitor) FLT3 (D835) FLT3 MUT FLT3:D835. Pan-TK inhibitor Lestaurtinib Responsive Case report PMID:16857985 RDientsmann 01/16 AML TRUE Lestaurtinib (Pan-TK inhibitor) FLT3 (D835) FLT3 MUT FLT3:D835. Pan-TK inhibitor Midostaurin Responsive Case report PMID:20733134 RDientsmann 01/16 AML TRUE Midostaurin (Pan-TK inhibitor) FLT3 (N676) FLT3 MUT FLT3:N676. Pan-TK inhibitor Midostaurin Responsive Pre-clinical PMID:24619500 RDientsmann 01/16 AML TRUE Midostaurin (Pan-TK inhibitor) FLT3 (D835,Y842) FLT3 MUT FLT3:D835.,Y842. BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor Ponatinib Resistant Pre-clinical PMID:23430109 RDientsmann 01/16 AML TRUE Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor) FLT3 (F691,D835,N676,Y842) FLT3 MUT FLT3:F691.,D835.,N676.,Y842. Pan-TK inhibitor Quizartinib Resistant Pre-clinical PMID:22504184;PMID:23878140 RDientsmann AML TRUE Quizartinib (Pan-TK inhibitor) FOXA1 amplification FOXA1 CNA FOXA1:amp [BCL2 inhibitor] [] Responsive Pre-clinical PMID:27397505 RDientsmann 07/16 COREAD TRUE BCL2 inhibitors FRS2 amplification FRS2 CNA FRS2:amp [FGFR inhibitor] [] Responsive Pre-clinical PMID:23393200 RDientsmann LIP TRUE FGFR inhibitors G6PD biallelic inactivation G6PD BIA G6PD:. Approved BRAF inhibitor Dabrafenib Increased Toxicity (Haemolytic Anemia) FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Dabrafenib (BRAF inhibitor) G6PD (S218F) G6PD MUT G6PD:S218F Approved BRAF inhibitor Dabrafenib Increased Toxicity (Haemolytic Anemia) FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Dabrafenib (BRAF inhibitor) G6PD (V98M) + G6PD (N156D) G6PD;G6PD MUT;MUT G6PD:V98M;G6PD:N156D Approved BRAF inhibitor Dabrafenib Increased Toxicity (Haemolytic Anemia) FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Dabrafenib (BRAF inhibitor) GATA3 oncogenic mutation GATA3 MUT GATA3:. [Aromatase ihibitor] [] Responsive Pre-clinical PMID:24758297 RDientsmann BRCA TRUE Aromatase ihibitors GNA11 (Q209L,Q209P) GNA11 MUT GNA11:Q209L,Q209P [PI3K pathway inhibitor;MEK inhibitor] [] Responsive Pre-clinical PMID:22733540;PMID:22808163 RDientsmann 01/16 CM TRUE PI3K pathway inhibitor + MEK inhibitors GNA11 (Q209L,Q209P) GNA11 MUT GNA11:Q209L,Q209P MEK inhibitor Selumetinib Responsive Early trials ASCO 2013 (abstr CRA9003) RDientsmann 01/16 CM TRUE Selumetinib (MEK inhibitor) GNA11 (Q209L,Q209P) GNA11 MUT GNA11:Q209L,Q209P HDAC inhibitor Vorinostat Responsive Pre-clinical NCT01587352 RDientsmann 01/16 CM TRUE Vorinostat (HDAC inhibitor) GNAQ (Q209) GNAQ MUT GNAQ:Q209. [HDAC inhibitor] [] Responsive Pre-clinical NCT01587352 RDientsmann 01/16 CM TRUE HDAC inhibitors GNAQ (Q209) GNAQ MUT GNAQ:Q209. [PKC inhibitor] [] Responsive Pre-clinical PMID:22653968;PMID:22253748 RDientsmann 01/16 CM TRUE PKC inhibitors GNAQ (Q209) GNAQ MUT GNAQ:Q209. [PI3K pathway inhibitor;MEK inhibitor] [] Responsive Pre-clinical PMID:22733540;PMID:22808163 RDientsmann 01/16 CM TRUE PI3K pathway inhibitor + MEK inhibitors GNAQ (Q209) GNAQ MUT GNAQ:Q209. MEK inhibitor Selumetinib Responsive Early trials ASCO 2013 (abstr CRA9003) RDientsmann 01/16 CM TRUE Selumetinib (MEK inhibitor) GNAS (R201) GNAS MUT GNAS:R201. [JAK inhibitor] [] Responsive Pre-clinical PMID:21835143 RDientsmann CANCER TRUE JAK inhibitors HDAC2 biallelic inactivation HDAC2 BIA HDAC2:. PARP inhibitor Olaparib Responsive Case report PMID:26510020 RDienstmann;CRubio-Perez 01/16 PRAD TRUE Olaparib (PARP inhibitor) HGF overexpression HGF EXPR HGF:over Indirect Approved Pan-kinase inhibitor Cabozantinib Responsive Pre-clinical Xenograft PMID:25534569 CRubio-Perez;ARodriguez-Vida UTC TRUE Cabozantinib (Pan-kinase inhibitor) HGF amplification + ERBB2 amplification HGF;ERBB2 CNA;CNA HGF:amp;ERBB2:amp ERBB2 mAb inhibitor Trastuzumab Resistant Early trials PMID:22850551 RDientsmann;CRubio-Perez BRCA TRUE Trastuzumab (ERBB2 mAb inhibitor) HIF1A overexpression HIF1A EXPR HIF1A:over Indirect Approved Pan-TK inhibitor Sunitinib Responsive Pre-clinical Cell line PMID:24086736 ARodriguez-Vida 09/15 R TRUE Sunitinib (Pan-TK inhibitor) HRAS oncogenic mutation HRAS MUT HRAS:. [PI3K pathway inhibitor;MEK inhibitor] [] Responsive Pre-clinical PMID:15950068 RDientsmann CER TRUE PI3K pathway inhibitor + MEK inhibitors HRAS oncogenic mutation HRAS MUT HRAS:. [MTOR inhibitor] [] Responsive Pre-clinical PMID:22345164 RDientsmann 01/16 CESC TRUE MTOR inhibitors HRAS oncogenic mutation HRAS MUT HRAS:. [MEK inhibitor +/- MTOR inhibitor] [] Responsive Pre-clinical PMID:22399013;PMID:22507781 RDientsmann AML TRUE MEK inhibitor +/- MTOR inhibitors HRAS oncogenic mutation HRAS MUT HRAS:. Farnesyltransferase inhibitor Tipifarnib Responsive Early trials NCT02383927 RDientsmann 01/16 CANCER TRUE Tipifarnib (Farnesyltransferase inhibitor) HRAS oncogenic mutation HRAS MUT HRAS:. Clinical Trials Farnesyltransferase inhibitor Tipifarnib Responsive Early trials NCT02383927 RDientsmann 11/15 CANCER TRUE Tipifarnib (Farnesyltransferase inhibitor) IDH1 oncogenic mutation IDH1 MUT IDH1:. Indirect Clinical Trials BCR-ABL inhibitor 2nd gen Dasatinib Responsive Early trials NCT02428855 CRubio-Perez CH TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) IDH1 oncogenic mutation IDH1 MUT IDH1:. Direct Clinical Trials IDH1 inhibitor AG-120 Responsive Early trials NCT02073994;PMID:23558169 MMartínez;RDientsmann;CRubio-Perez 09/15 G TRUE AG-120 (IDH1 inhibitor) IDH1 oncogenic mutation IDH1 MUT IDH1:. [IDH1 inhibitor] [] Responsive Early trials ENA 2014 (abstr 1LBA) RDientsmann 01/16 AML TRUE IDH1 inhibitors IDH1 oncogenic mutation IDH1 MUT IDH1:. [BCL2 inhibitor] [] Responsive Pre-clinical PMID:25599133 RDientsmann 01/16 AML TRUE BCL2 inhibitors IDH1 (R132) IDH1 MUT IDH1:R132 BCR-ABL inhibitor 2nd gen Dasatinib Responsive Pre-clinical PMID:27231123 RDientsmann 07/16 BT TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) IDH2 oncogenic mutation IDH2 MUT IDH2:. Indirect Clinical Trials BCR-ABL inhibitor 2nd gen Dasatinib Responsive Early trials NCT02428855 CRubio-Perez CH TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) IDH2 (R140K,R172K) IDH2 MUT IDH2:R140K,R172K Direct Clinical Trials IDH2 inhibitor AG-221 Responsive Early trials AACR 2014 (abstr CT103) RDientsmann HEMATO TRUE AG-221 (IDH2 inhibitor) IDH2 (R172) IDH2 MUT IDH2:R172 BCR-ABL inhibitor 2nd gen Dasatinib Responsive Pre-clinical PMID:27231123 RDientsmann 07/16 BT TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) IGF1R amplification IGF1R CNA IGF1R:amp EGFR inhibitor 1st gen Erlotinib Resistant Pre-clinical PMID:24458568 RDientsmann LUAD TRUE Erlotinib (EGFR inhibitor 1st gen) IGF2 amplification IGF2 CNA IGF2:amp [EGFR mAb inhibitor] [] Resistant Early trials PMID:25632036 RDientsmann COREAD TRUE EGFR mAb inhibitors IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion IL7R;SH2B3 MUT;CNA IL7R::consequence::inframe_insertion:237-255,::inframe_deletion:237-255;SH2B3:del [MTOR inhibitor] [] Responsive Pre-clinical PMID:22955920 RDientsmann 01/16 ALL TRUE MTOR inhibitors IL7R (S185C) + SH2B3 deletion IL7R;SH2B3 MUT;CNA IL7R:S185C;SH2B3:del [MTOR inhibitor] [] Responsive Pre-clinical PMID:22955920 RDientsmann 01/16 ALL TRUE MTOR inhibitors IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion IL7R;SH2B3 MUT;CNA IL7R::consequence::inframe_insertion:237-255,::inframe_deletion:237-255;SH2B3:del JAK inhibitor Ruxolitinib Responsive Pre-clinical PMID:22897847;PMID:22955920 RDientsmann 01/16 ALL TRUE Ruxolitinib (JAK inhibitor) IL7R (S185C) + SH2B3 deletion IL7R;SH2B3 MUT;CNA IL7R:S185C;SH2B3:del JAK inhibitor Ruxolitinib Responsive Pre-clinical PMID:22897847;PMID:22955920 RDientsmann 01/16 ALL TRUE Ruxolitinib (JAK inhibitor) INPP4B deletion INPP4B CNA INPP4B:del [PI3K pathway inhibitor] [] Responsive Pre-clinical PMID:23551093 RDientsmann BRCA TRUE PI3K pathway inhibitors INPP4B oncogenic mutation INPP4B MUT INPP4B:. [PI3K pathway inhibitor] [] Responsive Pre-clinical PMID:23551093 RDientsmann BRCA TRUE PI3K pathway inhibitors JAK1 (S646F;R683) JAK1 MUT JAK1:S646F;R683. JAK inhibitor Ruxolitinib Responsive Pre-clinical PMID:22955920;PMID:18805579 RDientsmann 01/16 ALL TRUE Ruxolitinib (JAK inhibitor) JAK1 oncogenic mutation JAK1 MUT JAK1:. [PD1 inhibitor] [] Resistant Case report PMID:27433843 RDientsmann 07/16 CM TRUE PD1 inhibitors JAK2 (V617F) JAK2 MUT JAK2:V617F [JAK inhibitor (alone or in combination)] [] Responsive Pre-clinical PMID:22829971 RDientsmann 01/16 AML TRUE JAK inhibitor (alone or in combination)s JAK2 amplification JAK2 CNA JAK2:amp [JAK inhibitor] [] Responsive Pre-clinical PMID:27075627 RDientsmann 06/16 BRCA TRUE JAK inhibitors JAK2 (V617F) JAK2 MUT JAK2:V617F Approved JAK inhibitor Ruxolitinib Responsive FDA guidelines FDA RDientsmann MY TRUE Ruxolitinib (JAK inhibitor) JAK2 (V617F) JAK2 MUT JAK2:V617F JAK inhibitor Ruxolitinib Responsive Early trials PMID:22422826 RDientsmann 01/16 AML TRUE Ruxolitinib (JAK inhibitor) JAK2-BRAF fusion JAK2 FUS JAK2__BRAF JAK inhibitor Ruxolitinib Responsive Pre-clinical PMID:22875628;PMID:22899477 RDientsmann 01/16 ALL TRUE Ruxolitinib (JAK inhibitor) JAK2 oncogenic mutation JAK2 MUT JAK2:. [PD1 inhibitor] [] Resistant Case report PMID:27433843 RDientsmann 07/16 CM TRUE PD1 inhibitors JAK3 (R657Q,I87T,Q501H) JAK3 MUT JAK3:R657Q,I87T,Q501H [JAK inhibitor] [] Responsive Pre-clinical PMID:18397343 RDientsmann MKB TRUE JAK inhibitors JAK3 (A572V,A573V) JAK3 MUT JAK3:A572V,A573V [JAK inhibitor] [] Responsive Pre-clinical PMID:22705984 RDientsmann LY TRUE JAK inhibitors KCNJ5 (L168R) KCNJ5 MUT KCNJ5:L168R Indirect Approved Na-Ca chanel blocker Amiloride Responsive Pre-clinical Cell line PMID:24506072 ECampo AA TRUE Amiloride (Na-Ca chanel blocker) KCNJ5 (L168R) KCNJ5 MUT KCNJ5:L168R Indirect Approved Na-Ca chanel blocker Verapamil Responsive Pre-clinical Cell line PMID:24506072 ECampo AA TRUE Verapamil (Na-Ca chanel blocker) KDR (A1065T) KDR MUT KDR:A1065T [VEGFR inhibitor] [] Responsive Pre-clinical PMID:24569783 RDientsmann CANCER TRUE VEGFR inhibitors KIT (449-514,550-592,627-664,664-714,788-828) KIT MUT KIT:449-514,550-592,627-664,664-714,788-828 Approved BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive FDA guidelines FDA CRubio-Perez;DTamborero;RDientsmann GIST TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) KIT (D816) KIT MUT KIT:D816. Approved BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Resistant FDA guidelines FDA CRubio-Perez;DTamborero;RDientsmann GIST;MDS;MDPS;HES;ECL;CML;ALL;SM TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) KIT (D816Y,D816F,D816V) KIT MUT KIT:D816Y,D816F,D816V BCR-ABL inhibitor 2nd gen Dasatinib Responsive Pre-clinical PMID:16397263 CRubio-Perez;RDientsmann CANCER TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) KIT (788-828,449-514) KIT MUT KIT:788-828,449-514 [HSP90 inhibitor] [] Responsive Pre-clinical PMID:21737509 RDientsmann 01/16 GIST TRUE HSP90 inhibitors KIT (550-592) KIT MUT KIT:550-592 [HSP90 inhibitor] [] Responsive Early trials PMID:22898035 RDientsmann 01/16 GIST TRUE HSP90 inhibitors KIT wildtype KIT MUT KIT::wildtype:. BCR-ABL inhibitor 2nd gen Dasatinib Responsive Pre-clinical PMID:16397263 RDientsmann 01/16 GIST TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) KIT (D816V) KIT MUT KIT:D816V BCR-ABL inhibitor 2nd gen Dasatinib Responsive Early trials PMID:18559612 RDientsmann 01/16 SM TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) KIT (D816V) KIT MUT KIT:D816V BCR-ABL inhibitor 2nd gen Dasatinib Responsive Case report PMID:18986703 RDientsmann 01/16 AML TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) KIT mutation in exon 11 or 13 KIT MUT KIT:550-592,627-664 BCR-ABL inhibitor 2nd gen Dasatinib Responsive Case report PMID:19671763 RDientsmann 01/16 CM TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) KIT (N822K) KIT MUT KIT:N822K BCR-ABL inhibitor 2nd gen Dasatinib Responsive Pre-clinical PMID:23149070 RDientsmann AML TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) KIT mutation in exon 11 or 13 KIT MUT KIT:550-592,627-664 Approved BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive NCCN guidelines NCCN RDientsmann CM TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) KIT inframe deletion (V560) KIT MUT KIT::consequence::inframe_deletion:V560. BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive Case report PMID:15201427 RDientsmann 01/16 THYM TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) KIT inframe deletion (416-422),inframe insertion (416-422) KIT MUT KIT::consequence::inframe_deletion:416-422,::inframe_insertion:416-422 BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive Pre-clinical PMID:15618474 RDientsmann AML TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) KIT mutation in exon 11 or 13 KIT MUT KIT:550-592,627-664 BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive Late trials PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812 RDientsmann 01/16 CM TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) KIT wildtype KIT MUT KIT::wildtype:. BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Resistant Late trials PMID:18955458 RDientsmann GIST TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) KIT (627-664,664-714,449-514) KIT MUT KIT:627-664,664-714,449-514 BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Resistant Late trials PMID:18955458;PMID:18955451;PMID:16624552 RDientsmann 01/16 GIST TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) KIT mutation in exon 17 or 18 KIT MUT KIT:788-828,829-860 BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Resistant Early trials PMID:21690468;PMID:21642685 RDientsmann CM TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) KIT (Y553N) KIT MUT KIT:Y553N BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive Case report PMID:21969494 RDientsmann 01/16 THYM TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D) KIT MUT KIT:V559I,H697Y,T670.,V654A,A829P,D816.,N822.,Y823D BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Resistant Pre-clinical PMID:23582185;PMID:21689725;PMID:17259998 RDientsmann GIST TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) KIT amplification KIT CNA KIT:amp BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib No Responsive Early trials PMID:23775962 RDientsmann CM TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) KIT (D820Y) KIT MUT KIT:D820Y BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive Case report PMID:23775962 RDientsmann 01/16 CM TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) KIT (788-828) KIT MUT KIT:788-828 BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Resistant Pre-clinical PMID:23840364 RDientsmann 01/16 GIST TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) KIT (T670I) KIT MUT KIT:T670I BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Resistant Case report PMID:24687822 RDientsmann GIST TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) KIT mutation in exon 11 or 13 KIT MUT KIT:550-592,627-664 BCR-ABL inhibitor 2nd gen Nilotinib Responsive Early trials PMID:22068222;PMID:25695690 RDientsmann 01/16 CM TRUE Nilotinib (BCR-ABL inhibitor 2nd gen) KIT (788-828) KIT MUT KIT:788-828 BCR-ABL inhibitor 2nd gen Nilotinib Responsive Early trials PMID:22119758;PMID:21456006 RDientsmann 01/16 GIST TRUE Nilotinib (BCR-ABL inhibitor 2nd gen) KIT (D820Y) KIT MUT KIT:D820Y BCR-ABL inhibitor 2nd gen Nilotinib Responsive Case report PMID:25695690 RDientsmann 01/16 CM TRUE Nilotinib (BCR-ABL inhibitor 2nd gen) KIT (788-828,829-860,550-592) KIT MUT KIT:788-828,829-860,550-592 BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor Ponatinib Responsive Early trials ASCO 2015 (abstr 10517);PMID:25239608;ASCO 2015 (abstr 10535) RDientsmann 01/16 GIST TRUE Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor) KIT (A829P,V654A,T670I) KIT MUT KIT:A829P,V654A,T670I BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor Ponatinib Responsive Pre-clinical PMID:25239608 RDientsmann GIST TRUE Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor) KIT (449-514,550-592,627-664,664-714,788-828) KIT MUT KIT:449-514,550-592,627-664,664-714,788-828 Approved Pan-kinase inhibitor Regorafenib Responsive FDA guidelines FDA RDientsmann GIST TRUE Exon 9,11,14,17 Regorafenib (Pan-kinase inhibitor) KIT wildtype KIT MUT KIT::wildtype:. Pan-TK inhibitor Sorafenib Responsive Early trials ASCO 2011 (abstr 10009) RDientsmann 01/16 GIST TRUE Sorafenib (Pan-TK inhibitor) KIT (550-592,627-664,788-828,829-860) KIT MUT KIT:550-592,627-664,788-828,829-860 Pan-TK inhibitor Sorafenib Responsive Case report PMID:18936790;PMID:20372153 RDientsmann 01/16 CM TRUE Sorafenib (Pan-TK inhibitor) KIT (D820E) KIT MUT KIT:D820E Pan-TK inhibitor Sorafenib Responsive Case report PMID:19461405 RDientsmann 01/16 THYM TRUE Sorafenib (Pan-TK inhibitor) KIT inframe deletion (577-579) KIT MUT KIT::consequence::inframe_deletion:577-579 Pan-TK inhibitor Sorafenib Responsive Case report PMID:20970876 RDientsmann 01/16 THYM TRUE Sorafenib (Pan-TK inhibitor) KIT (550-592,449-514) KIT MUT KIT:550-592,449-514 Pan-TK inhibitor Sorafenib Responsive Early trials PMID:22270258 RDientsmann 01/16 GIST TRUE Sorafenib (Pan-TK inhibitor) KIT (788-828) KIT MUT KIT:788-828 Pan-TK inhibitor Sorafenib Responsive Pre-clinical PMID:23840364 RDientsmann 01/16 GIST TRUE Sorafenib (Pan-TK inhibitor) KIT (449-514,550-592,627-664,664-714,788-828) KIT MUT KIT:449-514,550-592,627-664,664-714,788-828 Approved Pan-TK inhibitor Sunitinib Responsive FDA guidelines FDA RDientsmann GIST TRUE Sunitinib (Pan-TK inhibitor) KIT mutation in exon 11 or 13 KIT MUT KIT:550-592,627-664 Pan-TK inhibitor Sunitinib Responsive Late trials PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812 RDientsmann 01/16 CM TRUE Sunitinib (Pan-TK inhibitor) KIT (550-592) KIT MUT KIT:550-592 Pan-TK inhibitor Sunitinib Resistant Late trials PMID:18955458 RDientsmann 01/16 GIST TRUE Sunitinib (Pan-TK inhibitor) KIT wildtype KIT MUT KIT::wildtype:. Pan-TK inhibitor Sunitinib Responsive Late trials PMID:18955458 RDientsmann 01/16 GIST TRUE Sunitinib (Pan-TK inhibitor) KIT (H697Y) KIT MUT KIT:H697Y Pan-TK inhibitor Sunitinib Responsive Pre-clinical PMID:19861435 RDientsmann 01/16 THYM TRUE Sunitinib (Pan-TK inhibitor) KIT (H697Y) KIT MUT KIT:H697Y Pan-TK inhibitor Sunitinib Responsive Pre-clinical PMID:19861435 RDientsmann THYM TRUE Sunitinib (Pan-TK inhibitor) KIT amplification KIT CNA KIT:amp Pan-TK inhibitor Sunitinib No Responsive Early trials PMID:22261812 RDientsmann 01/16 CM TRUE Sunitinib (Pan-TK inhibitor) KIT (Y553N) KIT MUT KIT:Y553N Pan-TK inhibitor Sunitinib Responsive Case report PMID:23375402 RDientsmann 01/16 THYM TRUE Sunitinib (Pan-TK inhibitor) KIT (788-828) KIT MUT KIT:788-828 Pan-TK inhibitor Sunitinib Resistant Pre-clinical PMID:23840364 RDientsmann 01/16 GIST TRUE Sunitinib (Pan-TK inhibitor) KMT2D oncogenic mutation KMT2D MUT KMT2D:. AR inhibitor Bicalutamide Responsive Pre-clinical PMID:27397505 RDientsmann 07/16 LUSC TRUE Bicalutamide (AR inhibitor) KRAS oncogenic mutation KRAS MUT KRAS:. [EGFR inhibitor] [] Resistant Pre-clinical PMID:19238210 DTamborero NSCLC TRUE EGFR inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [pan-RAF inhibitor] [] Responsive Case report AACR 2016 (abstr CT005) RDientsmann 06/16 ED;L TRUE pan-RAF inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [FAS inhibitor] [] Responsive Case report AACR 2016, abstr LB214 RDientsmann 06/16 L TRUE FAS inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [FAS inhibitor] [] Responsive Case report AACR 2016;abstr RDientsmann 04/16 L TRUE FAS inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [PI3K pathway inhibitor;MEK inhibitor] [] No Responsive Early trials ASCO 2015 (abstr 4119) RDientsmann 01/16 PA TRUE PI3K pathway inhibitor + MEK inhibitors KRAS amplification KRAS CNA KRAS:amp [BRAF inhibitor;EGFR mAb inhibitor] [] Resistant Case report ENA 2014 (abstr 428) RDientsmann COREAD TRUE BRAF inhibitor + EGFR mAb inhibitors KRAS amplification KRAS CNA KRAS:amp [BRAF inhibitor;MEK inhibitor] [] Resistant Case report ENA 2014 (abstr 428) RDientsmann COREAD TRUE BRAF inhibitor + MEK inhibitors KRAS (G12) KRAS MUT KRAS:G12. [MEK inhibitor] [] Responsive Pre-clinical PMID:18701506 RDientsmann 01/16 ALL TRUE MEK inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [CDK4 inhibitor] [] Responsive Pre-clinical PMID:20609353 RDientsmann 04/16 L TRUE CDK4 inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [EGFR inhibitor 1st gen] [] Resistant NCCN guidelines PMID:20921461 RDientsmann L TRUE EGFR inhibitor 1st gens KRAS oncogenic mutation KRAS MUT KRAS:. [EGFR inhibitor 2nd gen] [] Resistant NCCN guidelines PMID:20921461 RDientsmann L TRUE EGFR inhibitor 2nd gens KRAS oncogenic mutation KRAS MUT KRAS:. [PI3K pathway inhibitor;MEK inhibitor] [] Responsive Pre-clinical PMID:21984976;PMID:22662154;PMID:22985491 RDientsmann 01/16 ED;MYMA TRUE PI3K pathway inhibitor + MEK inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [MEK inhibitor;PI3K pathway inhibitor] [] Responsive Pre-clinical PMID:22392911 RDientsmann 01/16 COREAD TRUE MEK inhibitor + PI3K pathway inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [MEK inhibitor] [] Responsive Pre-clinical PMID:22507781;PMID:22169769;PMID:19018267 RDientsmann AML;CER;OV TRUE MEK inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [EGFR mAb inhibitor] [] Resistant Pre-clinical PMID:22614881;PMID:22290393 RDientsmann ST TRUE EGFR mAb inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [PI3K pathway inhibitor] [] Resistant Pre-clinical PMID:22662154 RDientsmann ED TRUE PI3K pathway inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [HSP90 inhibitor (in combination)] [] Responsive Pre-clinical PMID:23012248;PMID:21907929 RDientsmann 04/16 L TRUE HSP90 inhibitor (in combination)s KRAS oncogenic mutation KRAS MUT KRAS:. [BET inhibitor] [] Responsive Pre-clinical PMID:23129625;PMID:24045185 RDientsmann 04/16 L TRUE BET inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [MEK inhibitor] [] Responsive Early trials PMID:23200175;PMID:24947927;PMID:25667274;PMID:25722381;PMID:23391555 RDientsmann 04/16 L;BT TRUE MEK inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [MEK inhibitor;BCL-XL inhibitor] [] Responsive Pre-clinical PMID:23245996 RDientsmann 01/16 COREAD TRUE MEK inhibitor + BCL-XL inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [FAK inhibitor] [] Responsive Pre-clinical PMID:23358651 RDientsmann 04/16 L TRUE FAK inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [ERK inhibitor] [] Responsive Pre-clinical PMID:23614898 RDientsmann 01/16 COREAD TRUE ERK inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [MEK inhibitor;IGF1R inhibitor] [] Responsive Pre-clinical PMID:24045180 RDientsmann 01/16 COREAD TRUE MEK inhibitor + IGF1R inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [MTOR inhibitor;BH3 mimetics] [] Responsive Pre-clinical PMID:24163374 RDientsmann 01/16 COREAD TRUE MTOR inhibitor + BH3 mimeticss KRAS oncogenic mutation KRAS MUT KRAS:. [JAK/TBK1/IKKε inhibitor] [] Responsive Pre-clinical PMID:24444711 RDientsmann 04/16 L TRUE JAK/TBK1/IKKε inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [EGFR mAb inhibitor;MEK inhibitor] [] Responsive Pre-clinical PMID:24553387 RDientsmann 01/16 COREAD TRUE EGFR mAb inhibitor + MEK inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [PI3K pathway inhibitor;MEK inhibitor] [] Responsive Early trials PMID:25516890 RDientsmann 04/16 L TRUE PI3K pathway inhibitor + MEK inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [EZH2 inhibitor] [] Resistant Pre-clinical PMID:26552009 RDientsmann 01/16 CANCER TRUE EZH2 inhibitors KRAS oncogenic mutation KRAS MUT KRAS:. [CDK4/6 inhibitor] [Palbociclib,Abemaciclib] Responsive Early trials PMID:26658964;NCT01291017 DTamborero;CRubio-Perez 04/16 NSCLC TRUE CDK4/6 inhibitors (Palbociclib,Abemaciclib,etc) KRAS oncogenic mutation KRAS MUT KRAS:. CDK4/6 inhibitor Abemaciclib Responsive Early trials PMID:27231123 RDientsmann 07/16 LUAD TRUE Abemaciclib (CDK4/6 inhibitor) KRAS oncogenic mutation KRAS MUT KRAS:. Approved EGFR mAb inhibitor Cetuximab Resistant FDA guidelines FDA guidelines CRubio-Perez;RDientsmann COREAD TRUE KRAS:.; no seria tambe NRAS?? Cetuximab (EGFR mAb inhibitor) KRAS (G13D) KRAS MUT KRAS:G13D EGFR mAb inhibitor Cetuximab No Responsive Late trials PMID:27114605 RDientsmann 06/16 COREAD TRUE Cetuximab (EGFR mAb inhibitor) KRAS oncogenic mutation KRAS MUT KRAS:. Chemotherapy;BCL2 inhibitor Decitabine;BCL2 inhibitor Responsive Pre-clinical PMID:25968887 RDientsmann 01/16 OV TRUE Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor) KRAS oncogenic mutation KRAS MUT KRAS:. Chemotherapy;MEK inhibitor Gemcitabine;MEK inhibitor Responsive Early trials PMID:23583440 RDientsmann 01/16 PA TRUE Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor) KRAS (G12) KRAS MUT KRAS:G12. BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Resistant Case report PMID:24687822 RDientsmann GIST TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) KRAS oncogenic mutation KRAS MUT KRAS:. Approved EGFR mAb inhibitor Panitumumab Resistant FDA guidelines FDA guidelines CRubio-Perez;RDientsmann COREAD TRUE Panitumumab (EGFR mAb inhibitor) KRAS oncogenic mutation KRAS MUT KRAS:. Pan-kinase inhibitor Regorafenib Resistant FDA guidelines FDA guidelines CRubio-Perez;RDientsmann COREAD COREAD TRUE Regorafenib (Pan-kinase inhibitor) KRAS oncogenic mutation KRAS MUT KRAS:. Clinical Trials MEK inhibitor Selumetinib Responsive Early trials NCT00890825 EArriola 09/15 NSCLC TRUE Selumetinib (MEK inhibitor) KRAS oncogenic mutation KRAS MUT KRAS:. MEK inhibitor Selumetinib No Responsive Early trials PMID:26802155 RDientsmann 04/16 L TRUE Selumetinib (MEK inhibitor) KRAS oncogenic mutation KRAS MUT KRAS:. Pan-TK inhibitor;MEK inhibitor Sorafenib;MEK inhibitor Responsive Early Trials,Case Report PMID:25294897 RDientsmann 01/16 HC TRUE Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor) KRAS oncogenic mutation KRAS MUT KRAS:. MEK inhibitor;BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor Trametinib;Ponatinib Responsive Pre-clinical PMID:27338794 RDientsmann 07/16 LUAD TRUE Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor) KRAS oncogenic mutation KRAS MUT KRAS:. ERBB2 mAb inhibitor;ERBB2 inhibitor Trastuzumab;Lapatinib Resistant Late trials ASCO 2015 (abstr 3508);NCT01104571;EBCC10 RDientsmann 01/16 COREAD TRUE Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor) LRP1B oncogenic mutation LRP1B MUT LRP1B:. Chemotherapy Liposomal Doxorubicin Resistant Early trials PMID:22896685 RDientsmann OV TRUE Liposomal Doxorubicin (Chemotherapy) LRP1B deletion LRP1B CNA LRP1B:del Chemotherapy Liposomal Doxorubicin Resistant Early trials PMID:22896685 RDientsmann OV TRUE Liposomal Doxorubicin (Chemotherapy) MAP2K1 (Q56P,P124S,P124L) MAP2K1 MUT MAP2K1:Q56P,P124S,P124L [MEK inhibitor] [] Resistant Case report PMID:19915144 DTamborero 03/16 CM TRUE MEK inhibitors MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N) MAP2K1 MUT MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N [MEK inhibitor] [] Resistant Pre-clinical PMID:19915144 RDientsmann CANCER TRUE Reference added by carlota MEK inhibitors MAP2K1 (P124L,K57N,C121S) MAP2K1 MUT MAP2K1:P124L,K57N,C121S [MEK inhibitor] [] Resistant Case report PMID:19915144;PMID:23444215;PMID:21383288 RDientsmann CM TRUE MEK inhibitors MAP2K1 (F129L,L215P,I103N,P124) MAP2K1 MUT MAP2K1:F129L,L215P,I103N,P124. [ERK inhibitor] [] Responsive Pre-clinical PMID:23614898 RDientsmann 01/16 CANCER TRUE ERK inhibitors MAP2K1 (C121S) MAP2K1 MUT MAP2K1:C121S [novel MEK inhibitor] [] Responsive Pre-clinical PMID:24448821 RDientsmann 01/16 CM TRUE novel MEK inhibitors MAP2K1 (P124) MAP2K1 MUT MAP2K1:P124. [BRAF inhibitor] [] Resistant Early trials PMID:25370473 RDientsmann CM TRUE BRAF inhibitors MAP2K1 (P124) MAP2K1 MUT MAP2K1:P124. [ERK inhibitor] [] Responsive Pre-clinical PMID:25370473 RDientsmann 01/16 CM TRUE ERK inhibitors MAP2K1 oncogenic mutation MAP2K1 MUT MAP2K1:. [EGFR mAb inhibitor] [] Resistant Case report PMID:26030179 RDientsmann COREAD TRUE EGFR mAb inhibitors MAP2K1 (K57T) MAP2K1 MUT MAP2K1:K57T EGFR mAb inhibitor;MEK inhibitor Panitumumab;Trametinib Responsive Case report PMID:26644315 RDientsmann 04/16 COREAD TRUE Panitumumab + Trametinib (EGFR mAb inhibitor + MEK inhibitor) MAP2K1 inframe deletion (56-60) MAP2K1 MUT MAP2K1::consequence::inframe_deletion:56-60 MEK inhibitor Selumetinib Responsive Case report PMID:26324360 RDientsmann 01/16 OV TRUE Selumetinib (MEK inhibitor) MAP2K1 (Q56P) MAP2K1 MUT MAP2K1:Q56P MEK inhibitor Trametinib Responsive Pre-clinical PMID:26582713 RDientsmann 04/16 CANCER TRUE Trametinib (MEK inhibitor) MAP2K1 (E203K,Q56P,K57E) MAP2K1 MUT MAP2K1:E203K,Q56P,K57E BRAF inhibitor Vemurafenib Resistant Case report PMID:23569304 RDientsmann CM TRUE Vemurafenib (BRAF inhibitor) MAP2K1 (Q56P,P124S,P124L;C121S) MAP2K1 MUT MAP2K1:Q56P,P124S,P124L;C121S [BRAF inhibitor] [] Resistant Case report PMID:19915144;PMID:21383288 RDientsmann;DTamborero 03/16 CM TRUE BRAF inhibitors MAP2K1 (P124S,I111S) + BRAF oncogenic mutation MAP2K1;BRAF MUT;MUT MAP2K1:P124S,I111S;BRAF:. [BRAF inhibitor] [] Responsive Case report PMID:22588879 RDientsmann 01/16 CM TRUE BRAF inhibitors MAP2K2 (V35M,L46F,N126D,C125S) MAP2K2 MUT MAP2K2:V35M,L46F,N126D,C125S [BRAF inhibitor] [] Resistant Pre-clinical PMID:24265153 RDientsmann CM TRUE BRAF inhibitors MAP2K2 (V35M,L46F,N126D,C125S) MAP2K2 MUT MAP2K2:V35M,L46F,N126D,C125S [MEK inhibitor] [] Resistant Pre-clinical PMID:24265153 RDientsmann CM TRUE MEK inhibitors MAP2K2 (Q60P) MAP2K2 MUT MAP2K2:Q60P [BRAF inhibitor] [] Resistant Case report PMID:24265154 RDientsmann CM TRUE BRAF inhibitors MAP2K2 (Q60P) MAP2K2 MUT MAP2K2:Q60P [MEK inhibitor] [] Resistant Case report PMID:24265154 RDientsmann CM TRUE MEK inhibitors MCL1 amplification MCL1 CNA MCL1:amp [Tubulin inhibitor] [] Resistant Pre-clinical PMID:21368834 RDientsmann CANCER TRUE Tubulin inhibitors MDM2 amplification MDM2 CNA MDM2:amp [MDM2 inhibitor] [] Responsive Early trials PMID:23084521;ASCO 2015 (abstr 10564) RDientsmann 01/16 LIP TRUE MDM2 inhibitors MDM4 amplification MDM4 CNA MDM4:amp [MDM2/MDMX inhibitor] [] Responsive Pre-clinical PMID:24336067 RDientsmann S TRUE MDM2/MDMX inhibitors MET amplification MET CNA MET:amp [EGFR inhibitor 1st gen] [] Resistant Early trials PMID:22189054;PMID:23729478 DTamborero NSCLC;COREAD TRUE EGFR inhibitor 1st gens MET amplification MET CNA MET:amp Approved [EGFR inhibitor 3rd gen] Osimertinib Resistant Case report PMID:27252416 EArriola 06/16 LUAD TRUE EGFR inhibitor 3rd gens (Osimertinib,etc) MET amplification MET CNA MET:amp [EGFR inhibitor 3rd gen] Rociletinib Resistant Case report PMID:27252416 EArriola 06/16 LUAD TRUE EGFR inhibitor 3rd gens (Rociletinib,etc) MET amplification MET CNA MET:amp Clinical Trials ALK inhibitor Crizotinib Responsive Early trials NCT02499614;ASCO 2015 (abstr 2595) EArriola;CRubio-Perez 01/16 NSCLC TRUE Crizotinib (ALK inhibitor) MET amplification MET CNA MET:amp [MET inhibitor] [] Responsive Case report ENA 2015 (abstract A55) RDientsmann 01/16 HC TRUE MET inhibitors MET amplification MET CNA MET:amp [MET inhibitor] [] Responsive Pre-clinical PMID:22729845;PMID:23327903 RDientsmann 01/16 ST TRUE MET inhibitors MET (H1112R) MET MUT MET:H1112R [MET inhibitor] [] Responsive Early trials PMID:23213094 RDientsmann 01/16 R TRUE REMAP:H1094r changed to H1112R MET inhibitors MET amplification MET CNA MET:amp [MET inhibitor] [] Responsive Early trials PMID:23213094;AACR 2016 (abstr CT2006) RDientsmann 06/16 R TRUE MET inhibitors MET (M1268T) MET MUT MET:M1268T [MET inhibitor] [] Responsive Case report PMID:23610116 RDientsmann 01/16 R TRUE MET inhibitors MET amplification MET CNA MET:amp [EGFR mAb inhibitor] [] Resistant Early trials PMID:23729478 RDientsmann COREAD TRUE EGFR mAb inhibitors MET (H1112L) MET MUT MET:H1112L [MET inhibitor] [Crizotinib] Responsive Pre-clinical AACR 2012 (abstr 1786) RDientsmann CANCER TRUE MET inhibitors (Crizotinib,etc) MET amplification MET CNA MET:amp Clinical Trials Pan-kinase inhibitor;EGFR mAb inhibitor Cabozantinib;Panitumumab Responsive Case report ENA 2015 (abstr A52) RDientsmann 11/15 COREAD TRUE Cabozantinib + Panitumumab (Pan-kinase inhibitor + EGFR mAb inhibitor) MET (1132-1330) MET MUT MET:1132-1330 ALK inhibitor Crizotinib Responsive Early trials AACR 2016 (abstr CT2006) RDientsmann 06/16 R TRUE EXON 16-19 Crizotinib (ALK inhibitor) MET amplification MET CNA MET:amp ALK inhibitor Crizotinib Responsive Early trials ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1) RDientsmann 01/16 LUAD;ST TRUE Crizotinib (ALK inhibitor) MET (V1110I,H1112R,M1268T,R988C,T1010I) MET MUT MET:V1110I,H1112R,M1268T,R988C,T1010I ALK inhibitor Crizotinib Responsive Pre-clinical PMID:17483355 RDientsmann CANCER TRUE REMAP:H1094R changed to H1112R, v1092i changed to v1110i (all mutations annotated in same transcript ENST00000318493; these mutations where from ENST00000397752) Crizotinib (ALK inhibitor) MET (Y1230C;Y1235D) MET MUT MET:Y1230C;Y1235D ALK inhibitor Crizotinib Resistant Pre-clinical PMID:17483355 RDientsmann CANCER TRUE Crizotinib (ALK inhibitor) MET amplification MET CNA MET:amp ALK inhibitor Crizotinib Responsive Case report PMID:22162573 RDientsmann 01/16 G TRUE Crizotinib (ALK inhibitor) MET amplification MET CNA MET:amp [BCL2 inhibitor] [] Responsive Pre-clinical PMID:27397505 RDientsmann 07/16 COREAD TRUE BCL2 inhibitors MET amplification + EGFR oncogenic mutation MET;EGFR CNA;MUT MET:amp;EGFR:. [EGFR TK inhibitor] [] Resistant Early trials ASCO 2015 (abstr 8089) RDientsmann 01/16 LUAD TRUE EGFR TK inhibitors MET amplification + ERBB2 amplification MET;ERBB2 CNA;CNA MET:amp;ERBB2:amp ALK inhibitor;ERBB2 mAb inhibitor Crizotinib;Trastuzumab Responsive Case report PMID:26432108 RDientsmann 01/16 ST TRUE Crizotinib + Trastuzumab (ALK inhibitor + ERBB2 mAb inhibitor) MET amplification + ERBB2 amplification MET;ERBB2 CNA;CNA MET:amp;ERBB2:amp ALK inhibitor;ERBB2 mAb inhibitor Crizotinib;Trastuzumab Responsive Case report PMID:26432108 RDientsmann 01/16 ST TRUE Crizotinib + Trastuzumab (ALK inhibitor + ERBB2 mAb inhibitor) MET amplification + ERBB2 amplification MET;ERBB2 CNA;CNA MET:amp;ERBB2:amp ERBB2 inhibitor Lapatinib Resistant Pre-clinical PMID:22238368 RDientsmann 01/16 ST TRUE Lapatinib (ERBB2 inhibitor) MET amplification + ERBB2 amplification MET;ERBB2 CNA;CNA MET:amp;ERBB2:amp ERBB2 mAb inhibitor Trastuzumab Resistant Early trials PMID:22850551 RDientsmann 01/16 BRCA TRUE Trastuzumab (ERBB2 mAb inhibitor) MET amplification + ERBB2 amplification MET;ERBB2 CNA;CNA MET:amp;ERBB2:amp ERBB2 mAb inhibitor Trastuzumab Resistant Early trials PMID:22850551; PMID:26432108 RDientsmann 01/16 BRCA;ST TRUE Trastuzumab (ERBB2 mAb inhibitor) MITF amplification MITF CNA MITF:amp [BRAF inhibitor] [] Resistant Case report PMID:24265153 RDientsmann 01/16 CM TRUE BRAF inhibitors MITF amplification MITF CNA MITF:amp [BRAF inhibitor] [] Resistant Case report PMID:24265153 RDientsmann CM TRUE BRAF inhibitors MKI67 overexpression MKI67 EXPR MKI67:over Indirect Approved Pan-TK inhibitor Sunitinib Responsive Pre-clinical Cell line PMID:24086736 ARodriguez-Vida 09/15 R TRUE Sunitinib (Pan-TK inhibitor) MLL fusion MLL FUS MLL__. Indirect Approved HDAC inhibitor Belinostat Responsive Early trials NCT00351975;NCT00357032;PMID:22015773 ECampo;RDientsmann AML TRUE Belinostat (HDAC inhibitor) MLL fusion MLL FUS MLL__. Indirect Clinical Trials DOTL1 inhibitor EPZ-5676 Responsive Early trials NCT02141828;NCT01684150;PMID:21741596 ECampo;RDientsmann AML;ALL;MDS TRUE EPZ-5676 (DOTL1 inhibitor) MLL fusion MLL FUS MLL__. [BET inhibitor] [] Responsive Pre-clinical PMID:21964340 RDientsmann 01/16 AML TRUE BET inhibitors MLL fusion MLL FUS MLL__. Approved Chemotherapy Daunorubicin Responsive FDA guidelines PMID:22417203 RDientsmann AML TRUE Daunorubicin (Chemotherapy) MPL (W515F) MPL MUT MPL:W515F [JAK inhibitor] [] Responsive Pre-clinical PMID:16834459 RDientsmann MDPS TRUE JAK inhibitors MSH3 oncogenic mutation MSH3 MUT MSH3:. [DNA-PKc inhibitor] [] Responsive Pre-clinical PMID:24556366 RDientsmann CANCER TRUE DNA-PKc inhibitors MTOR (F2108L) MTOR MUT MTOR:F2108L MTOR inhibitor Everolimus Resistant Case report PMID:25295501 DTamborero;RDientsmann THCA TRUE Metastatic THCA with superresponse putatively assoiated with TSC2 nonsense mutation developing resistance associated with MTOR mutation after 18months Everolimus (MTOR inhibitor) MTOR (F2108L) MTOR MUT MTOR:F2108L [MTOR kinase inhibitor] [] Responsive Pre-clinical PMID:25295501 RDientsmann 01/16 CANCER TRUE MTOR kinase inhibitors MTOR (I1973F) MTOR MUT MTOR:I1973F MTOR inhibitor Everolimus Responsive Case report ASCO 2015 (abstr 11010);PMID:26859683 RDientsmann 06/16 AS;R TRUE Everolimus (MTOR inhibitor) MTOR (K1771R) MTOR MUT MTOR:K1771R MTOR inhibitor Everolimus Responsive Case report ASCO 2015 (abstr 11010);PMID:26859683 RDientsmann 01/16 ST;AG TRUE Everolimus (MTOR inhibitor) MTOR (Q2223K) MTOR MUT MTOR:Q2223K MTOR inhibitor Everolimus Responsive Case report PMID:24622468 RDientsmann 01/16 R TRUE Everolimus (MTOR inhibitor) MTOR (E2014K,E2419K,N1421D) MTOR MUT MTOR:E2014K,E2419K,N1421D MTOR inhibitor Everolimus Responsive Case report PMID:24625776 RDientsmann 01/16 BLCA TRUE Everolimus (MTOR inhibitor) MTOR (N1421D) MTOR MUT MTOR:N1421D MTOR inhibitor Everolimus Responsive Case report PMID:26859683 RDientsmann 06/16 ST TRUE Everolimus (MTOR inhibitor) MTOR (L1460P,S2215Y,R2505P) MTOR MUT MTOR:L1460P,S2215Y,R2505P MTOR inhibitor Sirolimus Responsive Pre-clinical PMID:24631838 RDientsmann CANCER TRUE Sirolimus (MTOR inhibitor) MYC amplification MYC CNA MYC:amp [BET inhibitor] [] Responsive Pre-clinical PMID:21889194;PMID:23430699 RDientsmann MYMA;NB TRUE BET inhibitors MYC amplification MYC CNA MYC:amp [CDK7 inhibitor] [] Responsive Pre-clinical PMID:25416950 RDientsmann NB TRUE CDK7 inhibitors MYC amplification MYC CNA MYC:amp [PIM inhibitor] [] Responsive Pre-clinical PMID:25505253 RDientsmann PRAD TRUE PIM inhibitors MYC amplification MYC CNA MYC:amp [FACT inhibitor] [] Responsive Pre-clinical PMID:26537256 RDientsmann 11/15 NB TRUE FACT inhibitors MYC amplification MYC CNA MYC:amp Chemotherapy Temozolomide Responsive Pre-clinical PMID:27397505 RDientsmann 07/16 COREAD TRUE Temozolomide (Chemotherapy) MYD88 (L265P) MYD88 MUT MYD88:L265P BTK inhibitor Ibrutinib Responsive Case report PMID:23836557;PMID:25853747 RDientsmann 04/16 WM TRUE Ibrutinib (BTK inhibitor) NF1 biallelic inactivation NF1 BIA NF1:. BRAF inhibitor Vemurafenib Resistant Pre-clinical PMID:23171796 DTamborero CM TRUE Vemurafenib (BRAF inhibitor) NF1 oncogenic mutation NF1 MUT NF1:. Indirect Approved MTOR inhibitor Everolimus Responsive Late trials NCT01365468 MMartínez 09/15 NF TRUE benign Everolimus (MTOR inhibitor) NF1 oncogenic mutation NF1 MUT NF1:. [MEK inhibitor] [] Responsive Pre-clinical PMID:23221341 RDientsmann 07/16 MPN TRUE MEK inhibitors NF1 deletion NF1 CNA NF1:del [MEK inhibitor] [] Responsive Pre-clinical PMID:23221341 RDientsmann 07/16 MPN TRUE MEK inhibitors NF1 deletion NF1 CNA NF1:del [AURK inhibitor] [] Responsive Pre-clinical PMID:24373973 RDientsmann 07/16 MPN TRUE germline AURK inhibitors NF1 oncogenic mutation NF1 MUT NF1:. [AURK inhibitor] [] Responsive Pre-clinical PMID:24373973 RDientsmann 07/16 MPN TRUE germline AURK inhibitors NF1 deletion NF1 CNA NF1:del [BRD4 inhibitor] [] Responsive Pre-clinical PMID:24373973 RDientsmann 07/16 MPN TRUE germline BRD4 inhibitors NF1 oncogenic mutation NF1 MUT NF1:. [BRD4 inhibitor] [] Responsive Pre-clinical PMID:24373973 RDientsmann 07/16 MPN TRUE germline BRD4 inhibitors NF1 deletion NF1 CNA NF1:del [MTOR inhibitor;HSP90 inhibitor] [] Responsive Pre-clinical PMID:21907929 RDientsmann 07/16 MPN TRUE germline MTOR inhibitor + HSP90 inhibitors NF1 oncogenic mutation NF1 MUT NF1:. [MTOR inhibitor;HSP90 inhibitor] [] Responsive Pre-clinical PMID:21907929 RDientsmann 07/16 MPN TRUE germline MTOR inhibitor + HSP90 inhibitors NF1 deletion NF1 CNA NF1:del [PD1 Ab inhibitor] [] Responsive Early trials ASCO 2016 (abstr 105);PMID 26960397 RDientsmann 07/16 CM TRUE , PD1 expression higher in NF1 mutant melanoma (PMID 26960397) PD1 Ab inhibitors NF1 oncogenic mutation NF1 MUT NF1:. [PD1 Ab inhibitor] [] Responsive Early trials ASCO 2016 (abstr 105);PMID 26960397 RDientsmann 07/16 CM TRUE PD1 Ab inhibitors NF1 deletion NF1 CNA NF1:del [MTOR inhibitor] [] Responsive Pre-clinical PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877 RDientsmann 07/16 G;MPN;LK TRUE MTOR inhibitors NF1 oncogenic mutation NF1 MUT NF1:. [MTOR inhibitor] [] Responsive Pre-clinical PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877 RDientsmann 07/16 G;MPN;LK TRUE MTOR inhibitors NF1 deletion NF1 CNA NF1:del [KIT inhibitor;MTOR inhibitor] [] Responsive Pre-clinical PMID:24718867 RDientsmann 07/16 MPN TRUE germline KIT inhibitor + MTOR inhibitors NF1 oncogenic mutation NF1 MUT NF1:. [KIT inhibitor;MTOR inhibitor] [] Responsive Pre-clinical PMID:24718867 RDientsmann 07/16 MPN TRUE germline KIT inhibitor + MTOR inhibitors NF1 deletion NF1 CNA NF1:del [MEK inhibitor] [] Responsive Pre-clinical PMID:22573716;PMID:19727076 RDientsmann 07/16 G;LK TRUE MEK inhibitors NF1 oncogenic mutation NF1 MUT NF1:. [MEK inhibitor] [] Responsive Pre-clinical PMID:22573716;PMID:19727076 RDientsmann 07/16 G;LK TRUE MEK inhibitors NF1 deletion NF1 CNA NF1:del [Pan-RAF inhibitor;MEK inhibitor] [] Responsive Pre-clinical PMID:26351322 RDientsmann 07/16 CM TRUE Pan-RAF inhibitor + MEK inhibitors NF1 oncogenic mutation NF1 MUT NF1:. [Pan-RAF inhibitor;MEK inhibitor] [] Responsive Pre-clinical PMID:26351322 RDientsmann 07/16 CM TRUE Pan-RAF inhibitor + MEK inhibitors NF1 deletion NF1 CNA NF1:del VEGFR mAb inhibitor Bevacizumab Responsive Case report PMID:24232489;PMID:2485933 RDientsmann 07/16 G TRUE germline Bevacizumab (VEGFR mAb inhibitor) NF1 oncogenic mutation NF1 MUT NF1:. VEGFR mAb inhibitor Bevacizumab Responsive Case report PMID:24232489;PMID:2485933 RDientsmann 07/16 G TRUE germline Bevacizumab (VEGFR mAb inhibitor) NF1 deletion NF1 CNA NF1:del ALK inhibitor Cediranib No Responsive Early trials NCT00326872 RDientsmann 07/16 PLEN TRUE germline NCT00326872 (trial results section) Cediranib (ALK inhibitor) NF1 oncogenic mutation NF1 MUT NF1:. ALK inhibitor Cediranib No Responsive Early trials NCT00326872 RDientsmann 07/16 PLEN TRUE germline Cediranib (ALK inhibitor) NF1 deletion NF1 CNA NF1:del BCR-ABL inhibitor 2nd gen Dasatinib Resistant Pre-clinical PMID:24296828 RDientsmann 07/16 L TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) NF1 oncogenic mutation NF1 MUT NF1:. BCR-ABL inhibitor 2nd gen Dasatinib Resistant Pre-clinical PMID:24296828 RDientsmann 07/16 L TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) NF1 deletion NF1 CNA NF1:del EGFR inhibitor 1st gen Erlotinib Resistant Pre-clinical PMID:24535670 RDientsmann 07/16 L TRUE Erlotinib (EGFR inhibitor 1st gen) NF1 oncogenic mutation NF1 MUT NF1:. EGFR inhibitor 1st gen Erlotinib Resistant Pre-clinical PMID:24535670 RDientsmann 07/16 L TRUE Erlotinib (EGFR inhibitor 1st gen) NF1 (D1644A) NF1 MUT NF1:D1644A MTOR inhibitor Everolimus Responsive Case report ASCO 2015 (abstr 11010);PMID:26859683 RDientsmann 06/16 HNC TRUE Everolimus (MTOR inhibitor) NF1 deletion NF1 CNA NF1:del MTOR inhibitor Everolimus No Responsive Early trials NCT01365468 RDientsmann 07/16 MPN TRUE germline Everolimus (MTOR inhibitor) NF1 oncogenic mutation NF1 MUT NF1:. MTOR inhibitor Everolimus No Responsive Early trials NCT01365468 RDientsmann 07/16 MPN TRUE germline Everolimus (MTOR inhibitor) NF1 deletion NF1 CNA NF1:del MTOR inhibitor Everolimus Responsive Case report PMID:26859683;ASCO 2016 (abstr e17557) RDientsmann 07/16 HNC;SG TRUE Everolimus (MTOR inhibitor) NF1 oncogenic mutation NF1 MUT NF1:. MTOR inhibitor Everolimus Responsive Case report PMID:26859683;ASCO 2016 (abstr e17557) RDientsmann 07/16 HNC;SG TRUE Everolimus (MTOR inhibitor) NF1 deletion NF1 CNA NF1:del MTOR inhibitor;VEGFR mAb inhibitor Everolimus;Bevacizumab No Responsive Early trials ASCO 2016 (abstr 11053) RDientsmann 07/16 MPN TRUE germline Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor) NF1 oncogenic mutation NF1 MUT NF1:. MTOR inhibitor;VEGFR mAb inhibitor Everolimus;Bevacizumab No Responsive Early trials ASCO 2016 (abstr 11053) RDientsmann 07/16 MPN TRUE germline Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor) NF1 deletion NF1 CNA NF1:del MTOR inhibitor;EGFR inhibitor 1st gen Everolimus;Erlotinib No Responsive Case report PMID:24634382 RDientsmann 07/16 G TRUE Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen) NF1 oncogenic mutation NF1 MUT NF1:. MTOR inhibitor;EGFR inhibitor 1st gen Everolimus;Erlotinib No Responsive Case report PMID:24634382 RDientsmann 07/16 G TRUE Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen) NF1 deletion NF1 CNA NF1:del BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive Early trials PMID:23099009 RDientsmann 07/16 PLEN TRUE germline Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) NF1 oncogenic mutation NF1 MUT NF1:. BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive Early trials PMID:23099009 RDientsmann 07/16 PLEN TRUE germline Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) NF1 deletion NF1 CNA NF1:del BCR-ABL inhibitor 2nd gen Nilotinib Responsive Pre-clinical PMID:24173684 RDientsmann 07/16 PLEN;MPN TRUE germline Nilotinib (BCR-ABL inhibitor 2nd gen) NF1 oncogenic mutation NF1 MUT NF1:. BCR-ABL inhibitor 2nd gen Nilotinib Responsive Pre-clinical PMID:24173684 RDientsmann 07/16 PLEN;MPN TRUE germline Nilotinib (BCR-ABL inhibitor 2nd gen) NF1 deletion NF1 CNA NF1:del Pan-TK inhibitor PLX3397 Responsive Pre-clinical PMID:23099891 RDientsmann 07/16 PLEN TRUE germline PLX3397 (Pan-TK inhibitor) NF1 oncogenic mutation NF1 MUT NF1:. Pan-TK inhibitor PLX3397 Responsive Pre-clinical PMID:23099891 RDientsmann 07/16 PLEN TRUE germline PLX3397 (Pan-TK inhibitor) NF1 deletion NF1 CNA NF1:del [Retinoic Acid] [] Resistant Pre-clinical PMID:20655465 RDientsmann 07/16 NB TRUE Retinoic Acids NF1 oncogenic mutation NF1 MUT NF1:. [Retinoic Acid] [] Resistant Pre-clinical PMID:20655465 RDientsmann 07/16 NB TRUE Retinoic Acids NF1 deletion NF1 CNA NF1:del MEK inhibitor Selumetinib Responsive Early trials ASCO 2014 (abstr 10018) RDientsmann 07/16 PLEN TRUE germline Selumetinib (MEK inhibitor) NF1 oncogenic mutation NF1 MUT NF1:. MEK inhibitor Selumetinib Responsive Early trials ASCO 2014 (abstr 10018) RDientsmann 07/16 PLEN TRUE germline Selumetinib (MEK inhibitor) NF1 deletion NF1 CNA NF1:del MTOR inhibitor Sirolimus Responsive Early trials PMID:25314964 RDientsmann 07/16 PLEN TRUE germline Sirolimus (MTOR inhibitor) NF1 oncogenic mutation NF1 MUT NF1:. MTOR inhibitor Sirolimus Responsive Early trials PMID:25314964 RDientsmann 07/16 PLEN TRUE germline Sirolimus (MTOR inhibitor) NF1 deletion NF1 CNA NF1:del MTOR inhibitor;EGFR inhibitor 1st gen Sirolimus;Erlotinib Responsive Case report PMID:22434731 RDientsmann 07/16 G TRUE germline, rampamycin = sirolimus Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen) NF1 oncogenic mutation NF1 MUT NF1:. MTOR inhibitor;EGFR inhibitor 1st gen Sirolimus;Erlotinib Responsive Case report PMID:22434731 RDientsmann 07/16 G TRUE germline, rampamycin = sirolimus Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen) NF1 deletion NF1 CNA NF1:del Pan-TK inhibitor;MTOR inhibitor Sorafenib;Sirolimus Responsive Pre-clinical PMID:25810463 RDientsmann 07/16 MPN TRUE germline Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor) NF1 oncogenic mutation NF1 MUT NF1:. Pan-TK inhibitor;MTOR inhibitor Sorafenib;Sirolimus Responsive Pre-clinical PMID:25810463 RDientsmann 07/16 MPN TRUE germline Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor) NF1 deletion NF1 CNA NF1:del Hormonal therapy Tamoxifen Responsive Pre-clinical PMID:21075781 RDientsmann 07/16 MPN TRUE germline Tamoxifen (Hormonal therapy) NF1 oncogenic mutation NF1 MUT NF1:. Hormonal therapy Tamoxifen Responsive Pre-clinical PMID:21075781 RDientsmann 07/16 MPN TRUE germline Tamoxifen (Hormonal therapy) NF1 deletion NF1 CNA NF1:del Farnesyltransferase inhibitor Tipifarnib No Responsive Early trials PMID:24500418 RDientsmann 07/16 PLEN TRUE germline Tipifarnib (Farnesyltransferase inhibitor) NF1 oncogenic mutation NF1 MUT NF1:. Farnesyltransferase inhibitor Tipifarnib No Responsive Early trials PMID:24500418 RDientsmann 07/16 PLEN TRUE germline Tipifarnib (Farnesyltransferase inhibitor) NF1 deletion NF1 CNA NF1:del MEK inhibitor Trametinib Responsive Case report PMID:26936308 RDientsmann 07/16 G TRUE germline Trametinib (MEK inhibitor) NF1 oncogenic mutation NF1 MUT NF1:. MEK inhibitor Trametinib Responsive Case report PMID:26936308 RDientsmann 07/16 G TRUE germline Trametinib (MEK inhibitor) NF1 deletion NF1 CNA NF1:del MEK inhibitor Trametinib Responsive Pre-clinical PMID:24576830;PMID:2524381 RDientsmann 07/16 CM TRUE Trametinib (MEK inhibitor) NF1 oncogenic mutation NF1 MUT NF1:. MEK inhibitor Trametinib Responsive Pre-clinical PMID:24576830;PMID:2524381 RDientsmann 07/16 CM TRUE Trametinib (MEK inhibitor) NF1 deletion NF1 CNA NF1:del MEK inhibitor Trametinib No Responsive Case report PMID:26325560 RDientsmann 07/16 OS TRUE Trametinib (MEK inhibitor) NF1 oncogenic mutation NF1 MUT NF1:. MEK inhibitor Trametinib No Responsive Case report PMID:26325560 RDientsmann 07/16 OS TRUE Trametinib (MEK inhibitor) NF1 deletion NF1 CNA NF1:del Chemotherapy Vinblastine Responsive Early trials ASCO 2016 (abstr 2019) RDientsmann 07/16 G TRUE germline Vinblastine (Chemotherapy) NF1 oncogenic mutation NF1 MUT NF1:. Chemotherapy Vinblastine Responsive Early trials ASCO 2016 (abstr 2019) RDientsmann 07/16 G TRUE germline Vinblastine (Chemotherapy) NF1 deletion NF1 CNA NF1:del Chemotherapy;BCR-ABL inhibitor 2nd gen Vinblastine;Nilotinib Responsive Case report ASCO 2016 (abstr 10555) RDientsmann 07/16 G TRUE germline Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen) NF1 oncogenic mutation NF1 MUT NF1:. Chemotherapy;BCR-ABL inhibitor 2nd gen Vinblastine;Nilotinib Responsive Case report ASCO 2016 (abstr 10555) RDientsmann 07/16 G TRUE germline Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen) NF1 oncogenic mutation NF1 MUT NF1:. MTOR inhibitor;VEGFR inhibitor Everolimus;Pazopanib Responsive Case report PMID:24931142 RDientsmann 07/16 HC TRUE Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor) NF1 deletion + BRAF oncogenic mutation NF1;BRAF CNA;MUT NF1:del;BRAF:. MEK inhibitor Selumetinib Resistant Case report PMID:23444215 RDientsmann 07/16 CM TRUE Selumetinib (MEK inhibitor) NF1 oncogenic mutation + BRAF oncogenic mutation NF1;BRAF MUT;MUT NF1:.;BRAF:. MEK inhibitor Selumetinib Resistant Case report PMID:23444215 RDientsmann 07/16 CM TRUE Selumetinib (MEK inhibitor) NF1 deletion + BRAF oncogenic mutation NF1;BRAF CNA;MUT NF1:del;BRAF:. BRAF inhibitor Vemurafenib Resistant Case report PMID:23288408;PMID:231718 RDientsmann 07/16 CM TRUE Vemurafenib (BRAF inhibitor) NF1 oncogenic mutation + BRAF oncogenic mutation NF1;BRAF MUT;MUT NF1:.;BRAF:. BRAF inhibitor Vemurafenib Resistant Case report PMID:23288408;PMID:231718 RDientsmann 07/16 CM TRUE Vemurafenib (BRAF inhibitor) NF2 deletion NF2 CNA NF2:del [FAK inhibitor] [] Responsive Early trials ENA 2012 (abstr 610) RDientsmann 07/16 MESO TRUE FAK inhibitors NF2 oncogenic mutation NF2 MUT NF2:. [FAK inhibitor] [] Responsive Early trials ENA 2012 (abstr 610) RDientsmann 07/16 MESO TRUE FAK inhibitors NF2 deletion NF2 CNA NF2:del [FAK inhibitor] [] Responsive Pre-clinical PMID:24848258;PMID:24786638 RDientsmann 07/16 MESO;OV TRUE FAK inhibitors NF2 oncogenic mutation NF2 MUT NF2:. [FAK inhibitor] [] Responsive Pre-clinical PMID:24848258;PMID:24786638 RDientsmann 07/16 MESO;OV TRUE FAK inhibitors NF2 deletion NF2 CNA NF2:del [HSP90 inhibitor] [] Responsive Pre-clinical PMID:23714726 RDientsmann 07/16 MEN TRUE germline HSP90 inhibitors NF2 oncogenic mutation NF2 MUT NF2:. [HSP90 inhibitor] [] Responsive Pre-clinical PMID:23714726 RDientsmann 07/16 MEN TRUE germline HSP90 inhibitors NF2 deletion NF2 CNA NF2:del [PAK inhibitor] [] Responsive Pre-clinical PMID:23960073;PMID:25596744 RDientsmann 07/16 SCHW;MEN TRUE germline PAK inhibitors NF2 oncogenic mutation NF2 MUT NF2:. [PAK inhibitor] [] Responsive Pre-clinical PMID:23960073;PMID:25596744 RDientsmann 07/16 SCHW;MEN TRUE germline PAK inhibitors NF2 deletion NF2 CNA NF2:del [PDK1 inhibitor] [] Responsive Pre-clinical PMID:19359162 RDientsmann 07/16 SCHW TRUE germline PDK1 inhibitors NF2 oncogenic mutation NF2 MUT NF2:. [PDK1 inhibitor] [] Responsive Pre-clinical PMID:19359162 RDientsmann 07/16 SCHW TRUE germline PDK1 inhibitors NF2 deletion NF2 CNA NF2:del [MTOR inhibitor] [] Responsive Pre-clinical PMID:19451225;PMID:2242646 RDientsmann 07/17 MEN TRUE MTOR inhibitors NF2 oncogenic mutation NF2 MUT NF2:. [MTOR inhibitor] [] Responsive Pre-clinical PMID:19451225;PMID:2242646 RDientsmann 07/18 MEN TRUE MTOR inhibitors NF2 deletion NF2 CNA NF2:del [MEK inhibitor] [] Responsive Pre-clinical PMID:26359368 RDientsmann 07/16 TH TRUE MEK inhibitors NF2 oncogenic mutation NF2 MUT NF2:. [MEK inhibitor] [] Responsive Pre-clinical PMID:26359368 RDientsmann 07/16 TH TRUE MEK inhibitors NF2 deletion NF2 CNA NF2:del HDAC inhibitor AR42 Responsive Pre-clinical PMID:21778190 RDientsmann 07/16 SCHW TRUE germline AR42 (HDAC inhibitor) NF2 oncogenic mutation NF2 MUT NF2:. HDAC inhibitor AR42 Responsive Pre-clinical PMID:21778190 RDientsmann 07/16 SCHW TRUE germline AR42 (HDAC inhibitor) NF2 deletion NF2 CNA NF2:del HDAC inhibitor AR42 Responsive Early trials ASCO 2016 (abstr 2558) RDientsmann 07/16 MEN TRUE germline,minor response AR42 (HDAC inhibitor) NF2 oncogenic mutation NF2 MUT NF2:. HDAC inhibitor AR42 Responsive Early trials ASCO 2016 (abstr 2558) RDientsmann 07/16 MEN TRUE germline,minor response AR42 (HDAC inhibitor) NF2 deletion NF2 CNA NF2:del VEGFR mAb inhibitor Bevacizumab Responsive Early trials PMID:19587327;PMID:22805104;PMID:26022982 RDientsmann 07/16 SCHW TRUE germline Bevacizumab (VEGFR mAb inhibitor) NF2 oncogenic mutation NF2 MUT NF2:. VEGFR mAb inhibitor Bevacizumab Responsive Early trials PMID:19587327;PMID:22805104;PMID:26022982 RDientsmann 07/16 SCHW TRUE germline Bevacizumab (VEGFR mAb inhibitor) NF2 deletion NF2 CNA NF2:del EGFR inhibitor 1st gen Erlotinib No Responsive Early trials PMID:20736812 RDientsmann 07/16 SCHW TRUE germline Erlotinib (EGFR inhibitor 1st gen) NF2 oncogenic mutation NF2 MUT NF2:. EGFR inhibitor 1st gen Erlotinib No Responsive Early trials PMID:20736812 RDientsmann 07/16 SCHW TRUE germline Erlotinib (EGFR inhibitor 1st gen) NF2 deletion NF2 CNA NF2:del MTOR inhibitor Everolimus Responsive Early trials PMID:24311643;2556735 RDientsmann 07/16 SCHW TRUE germline, minor responsiv Everolimus (MTOR inhibitor) NF2 oncogenic mutation NF2 MUT NF2:. MTOR inhibitor Everolimus Responsive Early trials PMID:24311643;2556735 RDientsmann 07/16 SCHW TRUE germline, minor responsiv Everolimus (MTOR inhibitor) NF2 deletion NF2 CNA NF2:del MTOR inhibitor;Somatostatin analog Everolimus;Octreotide Responsive Pre-clinical PMID:26015296 RDientsmann 07/16 MEN TRUE Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog) NF2 oncogenic mutation NF2 MUT NF2:. MTOR inhibitor;Somatostatin analog Everolimus;Octreotide Responsive Pre-clinical PMID:26015296 RDientsmann 07/16 MEN TRUE Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog) NF2 deletion NF2 CNA NF2:del BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive Pre-clinical PMID:19509233;PMID:2290085 RDientsmann 07/16 SCHW TRUE germline Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) NF2 oncogenic mutation NF2 MUT NF2:. BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive Pre-clinical PMID:19509233;PMID:2290085 RDientsmann 07/16 SCHW TRUE germline Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) NF2 deletion NF2 CNA NF2:del MTOR inhibitor;Chemotherapy Tensirolimus;Chemotherapy Responsive Case report PMID:25878190 RDientsmann 07/16 BRCA TRUE Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy) NF2 oncogenic mutation NF2 MUT NF2:. MTOR inhibitor;Chemotherapy Tensirolimus;Chemotherapy Responsive Case report PMID:25878190 RDientsmann 07/16 BRCA TRUE Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy) NF2 deletion NF2 CNA NF2:del ERBB2 inhibitor Lapatinib Responsive Early trials PMID:22844108;NCT00973739 RDientsmann;MMartínez 07/16 SCHW;NF TRUE germline Lapatinib (ERBB2 inhibitor) NF2 oncogenic mutation NF2 MUT NF2:. ERBB2 inhibitor Lapatinib Responsive Early trials PMID:22844108;NCT00973739 RDientsmann;MMartínez 07/16 SCHW;NF TRUE germline Lapatinib (ERBB2 inhibitor) NF2 deletion + EGFR oncogenic mutation NF2;EGFR CNA;MUT NF2:del;EGFR:. EGFR inhibitor 1st gen;EGFR mAb inhibitor Erlotinib;Cetuximab Resistant Case report PMID:24813888 RDientsmann 07/16 L TRUE In Egfr Mutant Tumors Erlotinib + Cetuximab (EGFR inhibitor 1st gen + EGFR mAb inhibitor) NF2 oncogenic mutation + EGFR oncogenic mutation NF2;EGFR MUT;MUT NF2:.;EGFR:. EGFR inhibitor 1st gen;EGFR mAb inhibitor Erlotinib;Cetuximab Resistant Case report PMID:24813888 RDientsmann 07/16 L TRUE In Egfr Mutant Tumors Erlotinib + Cetuximab (EGFR inhibitor 1st gen + EGFR mAb inhibitor) NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain) NOTCH1 MUT NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2300-2536,::splice_acceptor_variant:2300-2536,::stop_gained:2300-2536,::stop_lost:2300-2536,::frameshift_variant:2300-2536 Indirect Clinical Trials [Gamma secretase inhibitor] [Ro4929097,Pf-03084014,Mk-0752] Responsive Early trials NCT01703572;NCT01778439; NCT01098344; NCT01981551 ECampo CANCER TRUE Gamma secretase inhibitors (Ro4929097,Pf-03084014,Mk-0752,etc) NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain) NOTCH1 MUT NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2300-2536,::splice_acceptor_variant:2300-2536,::stop_gained:2300-2536,::stop_lost:2300-2536,::frameshift_variant:2300-2536 Direct Clinical Trials NOTCH1 inhibitor OMP-52M51 Responsive Early trials NCT01703572;NCT01778439 ECampo CANCER TRUE OMP-52M51 (NOTCH1 inhibitor) NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain) NOTCH1 MUT NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2300-2536,::splice_acceptor_variant:2300-2536,::stop_gained:2300-2536,::stop_lost:2300-2536,::frameshift_variant:2300-2536 [Gamma secretase inhibitor] [] Responsive Early trials ASCO 2006 (abstr 6585) RDientsmann 01/16 ALL TRUE Gamma secretase inhibitors NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain) NOTCH1 MUT NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2300-2536,::splice_acceptor_variant:2300-2536,::stop_gained:2300-2536,::stop_lost:2300-2536,::frameshift_variant:2300-2536 [Gamma secretase inhibitor] [] Responsive Pre-clinical PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755 RDientsmann 01/16 ALL TRUE Gamma secretase inhibitors NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain) NOTCH1 FUS NOTCH1__. [Gamma secretase inhibitor] [] Responsive Pre-clinical PMID:16688224;PMID:23033986 RDientsmann 01/16 ALL TRUE Gamma secretase inhibitors NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain) NOTCH1 MUT NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2300-2536,::splice_acceptor_variant:2300-2536,::stop_gained:2300-2536,::stop_lost:2300-2536,::frameshift_variant:2300-2536 [Gamma secretase inhibitor;MTOR inhibitor] [] Responsive Pre-clinical PMID:19246562 RDientsmann 01/16 ALL TRUE Gamma secretase inhibitor + MTOR inhibitors NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain) NOTCH1 MUT NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2300-2536,::splice_acceptor_variant:2300-2536,::stop_gained:2300-2536,::stop_lost:2300-2536,::frameshift_variant:2300-2536 [Gamma secretase inhibitor;CDK4 inhibitor] [] Responsive Pre-clinical PMID:19318552 RDientsmann 01/16 ALL TRUE Gamma secretase inhibitor + CDK4 inhibitors NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain) NOTCH1 FUS NOTCH1__. [Gamma secretase inhibitor] [] Responsive Pre-clinical PMID:22101766 RDientsmann BRCA TRUE Gamma secretase inhibitors NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain) NOTCH1 MUT NOTCH1:. [Gamma secretase inhibitor] [] Responsive Pre-clinical PMID:22210878 RDientsmann MCL TRUE Gamma secretase inhibitors NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain) NOTCH1 MUT NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2300-2536,::splice_acceptor_variant:2300-2536,::stop_gained:2300-2536,::stop_lost:2300-2536,::frameshift_variant:2300-2536 [Gamma secretase inhibitor] [] Responsive Pre-clinical PMID:25564152 RDientsmann BRCA TRUE Gamma secretase inhibitors NOTCH2 activating mutation (missense in TAD or truncating in Cterm domain) NOTCH2 MUT NOTCH2::consequence::splice_donor_variant:2381-2420,::splice_acceptor_variant:2381-2420,::stop_gained:2381-2420,::stop_lost:2381-2420,::frameshift_variant:2381-2420 Direct Clinical Trials NOTCH2 inhibitor OMP-59R5 Responsive Early trials NCT01859741;NCT01277146 ECampo SOLID TRUE OMP-59R5 (NOTCH2 inhibitor) NOTCH2 activating mutation (missense in TAD or truncating in Cterm domain) NOTCH2 MUT NOTCH2::consequence::splice_donor_variant:2381-2420,::splice_acceptor_variant:2381-2420,::stop_gained:2381-2420,::stop_lost:2381-2420,::frameshift_variant:2381-2420 Direct Clinical Trials Gamma secretase inhibitor Mk-0752 Responsive Early trials PMID:25564152 KKarube;RDientsmann BRCA;AML;ALL TRUE Mk-0752 (Gamma secretase inhibitor) NOTCH2 activating mutation (missense in TAD or truncating in Cterm domain) NOTCH2 FUS NOTCH2__. [Gamma secretase inhibitor] [] Responsive Pre-clinical PMID:22101766 RDientsmann BRCA TRUE Gamma secretase inhibitors NPM1 oncogenic mutation NPM1 MUT NPM1:. Approved Chemotherapy Daunorubicin Responsive FDA guidelines PMID:22417203 RDientsmann AML TRUE Daunorubicin (Chemotherapy) NRAS oncogenic mutation NRAS MUT NRAS:. BRAF inhibitor Vemurafenib Resistant Pre-clinical PMID:20179705 DTamborero CM TRUE there is also some report in real patients with resistance, but not clear association Vemurafenib (BRAF inhibitor) NRAS oncogenic mutation NRAS MUT NRAS:. Indirect Approved [CDK4/6 inhibitor;MEK inhibitor] [] Responsive Early trials PMID:26658964;NCT01781572;NCT02065063;NCT02022982;ASCO 2014 (abstr 9009) DTamborero;CRubio-Perez;RDientsmann CM TRUE CDK4/6 inhibitor + MEK inhibitors NRAS (Q61) NRAS MUT NRAS:Q61. [Pan-RAF inhibitor] [] Responsive Case report ESMO 2015 (abstract 300) RDientsmann 01/16 CM TRUE Pan-RAF inhibitors NRAS oncogenic mutation NRAS MUT NRAS:. [MEK inhibitor] [] Responsive Pre-clinical PMID:22507781;PMID:23515407;PMID:18701506 RDientsmann AML;LUAD;ALL TRUE MEK inhibitors NRAS oncogenic mutation NRAS MUT NRAS:. [PI3K pathway inhibitor;MEK inhibitor] [] Responsive Pre-clinical PMID:22985491 RDientsmann MYMA TRUE PI3K pathway inhibitor + MEK inhibitors NRAS oncogenic mutation NRAS MUT NRAS:. [MEK inhibitor +/- PI3K pathway inhibitor] [] Responsive Pre-clinical PMID:23274911;PMID:22392911 RDientsmann 01/16 COREAD TRUE MEK inhibitor +/- PI3K pathway inhibitors NRAS (Q61) NRAS MUT NRAS:Q61. [MEK inhibitor] [] Responsive Late trials PMID:23414587,ASCO 2016 (abstr 9500) RDientsmann 06/16 CM TRUE MEK inhibitors NRAS (Q61) NRAS MUT NRAS:Q61. [HSP90 inhibitor] [] Responsive Pre-clinical PMID:23538902 RDientsmann 01/16 CM TRUE HSP90 inhibitors NRAS (Q61) NRAS MUT NRAS:Q61. [BRAF inhibitor] [] Resistant Early trials PMID:23569304;PMID:24265153 RDientsmann 01/16 CM TRUE BRAF inhibitors NRAS (G12C) NRAS MUT NRAS:G12C [ERK inhibitor] [] Responsive Pre-clinical PMID:23614898 RDientsmann CANCER TRUE ERK inhibitors NRAS (Q61) NRAS MUT NRAS:Q61. [ERK inhibitor] [] Responsive Pre-clinical PMID:23614898 RDientsmann 01/16 CM TRUE ERK inhibitors NRAS oncogenic mutation NRAS MUT NRAS:. Approved EGFR mAb inhibitor Cetuximab Resistant NCCN guidelines PMID:24024839;PMID:20619739;PMID:23325582 RDientsmann COREAD TRUE Cetuximab (EGFR mAb inhibitor) NRAS oncogenic mutation NRAS MUT NRAS:. Approved EGFR mAb inhibitor Panitumumab Resistant NCCN guidelines PMID:24024839;PMID:20619739;PMID:23325582 RDientsmann COREAD TRUE Panitumumab (EGFR mAb inhibitor) NRAS oncogenic mutation NRAS MUT NRAS:. Pan-TK inhibitor;MEK inhibitor Sorafenib;MEK inhibitor Responsive Early Trials,Case Report PMID:25294897 RDientsmann 01/16 HC TRUE Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor) NRG1 fusion NRG1 FUS NRG1__. ERBB2&EGFR inhibitor 2nd gen Afatinib Responsive Case report AACR 2016 (abstr 2631) RDientsmann 06/16 LUAD TRUE Afatinib (ERBB2&EGFR inhibitor 2nd gen) NRG1 fusion NRG1 FUS NRG1__. ERBB2 inhibitor Lapatinib Responsive Pre-clinical PMID:24727320 RDientsmann LUAD TRUE Lapatinib (ERBB2 inhibitor) NTRK1 fusion NTRK1 FUS NTRK1__. [Pan-TKR inhibitor] [] Responsive Early trials AACR 2016 (abstr CT007), AACR 2016 (abstr CT008) RDientsmann 06/16 CANCER TRUE Pan-TKR inhibitors NTRK1 fusion NTRK1 FUS NTRK1__. [Pan-TK inhibitor] [] Responsive Pre-clinical PMID:24162815 RDientsmann 01/16 LUAD TRUE Pan-TK inhibitors NTRK1 fusion NTRK1 FUS NTRK1__. [Pan-TK inhibitor] [Entrectinib] Responsive Case report PMID:26546295 RDientsmann 11/15 COREAD TRUE Pan-TK inhibitors (Entrectinib,etc) NTRK1 (G595R,G667C) NTRK1 MUT NTRK1:G595R,G667C [Pan-TK inhibitor] [Entrectinib] Resistant Case report PMID:26546295 RDientsmann 11/15 COREAD TRUE Pan-TK inhibitors (Entrectinib,etc) NTRK1 fusion NTRK1 FUS NTRK1__. ALK inhibitor Crizotinib Responsive Case report ASCO 2013 (abstr 8023) RDientsmann 01/16 LUAD TRUE Crizotinib (ALK inhibitor) NTRK3 fusion NTRK3 FUS NTRK3__. [IGF1R inhibitor] [] Responsive Pre-clinical PMID:21148487;PMID:23131561 RDientsmann BRCA TRUE IGF1R inhibitors NTRK3 fusion NTRK3 FUS NTRK3__. [PI3K pathway inhibitor] [] Responsive Pre-clinical PMID:21148487;PMID:23131561 RDientsmann BRCA TRUE PI3K pathway inhibitors NTRK3 fusion NTRK3 FUS NTRK3__. Pan-TK inhibitor Midostaurin Responsive Pre-clinical PMID:21148487;PMID:23131561 RDientsmann BRCA TRUE Midostaurin (Pan-TK inhibitor) PAK1 amplification PAK1 CNA PAK1:amp [PAK inhibitor] [] Responsive Pre-clinical PMID:23535073 RDientsmann CM TRUE PAK inhibitors PALB2 oncogenic mutation PALB2 MUT PALB2:. [PARP inhibitor] [] Responsive Early trials AACR 2015 (abstr CT322);PMID:26510020 RDientsmann 01/16 PRAD TRUE PARP inhibitors PALB2 deletion PALB2 CNA PALB2:del [PARP inhibitor] [] Responsive Early trials AACR 2015 (abstr CT322);PMID:26510020 RDientsmann 01/16 PRAD TRUE PARP inhibitors PALB2 oncogenic mutation PALB2 MUT PALB2:. [PARP inhibitor] [] Responsive Pre-clinical PMID:25263539;NCT01585805 RDientsmann 01/16 PA TRUE PARP inhibitors PALB2 deletion PALB2 CNA PALB2:del [PARP inhibitor] [] Responsive Pre-clinical PMID:25263539;NCT01585805 RDientsmann 01/16 PA TRUE PARP inhibitors PALB2 oncogenic mutation PALB2 MUT PALB2:. Chemotherapy Mytomycin C Responsive Case report PMID:21135251 RDientsmann 01/16 PA TRUE Mytomycin C (Chemotherapy) PALB2 deletion PALB2 CNA PALB2:del Chemotherapy Mytomycin C Responsive Case report PMID:21135251 RDientsmann 01/16 PA TRUE Mytomycin C (Chemotherapy) PALB2 oncogenic mutation PALB2 MUT PALB2:. Chemotherapy Platinum Agent Responsive Case report PMID:25719666 RDientsmann 01/16 PA TRUE Platinum Agent (Chemotherapy) PALB2 deletion PALB2 CNA PALB2:del Chemotherapy Platinum Agent Responsive Case report PMID:25719666 RDientsmann 01/16 PA TRUE Platinum Agent (Chemotherapy) PBRM1 undexpression PBRM1 EXPR PBRM1:under Approved MTOR inhibitor Everolimus Responsive Pre-clinical Cell line PMID:25997916 ARodriguez-Vida 09/15 R TRUE Everolimus (MTOR inhibitor) PBRM1 deletion PBRM1 CNA PBRM1:del [EZH2 inhibitor] [] Responsive Pre-clinical PMID:26552009 RDientsmann 01/16 CANCER TRUE EZH2 inhibitors PBRM1 oncogenic mutation PBRM1 MUT PBRM1:. [EZH2 inhibitor] [] Responsive Pre-clinical PMID:26552009 RDientsmann 01/16 CANCER TRUE EZH2 inhibitors PDGFRA overexpression PDGFRA EXPR PDGFRA:over Direct Approved Pan-TK inhibitor Sunitinib Responsive Pre-clinical Cell line PMID:24086736 ARodriguez-Vida 09/15 R TRUE Sunitinib (Pan-TK inhibitor) PDGFRA-FIP1L1 fusion PDGFRA FUS PDGFRA__FIP1L1 Approved BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive FDA guidelines EMA CRubio-Perez;DTamborero;RDientsmann HES;ECL TRUE http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) PDGFRA fusion PDGFRA FUS PDGFRA__. Approved BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive FDA guidelines EMA CRubio-Perez;DTamborero;RDientsmann MDS;MDPS TRUE http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) PDGFRA (D842V) PDGFRA MUT PDGFRA:D842V [HSP90 inhibitor] [] Responsive Pre-clinical PMID:18794084 RDientsmann 01/16 GIST TRUE HSP90 inhibitors PDGFRA amplification PDGFRA CNA PDGFRA:amp [PDGFR inhibitor] [] No Responsive Pre-clinical PMID:23544171 RDientsmann G TRUE PDGFR inhibitors PDGFRA (D842V) PDGFRA MUT PDGFRA:D842V FLT3 inhibitor Crenolanib Responsive Pre-clinical PMID:22745105 RDientsmann 01/16 GIST TRUE Crenolanib (FLT3 inhibitor) PDGFRA (V658A,P577S,R841K,H845Y,G853D) PDGFRA MUT PDGFRA:V658A,P577S,R841K,H845Y,G853D FLT3 inhibitor Crenolanib Responsive Pre-clinical PMID:24132921 RDientsmann CM TRUE Crenolanib (FLT3 inhibitor) PDGFRA wildtype PDGFRA MUT PDGFRA::wildtype:. BCR-ABL inhibitor 2nd gen Dasatinib Responsive Pre-clinical PMID:16397263 RDientsmann 01/16 GIST TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) PDGFRA (D842V) PDGFRA MUT PDGFRA:D842V BCR-ABL inhibitor 2nd gen Dasatinib Responsive Pre-clinical PMID:18794084 RDientsmann 01/16 GIST TRUE Dasatinib (BCR-ABL inhibitor 2nd gen) PDGFRA mutation in exon 12,14 or 18 PDGFRA MUT PDGFRA:552-596,631-668,814-854 Approved BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive NCCN guidelines NCCN guidelines RDientsmann GIST TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) PDGFRA (R748G,Y894C) PDGFRA MUT PDGFRA:R748G,Y894C Approved BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive NCCN guidelines NCCN guidelines RDientsmann GIST TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) PDGFRA inframe deletion (I843) PDGFRA MUT PDGFRA::consequence::inframe_deletion:I843. Approved BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive NCCN guidelines NCCN guidelines RDientsmann GIST TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) PDGFRA (T674I) PDGFRA MUT PDGFRA:T674I BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Resistant Case report PMID:12660384 RDientsmann HES TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) PDGFRA wildtype PDGFRA MUT PDGFRA::wildtype:. BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Resistant Late trials PMID:14645423;PMID:18955458 RDientsmann GIST TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) PDGFRA (D842V) PDGFRA MUT PDGFRA:D842V BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Resistant Late Trials,Pre-clinical PMID:22718859;PMID:16638875 RDientsmann 01/16 GIST TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) PDGFRA (P577S,R841K,H845Y,G853D) PDGFRA MUT PDGFRA:P577S,R841K,H845Y,G853D BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive Pre-clinical PMID:24132921 RDientsmann CM TRUE Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) PDGFRA mutation in exon 12,14 or 18 PDGFRA MUT PDGFRA:552-596,631-668,814-854 Approved Pan-kinase inhibitor Regorafenib Responsive NCCN guidelines NCCN guidelines RDientsmann GIST TRUE Mutation exon 12,14,18 Regorafenib (Pan-kinase inhibitor) PDGFRA wildtype PDGFRA MUT PDGFRA::wildtype:. Pan-TK inhibitor Sorafenib Responsive Early trials ASCO 2011 (abstr 10009) RDientsmann 01/16 GIST TRUE Sorafenib (Pan-TK inhibitor) PDGFRA mutation in exon 12,14 or 18 PDGFRA MUT PDGFRA:552-596,631-668,814-854 Approved Pan-TK inhibitor Sunitinib Responsive NCCN guidelines NCCN guidelines RDientsmann GIST TRUE Mutation exon 12,14,18 Sunitinib (Pan-TK inhibitor) PDGFRA wildtype PDGFRA MUT PDGFRA::wildtype:. Pan-TK inhibitor Sunitinib Responsive Late trials PMID:18955458 RDientsmann 01/16 GIST TRUE Sunitinib (Pan-TK inhibitor) PDGFRA (D842V) PDGFRA MUT PDGFRA:D842V Pan-TK inhibitor Sunitinib Resistant Late Trials,Pre-clinical PMID:22718859;PMID:16638875 RDientsmann 01/16 GIST TRUE Sunitinib (Pan-TK inhibitor) PDGFRB-COL1A1 fusion PDGFRB FUS PDGFRB__COL1A1 Approved BCR-ABL inhibitor 1st gen&KIT inhibitor Imatinib Responsive FDA guidelines EMA CRubio-Perez;DTamborero;RDientsmann MDS;MDPS TRUE http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor) PDPK1 amplification PDPK1 CNA PDPK1:amp [PI3K pathway inhibitor] [] Responsive Pre-clinical PMID:19602588 RDientsmann BRCA TRUE PI3K pathway inhibitors PIK3CA (E545*) PIK3CA MUT PIK3CA:E545* [BRAF inhibitor] [] Resistant Case report PMC3936420 DTamborero 03/16 CM TRUE BRAF inhibitors PIK3CA oncogenic mutation PIK3CA MUT PIK3CA:. [AKT inhibitor] [] Responsive Early trials ASCO 2015 (abstr 2500) RDientsmann 01/16 BRCA TRUE AKT inhibitors PIK3CA oncogenic mutation PIK3CA MUT PIK3CA:. [PI3K pathway inhibitor (alone or in combination)] [] Responsive Pre-clinical PMID:23136191;PMID:23475782;PMID:22392911 RDientsmann 01/16 L;COREAD TRUE PI3K pathway inhibitor (alone or in combination)s PIK3CA oncogenic mutation PIK3CA MUT PIK3CA:. [PI3K pathway inhibitor] [] Responsive Case report ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017) RDientsmann 01/16 BLCA;HNC;L TRUE PI3K pathway inhibitors PIK3CA oncogenic mutation PIK3CA MUT PIK3CA:. [PI3K pathway inhibitor] [] Responsive Pre-clinical PMID:19671762;PMID:21289267 RDientsmann G;THCA TRUE PI3K pathway inhibitors PIK3CA oncogenic mutation PIK3CA MUT PIK3CA:. [PI3K pathway inhibitor] [] Responsive Early trials PMID:22271473;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513) RDientsmann 01/16 BRCA;OV;CESC;ED TRUE PI3K pathway inhibitors PIK3CA amplification PIK3CA CNA PIK3CA:amp [PI3K pathway inhibitor] [] Resistant Pre-clinical PMID:24366379 RDientsmann BRCA TRUE PI3K pathway inhibitors PIK3CA oncogenic mutation PIK3CA MUT PIK3CA:. [PIK3CA inhibitor] [] Responsive Early trials AACR 2013 (abstr LB-64);ESMO 2013 (abstr P017) RDientsmann 01/16 BRCA TRUE PIK3CA inhibitors PIK3CA oncogenic mutation PIK3CA MUT PIK3CA:. [PIK3CA inhibitor] [] Responsive Case report ASCO 2015 (abstr 2501) RDientsmann 01/16 ST TRUE PIK3CA inhibitors PIK3CA oncogenic mutation PIK3CA MUT PIK3CA:. EGFR mAb inhibitor Cetuximab Resistant Late trials PMID:19223544;PMID:20619739 RDientsmann 01/16 COREAD TRUE Cetuximab (EGFR mAb inhibitor) PIK3CA oncogenic mutation PIK3CA MUT PIK3CA:. [PI3K pathway inhibitor] [] Responsive Case report PMID:26787751;PMID:26763254 RDientsmann 07/16 HNSC TRUE PI3K pathway inhibitors PIK3CA oncogenic mutation + ERBB2 amplification PIK3CA;ERBB2 MUT;CNA PIK3CA:.;ERBB2:amp MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy Everolimus;Trastuzumab;Chemotherapy Responsive Late trials PMID:27091708 RDientsmann 01/16 BRCA TRUE Everolimus + Trastuzumab + Chemotherapy (MTOR inhibitor + ERBB2 mAb inhibitor + Chemotherapy) PIK3CB oncogenic mutation PIK3CB MUT PIK3CB:. [AKT inhibitor] [] Responsive Pre-clinical PMID:23619167 RDientsmann 04/16 HNSC TRUE AKT inhibitors PIK3CB oncogenic mutation PIK3CB MUT PIK3CB:. [MTORC1/2 inhibitor] [] Responsive Pre-clinical PMID:23619167 RDientsmann 04/16 HNSC TRUE MTORC1/2 inhibitors PIK3CB oncogenic mutation PIK3CB MUT PIK3CB:. [PI3K pathway inhibitor] [] Responsive Pre-clinical PMID:23619167 RDientsmann HNSC TRUE PI3K pathway inhibitors PIK3CB (D1067Y) PIK3CB MUT PIK3CB:D1067Y [AKT inhibitor] [] Responsive Pre-clinical PMID:26759240 RDientsmann 04/16 BRCA TRUE AKT inhibitors PIK3CB (D1067Y) PIK3CB MUT PIK3CB:D1067Y [MTORC1/2 inhibitor] [] Responsive Pre-clinical PMID:26759240 RDientsmann 04/16 BRCA TRUE MTORC1/2 inhibitors PIK3CB (D1067Y) PIK3CB MUT PIK3CB:D1067Y [PI3K pathway inhibitor] [] Resistant Case report PMID:26759240 RDientsmann 04/16 BRCA TRUE PI3K pathway inhibitors PIK3R1 oncogenic mutation PIK3R1 MUT PIK3R1:. [PI3K pathway inhibitor] [] Responsive Case report ASCO 2015 (abstr 11075) RDientsmann 01/16 ED TRUE PI3K pathway inhibitors PIK3R1 oncogenic mutation PIK3R1 MUT PIK3R1:. [AKT inhibitor] [] Responsive Pre-clinical PMID:23166678 RDientsmann G TRUE AKT inhibitors PIK3R2 (A171V,N561D) PIK3R2 MUT PIK3R2:A171V,N561D [MTOR inhibitor] [] Responsive Pre-clinical PMID:21984976;PMID:19962665 RDientsmann ED TRUE MTOR inhibitors PLCG2 (R665W,L845F) PLCG2 MUT PLCG2:R665W,L845F Approved BTK inhibitor Ibrutinib Resistant Early trials PMID:24869598 RDientsmann CLL TRUE Ibrutinib (BTK inhibitor) PML-RARA fusion PML FUS PML__RARA Approved Retinoid Tretinoin Responsive FDA guidelines FDA DTamborero;CRubio-Perez 01/16 APML TRUE Tretinoin (Retinoid) PML-RARA fusion PML FUS PML__RARA Indirect Clinical Trials PLK1 inhibitor Volasertib Responsive Early trials NCT02198482;NCT01662505 ECampo AML TRUE Volasertib (PLK1 inhibitor) PML-RARA fusion PML FUS PML__RARA Approved Retinoid;Chemotherapy Tretinoin;Arsenic Trioxide Responsive FDA guidelines FDA RDientsmann AML TRUE PML is the oncogene or rara?? Tretinoin + Arsenic Trioxide (Retinoid + Chemotherapy) POLEexonuclease domain mutation POLE MUT POLE:268–471 [PD1 Ab inhibitor] [] Responsive Case report PMID:27001570;PMID:27159395 RDientsmann 06/16 G;ED TRUE Mutations in exonuclease domain. Domain coordinates from (PMID:23528559) PD1 Ab inhibitors PRKCH amplification + ABL1-BCR fusion PRKCH;ABL1 CNA;FUS PRKCH:amp;ABL1__BCR MEK inhibitor;BCR-ABL inhibitor 1st gen&KIT inhibitor Trametinib;Imatinib Responsive Pre-clinical PMID:25186176 RDientsmann CML TRUE Trametinib + Imatinib (MEK inhibitor + BCR-ABL inhibitor 1st gen&KIT inhibitor) PTCH1 oncogenic mutation PTCH1 MUT PTCH1:. MET inhibitor Foretinib Responsive Pre-clinical PMID:25391241 RDientsmann 01/16 MB TRUE Foretinib (MET inhibitor) PTCH1 oncogenic mutation PTCH1 MUT PTCH1:. Approved SHH inhibitor Vismodegib Responsive FDA guidelines PMID:19726763;PMID:19726761 RDientsmann BCC;MB TRUE Vismodegib (SHH inhibitor) PTCH1 oncogenic mutation PTCH1 MUT PTCH1:. Approved [SMO inhibitor] [] Responsive Pre-clinical PMID:24651015 DTamborero;RDientsmann 10/16 MB TRUE SMO inhibitors PTEN biallelic inactivation PTEN BIA PTEN:. Clinical Trials PIK3CA inhibitor BYL719 Resistant Case report PMID:25409150 DTamborero BRCA TRUE BYL719 (PIK3CA inhibitor) PTEN biallelic inactivation PTEN BIA PTEN:. Approved EGFR mAb inhibitor Cetuximab Resistant Case report Caris molecular intelligence DTamborero COREAD TRUE Cetuximab (EGFR mAb inhibitor) PTEN biallelic inactivation PTEN BIA PTEN:. EGFR mAb inhibitor Panitumumab Resistant Case report Caris molecular intelligence DTamborero COREAD TRUE Panitumumab (EGFR mAb inhibitor) PTEN oncogenic mutation PTEN MUT PTEN:. [PIK3CB inhibitor] [] Responsive Case report ASCO 2014 (abstr 2514) RDientsmann 01/16 PRAD TRUE PIK3CB inhibitors PTEN deletion PTEN CNA PTEN:del [PIK3CB inhibitor] [] Responsive Case report ASCO 2014 (abstr 2514) RDientsmann 01/16 PRAD TRUE PIK3CB inhibitors PTEN deletion PTEN CNA PTEN:del [EGFR mAb inhibitor] [] Resistant Late trials PMID:21163703;PMID:19398573 RDientsmann COREAD TRUE EGFR mAb inhibitors PTEN oncogenic mutation PTEN MUT PTEN:. [EGFR mAb inhibitor] [] Resistant Late trials PMID:21163703;PMID:19398573 RDientsmann COREAD TRUE EGFR mAb inhibitors PTEN oncogenic mutation PTEN MUT PTEN:. [PI3K pathway inhibitor] [] Responsive Pre-clinical PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669 RDientsmann 01/16 TH;G;L;OV;BRCA;CANCER;ED TRUE PI3K pathway inhibitors PTEN deletion PTEN CNA PTEN:del [PI3K pathway inhibitor] [] Responsive Pre-clinical PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669 RDientsmann 01/16 TH;G;L;OV;BRCA;CANCER;ED TRUE PI3K pathway inhibitors PTEN deletion PTEN CNA PTEN:del [PARP inhibitor] [] Responsive Case report PMID:21468130;PMID:20944090 RDientsmann ED TRUE (low estrogen) PARP inhibitors PTEN oncogenic mutation PTEN MUT PTEN:. [PARP inhibitor] [] Responsive Case report PMID:21468130;PMID:20944090 RDientsmann ED TRUE (low estrogen) PARP inhibitors PTEN oncogenic mutation PTEN MUT PTEN:. [PI3K pathway inhibitor;AR antagonist] [] Responsive Pre-clinical PMID:21575859 RDientsmann 01/16 PRAD TRUE PI3K pathway inhibitor + AR antagonists PTEN deletion PTEN CNA PTEN:del [PI3K pathway inhibitor;AR antagonist] [] Responsive Pre-clinical PMID:21575859 RDientsmann 01/16 PRAD TRUE PI3K pathway inhibitor + AR antagonists PTEN deletion PTEN CNA PTEN:del [PI3K pathway inhibitor;MEK inhibitor] [] Responsive Pre-clinical PMID:21632463 RDientsmann 01/16 OV TRUE PI3K pathway inhibitor + MEK inhibitors PTEN oncogenic mutation PTEN MUT PTEN:. [PI3K pathway inhibitor;MEK inhibitor] [] Responsive Pre-clinical PMID:21632463 RDientsmann 01/16 OV TRUE PI3K pathway inhibitor + MEK inhibitors PTEN deletion PTEN CNA PTEN:del [MTOR inhibitor] [] No Responsive Early trials PMID:21788564;PMID:23238879 RDientsmann 01/16 ED TRUE MTOR inhibitors PTEN oncogenic mutation PTEN MUT PTEN:. [MTOR inhibitor] [] No Responsive Early trials PMID:21788564;PMID:23238879 RDientsmann 01/16 ED TRUE MTOR inhibitors PTEN oncogenic mutation PTEN MUT PTEN:. [AKT inhibitor] [] Responsive Case report PMID:22025163 RDientsmann 01/16 PA TRUE AKT inhibitors PTEN deletion PTEN CNA PTEN:del [AKT inhibitor] [] Responsive Case report PMID:22025163 RDientsmann 01/16 PA TRUE AKT inhibitors PTEN deletion PTEN CNA PTEN:del [PD1 Ab inhibitor] [] Responsive Early trials PMID:26645196 RDientsmann 06/16 CM TRUE PD1 Ab inhibitors PTEN oncogenic mutation PTEN MUT PTEN:. [PD1 Ab inhibitor] [] Responsive Early trials PMID:26645196 RDientsmann 06/16 CM TRUE PD1 Ab inhibitors PTEN oncogenic mutation PTEN MUT PTEN:. MTOR inhibitor Everolimus Responsive Early trials PMID:23582881 RDientsmann 01/16 PRAD TRUE Everolimus (MTOR inhibitor) PTEN deletion PTEN CNA PTEN:del MTOR inhibitor Everolimus Responsive Early trials PMID:23582881 RDientsmann 01/16 PRAD TRUE Everolimus (MTOR inhibitor) PTEN deletion PTEN CNA PTEN:del MTOR inhibitor Sirolimus Responsive Early trials ASCO 2013 (abstr 2532) RDientsmann 01/16 CANCER TRUE Sirolimus (MTOR inhibitor) PTEN oncogenic mutation PTEN MUT PTEN:. MTOR inhibitor Sirolimus Responsive Early trials ASCO 2013 (abstr 2532) RDientsmann 01/16 CANCER TRUE Sirolimus (MTOR inhibitor) PTEN oncogenic mutation PTEN MUT PTEN:. [ATM inhibitor] [] Responsive Pre-clinical PMID:27397505 RDientsmann 07/16 BRCA TRUE ATM inhibitors PTEN deletion + BRAF oncogenic mutation PTEN;BRAF CNA;MUT PTEN:del;BRAF:. [BRAF inhibitor] [] Resistant Pre-clinical PMID:21317224;PMID:21725359 RDientsmann 01/16 CM TRUE BRAF inhibitors PTEN deletion + BRAF oncogenic mutation PTEN;BRAF CNA;MUT PTEN:del;BRAF:. [BRAF inhibitor] [] Resistant Pre-clinical PMID:21317224;PMID:21725359 RDientsmann CM TRUE BRAF inhibitors PTEN oncogenic mutation + BRAF oncogenic mutation PTEN;BRAF MUT;MUT PTEN:.;BRAF:. [BRAF inhibitor] [] Resistant Pre-clinical PMID:21317224;PMID:21725359 RDientsmann 01/16 CM TRUE BRAF inhibitors PTEN oncogenic mutation + BRAF oncogenic mutation PTEN;BRAF MUT;MUT PTEN:.;BRAF:. [BRAF inhibitor] [] Resistant Pre-clinical PMID:21317224;PMID:21725359 RDientsmann CM TRUE BRAF inhibitors PTEN deletion + BRAF oncogenic mutation PTEN;BRAF CNA;MUT PTEN:del;BRAF:. [MEK inhibitor] [] Resistant Pre-clinical PMID:23039341 RDientsmann 01/16 CM TRUE MEK inhibitors PTEN oncogenic mutation + BRAF oncogenic mutation PTEN;BRAF MUT;MUT PTEN:.;BRAF:. [MEK inhibitor] [] Resistant Pre-clinical PMID:23039341 RDientsmann 01/16 CM TRUE MEK inhibitors PTEN oncogenic mutation + ERBB2 amplification PTEN;ERBB2 MUT;CNA PTEN:.;ERBB2:amp MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy Everolimus;Trastuzumab;Chemotherapy Responsive Late trials PMID:27091708 RDientsmann 01/16 BRCA TRUE Everolimus + Trastuzumab + Chemotherapy (MTOR inhibitor + ERBB2 mAb inhibitor + Chemotherapy) RAC1 (P29S) + BRAF oncogenic mutation RAC1;BRAF MUT;MUT RAC1:P29S;BRAF:. [BRAF inhibitor] [] Resistant Case report PMID:25056119 RDientsmann 01/16 CM TRUE BRAF inhibitors RAC1 (P29S) + BRAF oncogenic mutation RAC1;BRAF MUT;MUT RAC1:P29S;BRAF:. [BRAF inhibitor] [] Resistant Case report PMID:25056119 RDientsmann CM TRUE BRAF inhibitors RAD50 (L1237F) + ATM deletion RAD50;ATM MUT;CNA RAD50:L1237F;ATM:del TOPO1 inhibitor;CHK1/2 inhibitor Irinotecan;CHK1/2 inhibitor Responsive Case report PMID:24934408 RDientsmann 01/16 CANCER TRUE Irinotecan + CHK1/2 inhibitor (TOPO1 inhibitor + CHK1/2 inhibitor) RAD51C oncogenic mutation RAD51C MUT RAD51C:. [PARP inhibitor] [] Responsive Early trials ASCO 2015 (abstr 5508) RDientsmann 01/16 OV TRUE PARP inhibitors RAD51C oncogenic mutation RAD51C MUT RAD51C:. [PARP inhibitor] [] Responsive Early trials ASCO 2015 (abstr 5508) RDientsmann 04/16 OV TRUE PARP inhibitors RAF1 fusion RAF1 FUS RAF1__. Direct Pre-clinical [Pan-RAF inhibitor] [] Responsive Pre-clinical Cell line PMID:20526349 ARodriguez-Vida 09/15 PRAD TRUE Pan-RAF inhibitors RAF1 fusion RAF1 FUS RAF1__. Indirect Approved MEK inhibitor U0126 Responsive Pre-clinical Cell line PMID:20526349 ARodriguez-Vida 09/15 PRAD TRUE U0126 (MEK inhibitor) RAF1 fusion RAF1 FUS RAF1__. Pan-TK inhibitor Sorafenib Responsive Pre-clinical PMID:20526349 RDientsmann PRAD TRUE Sorafenib (Pan-TK inhibitor) RAF1 overexpression RAF1 EXPR RAF1:over Pan-TK inhibitor Sorafenib Responsive Pre-clinical Cell line PMID:24375110 CdeTorres 10/16 OS TRUE Sorafenib (Pan-TK inhibitor) RAF1 (S257P,G361A,P261P) + BRAF oncogenic mutation RAF1;BRAF MUT;MUT RAF1:S257P,G361A,P261P;BRAF:. [BRAF inhibitor] [] Resistant Pre-clinical PMID:23737487 RDientsmann CM TRUE BRAF inhibitors RB1 overexpression RB1 EXPR RB1:over Indirect Pre-clinical CDK4/6 inhibitor PD-0332991 Responsive Pre-clinical Xenograft PMID:23708653 ARodriguez-Vida 09/15 PRAD TRUE PD-0332991 (CDK4/6 inhibitor) RB1 oncogenic mutation RB1 MUT RB1:. Indirect Approved Chemotherapy Cisplatin Responsive Early trials PMID:26238431 ARodriguez-Vida;RDientsmann BLCA BLCA TRUE Cisplatin (Chemotherapy) RB1 deletion RB1 CNA RB1:del Indirect Approved Chemotherapy Cisplatin Responsive Early trials PMID:26238431 ARodriguez-Vida;RDientsmann BLCA BLCA TRUE Cisplatin (Chemotherapy) RB1 oncogenic mutation RB1 MUT RB1:. [MDM2/MDMX inhibitor] [] Responsive Pre-clinical PMID:17080083;PMID:21515735 RDientsmann RB TRUE MDM2/MDMX inhibitors RB1 deletion RB1 CNA RB1:del [MDM2/MDMX inhibitor] [] Responsive Pre-clinical PMID:17080083;PMID:21515735 RDientsmann RB TRUE MDM2/MDMX inhibitors RB1 oncogenic mutation RB1 MUT RB1:. [HDAC inhibitor] [] Responsive Pre-clinical PMID:18483379 RDientsmann 01/16 RB TRUE HDAC inhibitors RB1 deletion RB1 CNA RB1:del [HDAC inhibitor] [] Responsive Pre-clinical PMID:18483379 RDientsmann 01/16 RB TRUE HDAC inhibitors RET fusion RET FUS RET__. [RET inhibitor] [] Responsive Pre-clinical PMID:22327624;PMID:22327622 RDientsmann 01/16 LUAD TRUE RET inhibitors RET-TPCN1 fusion RET FUS RET__TPCN1 [RET inhibitor] [] Responsive Pre-clinical PMID:23056499 RDientsmann 01/16 TH TRUE RET inhibitors RET (C634W,M918T) RET MUT RET:C634W,M918T [RET inhibitor] [] Responsive Pre-clinical PMID:23056499 RDientsmann 01/16 TH TRUE RET inhibitors RET (C634W,M918T) RET MUT RET:C634W,M918T Pan-kinase inhibitor Cabozantinib Responsive Pre-clinical PMID:21470995 RDientsmann 01/16 TH TRUE Cabozantinib (Pan-kinase inhibitor) RET-TPCN1 fusion RET FUS RET__TPCN1 Pan-kinase inhibitor Cabozantinib Responsive Pre-clinical PMID:21470995 RDientsmann THCA TRUE Cabozantinib (Pan-kinase inhibitor) RET fusion RET FUS RET__. Pan-kinase inhibitor Cabozantinib Responsive Early Trials,Case Report PMID:23533264;PMID:23584301;PMID:25366691;ASCO 2015 (abstr 8007);ENA 2015 (abstract LB-C17) RDientsmann 01/16 LUAD TRUE Cabozantinib (Pan-kinase inhibitor) RET fusion RET FUS RET__. Pan-TK inhibitor Nintedanib Responsive Case report PMID:26787234 RDientsmann 06/16 LUAD TRUE Nintedanib (Pan-TK inhibitor) RET (C634W,M918T) RET MUT RET:C634W,M918T Pan-TK inhibitor Sunitinib Responsive Pre-clinical PMID:21470995 RDientsmann 01/16 TH TRUE Sunitinib (Pan-TK inhibitor) RET-TPCN1 fusion RET FUS RET__TPCN1 Pan-TK inhibitor Sunitinib Responsive Pre-clinical PMID:21470995 RDientsmann THCA TRUE Sunitinib (Pan-TK inhibitor) RET (618,620,634,768,791,891,918,C634W,M918T) RET MUT RET:.618.,.620.,.634.,.768.,.791.,.891.,.918.,C634W,M918T Approved Pan-TK inhibitor Vandetanib Responsive FDA guidelines PMID:20065189;PMID:22025146 RDientsmann THCA TRUE Vandetanib (Pan-TK inhibitor) RET-TPCN1 fusion RET FUS RET__TPCN1 Pan-TK inhibitor Vandetanib Responsive Pre-clinical PMID:21470995 RDientsmann THCA TRUE Vandetanib (Pan-TK inhibitor) RET fusion RET FUS RET__. Pan-TK inhibitor Vandetanib Responsive Early Trials,Case Report PMID:23533264;PMID:23584301;PMID:25366691;ASCO 2015 (abstr 8007);ENA 2015 (abstract LB-C17) RDientsmann 01/16 LUAD TRUE Vandetanib (Pan-TK inhibitor) RICTOR amplification RICTOR CNA RICTOR:amp [MTORC1/2 inhibitor] [] Responsive Case report PMID:26370156 RDientsmann 01/16 L TRUE MTORC1/2 inhibitors RNF43 oncogenic mutation RNF43 MUT RNF43:. [Porcupine inhibitor] [] Responsive Case report ENA 2015 (abstr C45) RDientsmann 11/15 COREAD TRUE Porcupine inhibitors ROS1 fusion ROS1 FUS ROS1__. Clinical trials ALK inhibitor Crizotinib Responsive FDA guidelines FDA CRubio-Perez;EArriola NSCLC TRUE Crizotinib (ALK inhibitor) ROS1 fusion ROS1 FUS ROS1__. [HSP90 inhibitor] [] Responsive Pre-clinical PMID:23533265 RDientsmann 01/16 LUAD TRUE HSP90 inhibitors ROS1 (G2032R) ROS1 MUT ROS1:G2032R Pan-kinase inhibitor Cabozantinib Responsive Pre-clinical PMID:25351743 RDientsmann 01/16 LUAD TRUE Cabozantinib (Pan-kinase inhibitor) ROS1 (G2032R) ROS1 MUT ROS1:G2032R Approved ALK inhibitor Crizotinib Resistant Case report PMID:23724914;PMID:25688157 RDientsmann LUAD TRUE Crizotinib (ALK inhibitor) ROS1 fusion ROS1 FUS ROS1__. ALK inhibitor Crizotinib Responsive Case report PMID:24875859 RDientsmann 01/16 IM TRUE Crizotinib (ALK inhibitor) ROS1 fusion ROS1 FUS ROS1__. ALK inhibitor Crizotinib Responsive Early trials PMID:25264305 RDientsmann 01/16 LUAD TRUE Crizotinib (ALK inhibitor) SETD2 deletion SETD2 CNA SETD2:del [WEE1 inhibitor] [] Responsive Pre-clinical ENA 2014 (abstr 211) RDientsmann CANCER TRUE WEE1 inhibitors SETD2 oncogenic mutation SETD2 MUT SETD2:. [WEE1 inhibitor] [] Responsive Pre-clinical ENA 2014 (abstr 211) RDientsmann CANCER TRUE WEE1 inhibitors SF3B1 (K700E,K666N) SF3B1 MUT SF3B1:K700E,K666N [Spliceosome inhibitor] [] Responsive Pre-clinical ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858 RDientsmann CANCER TRUE Spliceosome inhibitors SH2B3 deletion SH2B3 CNA SH2B3:del [JAK inhibitor] [] Responsive Pre-clinical PMID:20404132 RDientsmann MDPS TRUE JAK inhibitors SH2B3 oncogenic mutation SH2B3 MUT SH2B3:. [JAK inhibitor] [] Responsive Pre-clinical PMID:20404132 RDientsmann MDPS TRUE JAK inhibitors SLC29A1 oncogenic mutation SLC29A1 MUT SLC29A1:. Chemotherapy Gemcitabine Resistant Pre-clinical PMID:21166756 ARodriguez-Vida 09/15 BLCA BLCA TRUE SLC29A1 is HENT1 used symbol Gemcitabine (Chemotherapy) SMARCA1 oncogenic mutation SMARCA1 MUT SMARCA1:. [EZH2 inhibitor] [] Responsive Pre-clinical PMID:26552009 RDientsmann 01/16 CANCER TRUE EZH2 inhibitors SMARCA4 deletion SMARCA4 CNA SMARCA4:del [EZH2 inhibitor] [] Responsive Case report ESMO 2015 (abstract 302) RDientsmann 11/15 OV TRUE EZH2 inhibitors SMARCA4 oncogenic mutation SMARCA4 MUT SMARCA4:. [EZH2 inhibitor] [] Responsive Case report ESMO 2015 (abstract 302) RDientsmann 11/15 OV TRUE EZH2 inhibitors SMARCB1 deletion SMARCB1 CNA SMARCB1:del [EZH2 inhibitor] [] Responsive Case report ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302) RDientsmann 01/16 MRT TRUE INI1 gene symbol: SMARCB1 EZH2 inhibitors SMARCB1 oncogenic mutation SMARCB1 MUT SMARCB1:. [EZH2 inhibitor] [] Responsive Case report ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302) RDientsmann 01/16 MRT TRUE INI1 gene symbol: SMARCB1 EZH2 inhibitors SMARCB1 deletion SMARCB1 CNA SMARCB1:del Clinical Trials [EZH2 inhibitor] [] Responsive Early trials ESMO 2015 (abstract 302) RDientsmann 11/15 MRT TRUE EZH2 inhibitors SMARCB1 oncogenic mutation SMARCB1 MUT SMARCB1:. [HDAC inhibitor] [] Responsive Pre-clinical PMID:26920892 RDientsmann 07/16 MRT TRUE HDAC inhibitors SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W) SMO MUT SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W SHH inhibitor Vismodegib Resistant Case report PMID:25759020;PMID:25306392 DTamborero;RDientsmann 04/16 BCC TRUE Vismodegib (SHH inhibitor) SMO (D473H) SMO MUT SMO:D473H SHH inhibitor Vismodegib Resistant Case report PMID:19726788;PMID:25759019 RDientsmann MB TRUE Vismodegib (SHH inhibitor) SMO (L225R,N223D,S391N,D338N,D473H,G457S,E518) SMO MUT SMO:L225R,N223D,S391N,D338N,D473H,G457S,E518. [SMO inhibitor] [] Resistant Pre-clinical PMID:24951114 DTamborero;RDientsmann MB TRUE SMO inhibitors MYCN amplification MYCN CNA MYCN:amp [SMO inhibitor] [] Resistant Pre-clinical PMID:24951114 DTamborero;RDientsmann MB TRUE SMO inhibitors GLI2 amplification GLI2 CNA GLI2:amp [SMO inhibitor] [] Resistant Pre-clinical PMID:24951114 DTamborero;RDientsmann MB TRUE SMO inhibitors CCND1 amplification CCND1 CNA CCND1:amp [SMO inhibitor] [] Resistant Pre-clinical PMID:24951114 DTamborero;RDientsmann MB TRUE SMO inhibitors SRSF2 oncogenic mutation SRSF2 MUT SRSF2:. [Spliceosome inhibitor] [] Responsive Pre-clinical PMID:27135740 RDientsmann 06/16 AML TRUE Spliceosome inhibitors STAG2 oncogenic mutation STAG2 MUT STAG2:. [PARP inhibitor] [] Responsive Pre-clinical PMID:24356817 RDientsmann G TRUE PARP inhibitors STK11 deletion STK11 CNA STK11:del [MEK inhibitor] [] Responsive Pre-clinical PMID:19165201 RDientsmann LUAD TRUE MEK inhibitors STK11 oncogenic mutation STK11 MUT STK11:. [MEK inhibitor] [] Responsive Pre-clinical PMID:19165201 RDientsmann LUAD TRUE MEK inhibitors STK11 deletion STK11 CNA STK11:del [MTOR inhibitor] [] Responsive Pre-clinical PMID:19541609 RDientsmann CANCER TRUE MTOR inhibitors STK11 oncogenic mutation STK11 MUT STK11:. [MTOR inhibitor] [] Responsive Pre-clinical PMID:19541609 RDientsmann CANCER TRUE MTOR inhibitors STK11 deletion STK11 CNA STK11:del [SRC inhibitor;PI3K/MEK inhibitor] [] Responsive Pre-clinical PMID:20541700 RDientsmann 01/16 LUAD TRUE SRC inhibitor + PI3K/MEK inhibitors STK11 oncogenic mutation STK11 MUT STK11:. [SRC inhibitor;PI3K/MEK inhibitor] [] Responsive Pre-clinical PMID:20541700 RDientsmann 01/16 LUAD TRUE SRC inhibitor + PI3K/MEK inhibitors STK11 oncogenic mutation STK11 MUT STK11:. [BET inhibitor] [] Resistant Pre-clinical PMID:23129625;PMID:24045185 RDientsmann 04/16 L TRUE BET inhibitors STK11 (D194E) STK11 MUT STK11:D194E MTOR inhibitor Everolimus Responsive Case report PMID:21189378 RDientsmann 01/16 PA TRUE Everolimus (MTOR inhibitor) STK11 deletion STK11 CNA STK11:del Anti-diabetic Phenformin Responsive Pre-clinical PMID:23352126 RDientsmann 01/16 LUAD TRUE Phenformin (Anti-diabetic) STK11 oncogenic mutation STK11 MUT STK11:. Anti-diabetic Phenformin Responsive Pre-clinical PMID:23352126 RDientsmann 01/16 LUAD TRUE Phenformin (Anti-diabetic) STK11 deletion + KRAS oncogenic mutation STK11;KRAS CNA;MUT STK11:del;KRAS:. MEK inhibitor;Chemotherapy MEK inhibitor;Docetaxel Resistant Pre-clinical PMID:22425996 RDientsmann 01/16 LUAD TRUE MEK inhibitor + Docetaxel (MEK inhibitor + Chemotherapy) STK11 oncogenic mutation + KRAS oncogenic mutation STK11;KRAS MUT;MUT STK11:.;KRAS:. MEK inhibitor;Chemotherapy MEK inhibitor;Docetaxel Resistant Pre-clinical PMID:22425996 RDientsmann 01/16 LUAD TRUE MEK inhibitor + Docetaxel (MEK inhibitor + Chemotherapy) SUZ12 deletion SUZ12 CNA SUZ12:del [BET inhibitor] [] Responsive Pre-clinical PMID:25119042 RDientsmann CANCER TRUE BET inhibitors SUZ12 oncogenic mutation SUZ12 MUT SUZ12:. [BET inhibitor] [] Responsive Pre-clinical PMID:25119042 RDientsmann CANCER TRUE BET inhibitors SYK amplification SYK CNA SYK:amp [SYK inhibitor] [] Responsive Pre-clinical PMID:16409295;PMID:19549911 RDientsmann MCL;CLL TRUE SYK inhibitors TMPRSS2 fusion TMPRSS2 FUS TMPRSS2__. [DNA-PKc inhibitor] [] Responsive Pre-clinical PMID:21575865 RDientsmann 01/16 PRAD TRUE DNA-PKc inhibitors TMPRSS2 fusion TMPRSS2 FUS TMPRSS2__. [PARP inhibitor] [] Responsive Pre-clinical PMID:21575865 RDientsmann PRAD TRUE PARP inhibitors TOP2A amplification TOP2A CNA TOP2A:amp Chemotherapy Anthracyclines Responsive Late trials PMID:22864769 RDientsmann 01/16 BRCA TRUE Anthracyclines (Chemotherapy) TP53 deletion TP53 CNA TP53:del Indirect Clinical Trials ATR inhibitor AZD6738 Responsive Early trials NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html ECampo BCL TRUE AZD6738 (ATR inhibitor) TP53 oncogenic mutation TP53 MUT TP53:. Indirect Clinical Trials ATR inhibitor AZD6738 Responsive Early trials NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html ECampo BCL TRUE AZD6738 (ATR inhibitor) TP53 oncogenic mutation TP53 MUT TP53:. Indirect Clinical Trials WEE1 inhibitor MK-1775 Responsive Early trials NCT01357161;ASCO2015 (abstr 2507) KKarube;RDientsmann OV TRUE MK-1775 (WEE1 inhibitor) TP53 oncogenic mutation TP53 MUT TP53:. [MDM2 inhibitor] [] Resistant Early trials PMID:23084521;ASCO 2015 (abstr 10564) RDientsmann 01/16 LIP TRUE MDM2 inhibitors TP53 oncogenic mutation TP53 MUT TP53:. [WEE1 inhibitor] [] Responsive Pre-clinical PMID:25125259 RDientsmann HNC TRUE WEE1 inhibitors TP53 (R248Q,R175H) TP53 MUT TP53:R248Q,R175H [HSP90 inhibitor] [] Responsive Pre-clinical PMID:26009011 RDientsmann 04/16 CANCER TRUE HSP90 inhibitors TP53 (R248Q,R175H) TP53 MUT TP53:R248Q,R175H [HSP90 inhibitor] [] Responsive Pre-clinical PMID:26009011 RDientsmann CANCER TRUE REMAP:R172H changed to R175H it was not the human mutation HSP90 inhibitors TP53 oncogenic mutation TP53 MUT TP53:. Amylin analogue Pramlintide Responsive Pre-clinical PMID:25409149 RDientsmann THYM TRUE Pramlintide (Amylin analogue) TP53 deletion TP53 CNA TP53:del Amylin analogue Pramlintide Responsive Pre-clinical PMID:25409149 RDientsmann THYM TRUE Pramlintide (Amylin analogue) TP53 oncogenic mutation TP53 MUT TP53:. CDK4/CDK6 inhibitor Abemaciclib Resistant Early trials PMID:27231123 RDientsmann 07/16 BRCA TRUE Abemaciclib (CDK4/CDK6 inhibitor) TP53 oncogenic mutation TP53 MUT TP53:. Chemotherapy Mitomycin C Responsive Pre-clinical PMID:27397505 RDientsmann 07/16 BLCA TRUE Mitomycin C (Chemotherapy) TP53 oncogenic mutation TP53 MUT TP53:. Chemotherapy Gemcitabine Responsive Pre-clinical PMID:27397505 RDientsmann 07/16 BLCA TRUE Gemcitabine (Chemotherapy) TP53 oncogenic mutation TP53 MUT TP53:. Anthracycline antitumor antibiotic Doxorubicin Responsive Pre-clinical PMID:27397505 RDientsmann 07/16 BLCA TRUE Doxorubicin (Anthracycline antitumor antibiotic) TPMT biallelic inactivation TPMT BIA TPMT:. Approved Chemotherapy Cisplatin Increased Toxicity (Ototoxicity) FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Cisplatin (Chemotherapy) TPMT (A80P,Y240C,A154T,A167G) TPMT MUT TPMT:A80P,Y240C,A154T,A167G Approved Chemotherapy Cisplatin Increased Toxicity (Ototoxicity) FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Cisplatin (Chemotherapy) TPMT splice acceptor variant TPMT MUT TPMT::consequence::splice_acceptor_variant:. Approved Chemotherapy Cisplatin Increased Toxicity (Ototoxicity) FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Cisplatin (Chemotherapy) TPMT biallelic inactivation TPMT BIA TPMT:. Approved Purine analog Mercaptopurine Increased Toxicity (Myelosupression) FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Mercaptopurine (Purine analog) TPMT (A80P,Y240C,A154T,A167G) TPMT MUT TPMT:A80P,Y240C,A154T,A167G Approved Purine analog Mercaptopurine Increased Toxicity (Myelosupression) FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Mercaptopurine (Purine analog) TPMT splice acceptor variant TPMT MUT TPMT::consequence::splice_acceptor_variant:. Approved Purine analog Mercaptopurine Increased Toxicity (Myelosupression) FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Mercaptopurine (Purine analog) TPMT biallelic inactivation TPMT BIA TPMT:. Approved Guanine analog Thioguanine Increased Toxicity (Myelosupression) FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Thioguanine (Guanine analog) TPMT (A80P,Y240C,A154T,A167G) TPMT MUT TPMT:A80P,Y240C,A154T,A167G Approved Guanine analog Thioguanine Increased Toxicity (Myelosupression) FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Thioguanine (Guanine analog) TPMT splice acceptor variant TPMT MUT TPMT::consequence::splice_acceptor_variant:. Approved Guanine analog Thioguanine Increased Toxicity (Myelosupression) FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Thioguanine (Guanine analog) TSC1 oncogenic mutation TSC1 MUT TSC1:. Approved MTOR inhibitor Everolimus Responsive FDA guidelines FDA ARodriguez-Vida 09/15 RA RA TRUE TSC positive.Renal angilypoma is benign tumor Everolimus (MTOR inhibitor) TSC1 oncogenic mutation TSC1 MUT TSC1:. Approved MTOR inhibitor Everolimus Responsive FDA guidelines FDA DTamborero 04/16 GCA TRUE Tuberous sclerosis complex in 80% of cases = mutations in TSC1 or TSC2 Everolimus (MTOR inhibitor) TSC1 oncogenic mutation TSC1 MUT TSC1:. [MTOR inhibitor] [] Responsive Early trials PMID:23312829;PMID:21525172;PMID:20048174 RDientsmann 01/16 RA TRUE MTOR inhibitors TSC1 oncogenic mutation TSC1 MUT TSC1:. Indirect Approved MTOR inhibitor Everolimus Responsive Early trials PMID:22923433 RDientsmann 01/16 BLCA TRUE TSC1 or TSC2 mutated Everolimus (MTOR inhibitor) TSC1 deletion TSC1 CNA TSC1:del MTOR inhibitor Everolimus Responsive Case report PMID:24622468;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519) RDientsmann 01/16 R TRUE Everolimus (MTOR inhibitor) TSC1 oncogenic mutation TSC1 MUT TSC1:. MTOR inhibitor Everolimus Responsive Case report PMID:24622468;PMID:26859683;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519) RDientsmann 01/16 R TRUE Everolimus (MTOR inhibitor) TSC1 oncogenic mutation TSC1 MUT TSC1:. Approved MTOR inhibitor Everolimus Responsive Case report PMID:26859683 RDientsmann 06/16 S;ST TRUE Everolimus (MTOR inhibitor) TSC1 (E17K) TSC1 MUT TSC1:E17K MTOR inhibitor Tensirolimus Responsive Case report PMID:27016228 RDientsmann 07/16 ED TRUE Tensirolimus (MTOR inhibitor) TSC2 oncogenic mutation TSC2 MUT TSC2:. Approved MTOR inhibitor Everolimus Responsive FDA guidelines FDA ARodriguez-Vida;DTamborero 04/16 RA;GCA RA TRUE TSC positive.Renal angilypoma is benign tumor Everolimus (MTOR inhibitor) TSC2 (Q1178*) TSC2 MUT TSC2:Q1178* Indirect Approved MTOR inhibitor Everolimus Responsive Case report PMID:25295501 CRubio-Perez;RDientsmann 01/16 THCA TRUE Everolimus (MTOR inhibitor) TSC2 oncogenic mutation TSC2 MUT TSC2:. [MTOR inhibitor] [] Responsive Early trials PMID:23312829;PMID:21525172;PMID:20048174 RDientsmann 01/16 RA TRUE MTOR inhibitors TSC2 deletion TSC2 CNA TSC2:del [SRC inhibitor] [] Responsive Pre-clinical PMID:24691995 RDientsmann LAM TRUE Lymphangioleiomyomatosis (LAM) is a rare, progressive, systemic disease that typically results in cystic lung destruction SRC inhibitors TSC2 oncogenic mutation TSC2 MUT TSC2:. [SRC inhibitor] [] Responsive Pre-clinical PMID:24691995 RDientsmann LAM TRUE SRC inhibitors TSC2 oncogenic mutation TSC2 MUT TSC2:. Indirect Approved MTOR inhibitor Everolimus Responsive Early trials PMID:22923433 RDientsmann 01/16 BLCA TRUE TSC1 or TSC2 mutated Everolimus (MTOR inhibitor) TSC2 (E17K) TSC2 MUT TSC2:E17K MTOR inhibitor Tensirolimus Responsive Case report PMID:27016228 RDientsmann 07/16 ED TRUE Tensirolimus (MTOR inhibitor) TUBB3 overexpression TUBB3 EXPR TUBB3:over Taxane Paclitaxel Resistant Pre-clinical PMID:23184177 ARodriguez-Vida 09/15 BLCA BLCA TRUE Paclitaxel (Taxane) U2AF1 oncogenic mutation U2AF1 MUT U2AF1:. [FLT3 inhibitor] [] Responsive Pre-clinical PMID:27397505 RDientsmann 07/16 CANCER TRUE FLT3 inhibitors UGT1A1 biallelic inactivation UGT1A1 BIA UGT1A1:. Approved TOPO1 inhibitor Irinotecan Increased Toxicity FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Irinotecan (TOPO1 inhibitor) UGT1A1 (G71R,P229Q) UGT1A1 MUT UGT1A1:G71R,P229Q Approved TOPO1 inhibitor Irinotecan Increased Toxicity FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Irinotecan (TOPO1 inhibitor) UGT1A1 biallelic inactivation UGT1A1 BIA UGT1A1:. Approved BCR-ABL inhibitor 2nd gen Nilotinib Increased Toxicity (Hyperbilirubinemia) FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Nilotinib (BCR-ABL inhibitor 2nd gen) UGT1A1 (G71R,P229Q) UGT1A1 MUT UGT1A1:G71R,P229Q Approved BCR-ABL inhibitor 2nd gen Nilotinib Increased Toxicity (Hyperbilirubinemia) FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Nilotinib (BCR-ABL inhibitor 2nd gen) UGT1A1 biallelic inactivation UGT1A1 BIA UGT1A1:. Approved VEGFR inhibitor Pazopanib Increased Toxicity (Hyperbilirubinemia) FDA guidelines FDA DTamborero;CRubio-Perez 01/16 CANCER TRUE Pazopanib (VEGFR inhibitor) VEGFA amplification VEGFA CNA VEGFA:amp Pan-TK inhibitor Sorafenib Responsive Early trials PMID:24687604 RDientsmann 01/16 HC TRUE Sorafenib (Pan-TK inhibitor) VHL oncogenic mutation VHL MUT VHL:. Indirect Approved [VEGFR inhibitor] [Sorafenib,Sunitinib,Bevacizumab,Axitinib] Responsive Pre-clinical Retrospective analysis PMID:18635227 ARodriguez-Vida 09/15 R TRUE VEGFR inhibitors (Sorafenib,Sunitinib,Bevacizumab,Axitinib,etc) ZBTB16 undexpression ZBTB16 EXPR ZBTB16:under [LHRH analogues or antagonist] [] Resistant Pre-clinical PMID:16637071 ARodriguez-Vida 09/15 PRAD PR TRUE LHRH analogues or antagonists ZNRF3 oncogenic mutation ZNRF3 MUT ZNRF3:. [Porcupine inhibitor] [] Responsive Pre-clinical PMID:26023187 RDientsmann COREAD TRUE Porcupine inhibitors